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Abstract
The aim of the studies in this thesis was to investigate drug delivery systems using a
variety of fabrication techniques that can be used for biomedical devices. This thesis
was conducted in partnership with the HEARing Cooperative Research Centre (CRC)
with the aim of developing drug delivery systems that can be incorporated into the
cochlear implant (Cochlear Pty. Ltd is a partner of the HEARing CRC). Therefore
the materials used to form the drug delivery systems and the fabrication approaches
were chosen and used with the final application of the cochlear implant in mind.

First,

a

multifunctional

polypyrrole

based

system

was

developed

to

electrochemically deliver dexamethasone disodium phosphate (DexP) - a derivative
of anti-inflammatory drug dexamethasone (Dex). Additionally this system was
modified to render the surface resistance to nonspecific protein adsorption. This
study investigated different conditions for the electropolymerisation of DexP doped
polypyrrole (PPy/DexP) films, and their impacts on the film properties (e.g.
morphology, impedance) and the electrically-stimulated drug release profiles.
Poly(ethylene glycol) methyl ether thiol (PEG-SH) with different molecular weights
were introduced to modify the PPy/DexP film surface and a quartz crystal
microbalance (QCM) was used to study the modification of the PPy/DexP films, as
well as protein interaction with PPy/DexP films before and after the PEG-SH
modification.

The second part of this study involved exploring the possibility to increase the
loading of the anti-inflammatory drug using a hydrogel reservoir system. A multipleprinthead inkjet printer was developed to print alginate-chitosan hydrogels. The ink
V|Page

formulations were investigated and optimised to achieve optimum printing with
alginate or chitosan, as well as the reactive printing of alginate-chitosan hydrogel
with both inks. Phenol red or DexP was loaded in the alginate ink and incorporated
into the printed alginate-chitosan hydrogel samples during the reactive printing, and
their in vitro release profiles were studied.

In the third part of this study, the application of melt extrusion printing to fabricate
three-dimensional

(3D)

scaffolds

for

drug

delivery

was

demonstrated.

Polycaprolactone (PCL) was chosen for its good biocompatibility and processability.
PCL-Dex material was made by mixing Dex within PCL at varying concentrations
using a solvent casting method. The processability of PCL-Dex was investigated
through a series of characterisation methods, including thermal gravimetric analysis,
differential scanning calorimetry, and rheometry. The ability to control the release of
Dex from intricately fabricated 3D scaffolds was demonstrated in vitro.
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Chapter 1
Introduction
The aim of the studies in this thesis was to investigate drug delivery systems using a
variety of fabrication techniques that can be incorporated into the cochlear implant.
A cochlear implant is a neural bionic device that restores hearing for patients with
sensorineural hearing loss. By directly interacting with sensory neurons in the inner
ear (cochlea), the cochlear implant translates sounds into electrical signals to
overcome the loss or damage of hair cells in the cochlea. As one of the most
successful neural bionic devices, cochlear implants have highlighted the emerging
research area of neural interface systems through which direct communication
between the central nervous system and biomedical electronic devices has been
made possible, hence the name “neural bionic devices”. By recording and
stimulating the neural tissue, neural bionic devices provide two-way communication
between the nervous system and the outside world, holding the promise to treat a
wide range of neural function disabilities, such as epilepsy, Parkinson’s disease,
hearing loss and movement disorders. Due to the vast number of possible biomedical
therapeutic applications to which this technology may be applied, enormous effort
has been devoted to developing neural bionic devices.

However, the development of neural bionic devices does face various mechanical
and biological challenges. For example, during the implantation process, mechanical
and/or acoustic traumas are unavoidably caused by surgical procedures. Furthermore,
the implantation of the device introduces a neural-biomaterial interface between the
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implant and surrounding tissues that can induce a series of foreign body responses
which can be detrimental to the performance of the neural bionic device and
eventually lead to device failure. Therefore a great deal of effort has been invested
into the study of neural interface systems to aid the development of neural bionic
devices. For their successful development, it is essential that a good understanding of
the theory of neural bionic devices is coupled with both physical and chemical
strategies through which foreign body response and mechanical trauma at the site of
the implantation may be controlled.

In this chapter, I will review the current status of neural bionic devices, the
challenges for implanted neural bionic device systems and the solutions for these
challenges. The fast developing technique of additive fabrication has provided a
great opportunity for the biofabrication of neural bionic devices and will also be
reviewed.

1.1 Neural Bionic Devices
Neural bionic devices aim to link machines to the nervous system by forming a
direct interaction between the brain and the outside world. This is achieved by either
recording or stimulating the central or peripheral nervous system1, which normally
falls into three categories2: output signalling, input signalling, and closed-loop
control- a combination of both output and input signalling.

Recording and deciphering of the signals from the central or peripheral nervous
system- also referred as output signalling3- helps to predict cognitive intentions or
2|Page

motor plans, and therefore can be used to directly control motor prosthesis or skeletal
muscles to restore movement. This will benefit patients with neuromuscular
disorders such as brainstem stroke, amyotrophic lateral sclerosis, or paralyses from
spinal cord injuries. A large number of studies have demonstrated the great potential
of such neurotechnology. For example, in 2008 researchers demonstrated that ablebodied monkeys could use their motor cortical activity to control a robotic arm for
self-feeding by implanting intracortical microelectrode arrays in the primary motor
cortices4. More recent work has shown that individuals with long-standing
tetraplegia were able to control a robotic arm to perform three-dimensional reach and
grasp movements using the decoded signals recorded from an implanted 96-channel
microelectrode array5, 6.

Input signalling, on the other hand, creates signals carrying information from the
outside world and stimulates the central or peripheral nervous system to restore or
improve the degenerated sensory functions associated with neural diseases.
Examples include implantation of electrode arrays to restore sensory functions such
as vision7 or hearing8, and routine clinical use of deep brain stimulation to relieve the
symptoms of Parkinson’s disease9 or essential tremor10. Scientists have been
attempting to restore deaf patients’ hearing since the 1950s. This work eventually
saw the commercialisation of the bionic ear (cochlear implant) that has been on the
market for over twenty years and has benefited more than 200 000 recipients
worldwide11. A recent study12 demonstrated the possibility to restore blind patients’
vision. Each patient was implanted with an electrode array that consists of 1500
microphotodiodes in their subretinal space, and by directly stimulating the overlying
neurons the patient was able to read large letters. Parkinson’s disease is the second
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most common age-related neurodegenerative disease (after Alzheimer’s disease),
which results from the death of dopaminergic neurons in the substantia nigra and
causes tremor, slowness, rigidity and involuntary movement13. Deep brain
stimulation is a routine clinical treatment for Parkinson’s disease. It involves placing
high frequency electrodes and stimulating a chosen region of the brain tissue to treat
people with a variety of neurologic conditions14. Deep brain stimulation is
considered as an effective treatment for Parkinson’s disease and is recommended to
patients who have medically intractable motor fluctuations, intractable tremor or
intolerance of medication that can cause several adverse side effects15. Studies have
shown long-term improvement in Parkinsonian symptoms through the stimulation of
either the internal segment of the globus pallidus or the subthalamic nucleus16 in the
patients’ brain.

Closed-loop control17, or responsive stimulation, records neural activities and reacts
to stimulate the neural tissue. One application of this closed-loop system is for the
treatment of epilepsy. Epilepsy is a common chronic neurological disorder for which
as many as 50% of patients have persistent seizures18. Direct cortical stimulation has
been proven safe and efficacious in treating medically intractable epilepsy. However,
continuous stimulation can cause habituation in long-term treatment19, therefore
closed-loop stimulation has been introduced into epilepsy treatment20. Rather than
providing stimulation regardless of neuronal activity, the closed-loop stimulation
detects early seizure activity and triggers the system to administer a stimulation to
counteract and nullify the seizure activity. Therefore this approach is considered
more effective at minimising the adverse reactions produced by continuous
stimulation21.
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Amongst all the current neural bionic devices, the cochlear implant is one of the
most successful. To develop a drug delivery system and to improve the neural-device
interface associated with the cochlear implant has been the initiative of this work.

1.1.1 Cochlear Implants
The cochlear implant (CI) is a bionic device that treats severe to profound
sensorineural hearing loss (SNHL) by stimulating spiral ganglion neurons (SGN) in
the cochlea with electrical pulses22. The human peripheral auditory system consists
of the ear and the nervous system. There are three main components of the ear
(Figure 1.1): the outer ear, the middle ear and the inner ear. The outer ear is
composed of the visible part of the ear (the helix, the auricle and the lobule), the
external auditory canal and the eardrum (tympanic membrane). Sound travels
through the external auditory canal as waves and cause the eardrum to vibrate at
different frequencies. The middle ear is an air filled chamber called the tympanic
cavity, and contains the auditory ossicles which are the three smallest bones in the
human body that help to transmit and amplify the vibration from the eardrum to the
cochlea (inner ear). The cochlea is a spiral shaped tube filled with fluid, which has
three main sections: the scala media, the scala tympani and the scala vestibule. The
scala media contains the core component of the cochlea- the organ of Corti, which
lies on the basilar membrane and contains auditory hair cells. The basilar membrane
has different regions that resonate selectively with different frequencies, with the
resonance moving the hair cells lying on the membrane surface, making them send
electrical impulses to the auditory nerve fibres (ANFs) attached.
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Figure 1.1 Anatomy of the human ear.

A healthy cochlea contains roughly 3000 inner hair cells that transmit signals along
30 000 auditory neurons23. However, hair cells are fragile structures that are
vulnerable to damage via a variety of avenues, such as infectious diseases, ototoxic
drugs, overexposure to loud sounds, and aging. In most cases, deafness and severe
hearing loss are caused by the damaging or destruction of the hair cells in the
cochlea. Cochlear implantation is the only treatment currently available to treat
severe to profound sensorineural hearing loss; by bypassing the missing or damaged
sensorial hair cells, the cochlear implant directly stimulates the neurons in the
auditory nerves and reinstates the afferent input to the central nervous system.

The cochlear implant device is made up of two separate units- external and internal,
and has four key components (Figure 1.2)22- a microphone to pick up sound, a
processor to convert sound to electrical signals, a transmitter to transmit the signals
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to implanted electrodes and an electrode array which is implanted into the cochlea to
stimulate the auditory nerve fibres.

b
○
a
○

c
○

e
○
d
○

a The microphone
○
b The external processor and
○
transmitter
c The implantable electronics
○
package
d The electrode array
○
e The auditory nerve
○

Figure 1.2 Schematics of the components of a cochlear implant24.

The external part is composed of a microphone, a sound processor, and an
information transmission device. The microphone is generally fitted on the patient’s
ear. It receives sound, converts it to an analogue signal and sends it to the sound
processor. The processor is fixed on the scalp by magnets. It encodes the sound
information into a format that can be used to stimulate the cochlea and transmits the
information to the internal unit. The communication between the external and
internal units is through a radio frequency link across the skin by the transmitter. All
of the components of the external unit are powered by a battery.

The internal unit is powered by the radio frequency link across the skin. It contains a
hermetically sealed electronics package which decodes the data and provides current
stimulation to the electrode array. The Nucleus® 5 cochlear implant made by
Cochlear Ltd. has an electrode array with 22 half-band platinum electrodes. The first
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cochlear implants were designed with only a single electrode, and proved the
concept of direct electrical stimulation of the auditory system by demonstrating that
patients with profound hearing loss could hear environmental sounds and perform
better at lip reading. However, it was not until the development of multiple-channel
cochlear implants that patients began to understand speech25. This is because
multiple distinct stimuli are required to stimulate the auditory nerve system. The
human hearing range is from 20 Hz to 20 000 Hz, and different sound frequencies
cause maximum vibration amplitudes at different points along the basilar membrane,
where low frequency sounds cause the basilar membrane to vibrate with the largest
amplitude of displacement at the apex and high frequency sounds cause the basilar
membrane to vibrate with the largest amplitude of displacement at the base of the
basilar membrane. To mimic the functions of the human cochlea, it is necessary to
design an electrode array embedded with multiple channels to pass the stimulation
along the cochlea, instead of stimulating a single localised position. Australian
pioneer Professor Graeme Clark and his team began their work on multichannel
electrodes in the 1970s26 and provided the foundation for the early Nucleus devices.

1.1.2 Biomaterials in Cochlear Implants
The cochlear implant is required to be placed into the human body and remain there
for a considerably long period to fully perform its function. As such the choice of
materials used to construct the cochlear implant is critical, particularly for those
components that come into direct contact with body fluids and tissues. Specific
criteria and protocols have been developed for the selection of appropriate materials
for cochlear implants. First, the materials used to construct the cochlear implant
surface components must be biocompatible. Second, ensuring long-term stability and
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long-term functioning of the device is a major clinical requirement. These devices
are expected to have an intended functional life of several decades to prevent the
need for revision surgery or for operations to replace the implant, as these processes
can further damage the cochlear and biological auditory apparatus. Furthermore,
certain parts of the implant face considerable mechanical challenges, such as the
need for the implant casing to be able to withstand external forces and for the
electrode array to be both flexible and resistant to breakage as well as possess
desirable electrical properties27.

1 Receiver stimulator
○
2 Implant coil enabling telemetry
○
3 Two extracochlear electrodes
○
for different stimulation modes
4
○
22
half-banded
platinum
electrodes
5 Removable magnets for MRI
○
safety
6 Symmetrical exit leads
○

Figure 1.3 A photo of a Nucleus® 5 cochlear implant (CI512) internal unit24.

The cochlear implant had originally been developed largely out of cardiac
pacemaker technology, in terms of using suitable materials and benefiting from the
production technology28. The following materials have been used in cochlear
implants coming into contact with the human body: silicone, platinum, titanium and
ceramics (Figure 1.3). Silicone forms the backbone of the implanted electrodes. The
stimulation electrode array is made of platinum. The wires that connect the
electrodes to the stimulator are platinum/iridium 90/10 with a Teflon insulating
coating, and are embedded in silicone. The electronics package is tightly sealed in
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either a titanium or ceramic casing, depending on the manufacturer and the implant
model, and in most models the casing is coated with a thin layer of silicone.
Silicones are polymerised siloxanes and have been used in medical research for more
than 60 years due to their good biostability and flexibility. In cochlear implants,
silicone material is the major component that comes into contact with the human
body.

Precious metals are preferred as contact materials where electrical stimulation is
involved. Studies have shown that for platinum electrodes, gas has been observed to
form at electrical stimulation charge densities of 300 µC/cm2 and above29; corrosion
can be observed at 500 µs/pulse and above or at a current density of 2 mA/mm2 and
above30. These values well exceed the parameters used in clinical practice
(30 µC/cm2, 0.9 mA and 25 µs/pulse), which makes platinum an ideal stimulation
electrode material.

1.2 Challenges for Implanted Neural Bionic Devices
After decades’ of development, the cochlear implant has proven to be extremely
successful and has benefited thousands of patients worldwide. However, it continues
to face challenges that are critical to future development and improvement of device
performance. The identification and application of technologies through which
device design and functionality may be enhanced is vital to improving clinical
outcomes for patients receiving the cochlear implant, and remains the key challenge
to researchers in this field.

10 | P a g e

Biocompatibility is critical for materials used in implants that come into contact with
the human body. Biocompatibility is defined as the ability of a material to provide
with an appropriate host response in a specific situation and therefore the materials
used in bionic devices must fulfil this criteria31. For example, there have been
individual instances where silicone materials have generated an allergic reaction or
intolerance that has caused implantation failure32, 33. However, the complication rate
due to silicone intolerance is low, and this complication can be avoided by
individualised compatibility testing prior to implantation to rule out possible allergic
responses. For the majority of cases where post-implantation complications or device
failure occurs, the likely source of these complications are derived from the
mechanical trauma of insertion and/or the tissue foreign body responses at the
implanted neural interface.

1.2.1 Trauma Associated with Implant Insertion
Trauma to the delicate structures of the inner ear frequently occurs during the
insertion of the cochlear implant electrodes. Both the scala tympani (ST) and scala
vestibuli (SV) had been considered as intracochlear compartments for the electrode
array implantation34 (Figure 1.4). However, ST is preferred as it provides closer and
more direct access to the excitable elements within the cochlea, and studies have
demonstrated that patients with electrode arrays implanted exclusively in the ST
performed better in speech perception tests than patients with electrode arrays
implanted in the SV or both the ST and SV35.
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Figure 1.4 Schematics of (A) the cross section of the cochlea and (B) the organ of
Corti.

There are two clinical routes used for ST insertion: either through the round window
membrane of the cochlea or through a cochleostomy placement. The round window
route provides convenient access to the ST, however, deep insertion of the electrode
array can be difficult. This is because the cochlear hook region36 makes it harder for
the array to be guided through the curvature of the cochlea, and the friction between
the tissue and the array can cause rupture of the lateral wall or misplacing of the
array into the scala media or the scala vestibule37. It was proposed in the 1980s38 that
direct access to the intracochlear lumen may be achieved by drilling through the
promontory bone, a procedure that has become known as a cochleostomy. A recent
study39 showed that an initiation drilling from inferior to the round window annulus
is a safer approach than others. This route provides an insertion trajectory where the
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electrode array can be inserted into the cochlea in a straight fashion for 8 to10 mm
until reaching the first basal turn. Therefore this approach is preferred over the round
window insertion40.

The insertion of the cochlear implant generally causes mechanical trauma, as well as
acoustic trauma due to the application of the drilling procedure during the
cochleostomy. Therefore special precautions must be considered to prevent the high
sound pressure level delivered by the drilling which may reach 130 dB and provoke
acoustic trauma41.

Through advanced design of the electrode array and appropriate surgical techniques,
the direct trauma caused by mechanical damage of insertion and acoustic trauma of
cochleostomy drilling can be largely limited. (Details of these solutions will be
discussed in Section 1.3.1) However, studies have shown the preservation of the
functional residual hearing for electrical stimulation could only be achieved in 44%
to 86% of cases after cochlear implantation42,

43, 44, 45, 46

, indicating a mechanism

other than the initial trauma is underlying the postoperative hearing loss.

1.2.2 Tissue Reactions to the Implanted Devices
Implanted materials have been well recognised to induce an inflammatory immune
response that is derived both from the surgical injury during implantation, and the
host body response to the biomaterial itself47,

48, 49

. Generally termed foreign body

response (FBR), the implantation of the biomaterial initiates a series of host
responses that drive several mechanisms that act in concert to facilitate wound and
tissue healing49. There have been several published cases of FBRs resulting from the
implantation of the cochlear implant50,

51, 52, 53

. While major complications from
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FBR are generally rare, in many cases where severe FBR reactions occur there is the
need for revision surgery that often requires explantation of the device. These
complications are often traumatic for the patients whom in some instances chose to
refuse re-implantation of a cochlear implant device. In addition to major
complications, FBR has been linked to the common development of fibrotic tissue
around the implant electrode array, which will increase the impedance and threshold
for the electrical stimulation54, and thus the efficacy of the device.

FBR is primarily directed by the innate immune system response that provides a
non-specific “first line of defence” against injury and the introduction of foreign
materials into the body. The innate immune system employs several avenues to
direct the migration of a range of inflammatory cells, including neutrophils,
macrophages and dendritic cells, to the site of injury. Aimed at “neutralising” foreign
materials and expediting the wound healing process, inflammatory cells may arrive
to the site of injury through both biomaterial dependant and independent
mechanisms. There is evidence that surgical injury alone may attract neutrophils to
the site of surgical injury, while macrophages are not attracted without the presence
of a biomaterial55. Because the size of most implants is orders of magnitude larger
than that of the cells, some of the inflammatory cells fuse to form foreign body giant
cells. The foreign body giant cells release cell signalling molecules and eventually
attract connective tissue cells such as fibroblasts to the region. Ultimately the
implants will be sequestered in a layer of fibrosis cells and lose connection to the
surrounding tissue56,

57

. Foreign body response may be triggered by a range of

factors, including non-mechanical compliance between the biomaterial and
surrounding tissue, friction between the material and neighbouring tissue, and
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specific biomolecular and cellular interactions and responses to a range of material
properties at the biomaterial surface.

1.2.2.1

Inflammatory Response

Acute and chronic inflammatory responses progress immediately after the
development of the primary protein layer on the material surface, sometimes called
the “provisional matrix”. As described by Anderson et al48, acute inflammation is
often characterised by the arrival of multinucleate neutrophils, an abundant type of
white blood cells, which migrate through surrounding tissue to the biomaterial-tissue
interface. Chronic inflammation is characterised by the arrival of mononucleate cells
at the implant site, including monocytes and lymphocytes. During chronic
inflammatory responses, monocytes, macrophages and foreign body giant cells may
be present at the biomaterial interface. Macrophage lineage cells are identified as
being a key component of inflammatory lesions and can perpetuate the host immune
inflammatory reaction, often through the production of inflammatory mediators47.
Acute and chronic host responses to an implanted biomaterial can ultimately lead to
encapsulation of the implant by fibrotic tissue and thus either restrict the ability for a
material to effectively perform the intended functions or result in total device failure.

It is known that the biomaterial surface properties play a key role in modulating the
FBR to the implant, particularly over the first 4 weeks post implantation, although
the FBR is ultimately persistent for the life of the implant48. Critical to the mediation
of host inflammatory responses is the composition and nature of the provisional
matrix that adsorbs to the material surface immediately upon implantation. The
fundamental interactions at the biomaterial-tissue interface are largely mediated by
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an adsorbed protein layer that binds to the material surface within nanoseconds of
being introduced into the in vivo biological environment, and therefore the nature of
this initial protein layer is key to translating the material interfacial properties which
can result in the activation of biomolecular and cellular interactions at the material
interface. Both the identity and conformation of proteins adsorbed to a material
surface have been demonstrated to drive the inflammatory response. For example,
the surface activation of fibrinogen (a plasma glycoprotein) on some surfaces acts to
expose integrin binding domains specific to the activation of phagocyte cells58,

59

.

Other proteins and factors, such as coagulation factor XII, a serum protein that plays
a vital role in the coagulation cascade, have been demonstrated to be surface
activated on synthetic materials, driving a series of biomolecular reactions that result
in the production of thrombin and ultimately leading to the generation of a fibrous
mesh around the biomaterial implant49.

The nature of protein-biomaterial interactions, and therefore their bioactivity at the
material interface, is known to be significantly influenced by material interfacial
properties including surface chemistry, morphology and wettability. As such,
understanding these protein-material interactions is critical to both limiting the FBR
to the implant and enabling the directed design of biomaterials to nullify or control
the host FBR, ensuring the biomaterial performs its desired function efficiently.

1.2.2.2

Biomaterial-Protein Interaction

The adsorption of proteins to a biomaterial surface is a fundamental process that is
critical in determining the ultimate biocompatibility and biofunctionality of an
implant or device. Protein adsorbs to a material surface within seconds following
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immersion into an in vitro or in vivo biological environment, forming a
proteinaceous conditioning layer that effectively mediates all subsequent interfacial
interactions between the material and the surrounding biological environment60, 61, 62.
Moreover, the speed and efficiency of this process makes it reasonable to propose
that cells and tissues may never interact directly with the native biomaterial surface
itself63. The adsorption of proteins to a biomaterial may be either favourable or
detrimental to the function of the implant or device, depending on the intended
application. For example, the immediate adsorption of fibrinogen from blood plasma
to the surface of vascular stents is understood to facilitate coagulation via the binding
of platelets to the stent surface, initiating a cascade of events that may result in local
thrombus (blood clot) formation at the stent, requiring the patient to undergo
treatment with anti-coagulation medication for up to six months post-surgery.
Monocyte and macrophage adhesion behaviour has been shown to be modulated by
both the identity of the surface protein layer and the underlying substratum chemistry,
illustrating biomaterial surface chemistry and adsorbed proteins to act in concert to
mediate subsequent adhesion of inflammatory cells64.

The ability for a material to recruit and retain proteins, as well as influence the
surface bound molecular conformation, has been recognised as being critical to
gaining a fundamental understanding of the nature of the biological responses
elicited from the host cells and tissues. A suite of biomaterial surface properties have
been demonstrated to dramatically alter the fundamental interactions between
proteins and the material surface, and as a result determine the biological
functionality and activity of the surface bound protein. Interfacial material properties
such as surface roughness, energy, chemistry and charge have all been shown to
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influence the nature of protein-substrate interactions. For example, surface
nanotopography has been demonstrated to significantly influence both the mass and
conformation of adsorbed bovine serum albumin (BSA) as a function of surface
topography on both stochastically rough and discrete surface geometries 65,

66, 67, 68

.

Large proteins such as fibrinogen and fibronectin have also been shown to alter in
total adsorbed mass and bioactivity as a function of surface topography69, 70. Surface
energy, or wettability, has been demonstrated to considerably alter the nature of
protein-surface interaction, with both protein mass and protein conformational
dynamics significantly altered on surfaces of varying wettability71. Several
extracellular matrix proteins have been demonstrated to vary in the degree of
adsorption as a function of surface wettability and undergo significant molecular
reorganisation upon adsorption to hydrophobic surfaces72. In one study, the
bioactivity of the extracellular protein fibronectin was illustrated to be enhanced
upon adsorption to a hydrophilic surface, resulting from the surface-induced
extension of the dimer arms that presented a more bioactive conformation73.

However, the specific nature of protein interactions with surfaces can be ambiguous,
with reports in the literature often presenting varying and conflicting data. It is clear
that protein-surface interactions are complex and generalisations regarding the
mechanics of protein interaction with surfaces as a function of a particular surface
property are difficult. It is likely that a range of material interfacial properties,
including surface chemistry, topography, charge and wettability, act in concert to
guide protein adsorption and conformation to the material surface.

1.2.2.3

Protein Adsorption to Bionic Devices
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Depending on the specific application, protein adsorption to a bionic device may be
highly desirable, or alternatively highly problematic. As discussed earlier, the
fundamental role of the cochlear implant is to deliver an electrical signal derived
from the translation of an external audible signal via a microphone directly into the
inner ear through a platinum electrode array, providing a stimulus to the
neighbouring neural cells. The electrode transmits the electrical signal through an
electrolyte solution known as perilymph in the cochlea, containing a suite of proteins
that are known to bind to various components of the implant, including the platinum
electrodes themselves. The adsorption of protein to electrode surfaces has been
shown to increase the impedance of the electrodes and therefore is detrimental to the
performance of the implant74. Additionally protein adsorption may result in the
development of foreign body responses and the migration of cells to the electrode
surface, resulting in the fibrous encapsulation of the electrode and in turn greatly
impeding the ability for the electrode to deliver the electrical stimulus to the desired
cells and tissues.

1.3 Solutions

for

the

Implanted Bionic Devices

Interface
Innovative advancements in material design and fabrication, and surgical techniques
are in demand for the cochlear implant to meet the challenges at the implanted neural
interface which have been discussed in the previous sections. A number of solutions
have been sought to address the raised issues. The focus has been on developing
advanced designs and sophisticated clinical routines to minimise the insertion trauma,
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incorporating drug delivery systems to prevent the inflammatory reaction or nerve
degeneration, and enhancing biomaterial properties to optimise the neural-implant
interface.

1.3.1 Design of Electrode Arrays
The cochlear implant electrode array consists of silicone with multiple-channel
electrodes that has been the result of continual development of advanced signal
processing and micro-scaled fabrication techniques. The electrode array’s stiffness,
size, shape and insertion depth all have important impacts on insertion trauma during
surgery and therefore affect the post-implantation performance of the device. Three
goals are widely accepted for the future design of cochlear implant electrode arrays75.
First, the electrode array design must aim for an atraumatic insertion and minimise
the associated intracochlear damage during surgery. Second, greater operating
efficiency is desired as it provides the cochlear implant with a reduction in the
stimulus charge that is required to produce a comfortable loudness level. Third, a
deeper insertion into the scala tympani is desirable as the regions with low frequency
sensing neurons are located further along the cochlear spiral and have been shown to
be important for distinction of the primary speech formants76, 77.

Figure 1.5 MED-EL MAESTRO electrode arrays featuring wave-shaped platinumiridium wires which make the electrode arrays ultra-flexible78.
20 | P a g e

Silicones have been chosen as the carrier material for the cochlear implant electrode
arrays for their excellent flexibility and biostability. The manufacturers have since
been developing the electrode arrays towards soft and flexible features in order to
reduce insertion force and surgical trauma to help preserve residual hearing. MEDEL GmbH (Austria) has designed their MAESTRO electrode arrays with waveshaped platinum-iridium wires (Figure 1.5), which reduces the rigidity by half
compared to a straight-wire electrode array78. The Nucleus 24 series device
(Cochlear Ltd, Australia) added a tapered soft tip to decrease trauma during
insertion79.

A

B

Figure 1.6 Photographs of the Contour electrode array (Cochlear Ltd.) with 22 halfband platinum electrodes on the modiolar side of the silicone carrier: with the stylet
in place (A), the electrode array is held nearly straight; the electrode array recoils (B)
after the stylet has been withdrawn80.

21 | P a g e

The efficiency of an electrode array can be increased by positioning it closer to the
neural element to reduce the stimulation thresholds. The conventional straight
electrode array possesses an upward bending force when inserted into the spiral
shaped cochlea, which forces the array away from the modiolus (central axis in the
cochlea) and the spiral ganglion neurons which are the target cells for stimulation.
This upward bending force has also caused most damage to the lateral wall during
insertion. To overcome this challenge, a “perimodiolar” electrode array design has
been introduced. The Cochlear Ltd designed their Contour electrode with a precoiled shape, and used an Advance Off-Stylet (AOS) system to help with insertion
(Figure 1.6). The electrode array is straight while the stylet is held in place, so
surgeons can easily insert the electrode array into the cochlea through the
cochleostomy. When the marker approximates the cochleostomy (Figure 1.7),
indicating the tip is reaching the first basal turn, the stylet is held in place while the
electrode array is being inserted, which makes the electrode array curve towards the
modiolus. The array is slowly pushed off the stylet while inserted into the cochlea,
and eventually removed from the stylet. This AOS technique will eliminate contact
of the precurved array with the lateral wall therefore largely avoiding incidence of
damage during insertion. Analyses have indicated that the perimodiolar electrodes
are positioned closer to the modiolus than the standard straight arrays and result in
less insertional force and intracochlear trauma80, 81.
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A

B

C

D

Figure 1.7 Schematic of the Advance Off-Stylet technique79. (A) the electrode is
inserted until the marker “1” approximates the cochleostomy site, (B) the stylet is
held in place as (C) the array is slowly advanced off of the stylet, and (D) removed
from the field.

The elimination of contact between the precurved array and the lateral wall mainly
relies on the electrode array being pushed off the stylet at the first basal turn before
contact occurs, and the preformed electrode array curving towards the modulus. If
the stylet-inserted electrode array reaches the lateral wall before the array is
advanced off the stylet, the contact will not be eliminated and often results in
penetration of the basilar membrane82. Therefore it is critical to obtain an accurate
estimation of the ideal insertion depth for the stylet tip. However, there is large
variation in the distance from the cochleostomy site to the beginning of curvature in
the first cochlear turn, and the dimension can vary by more than 50 percent ranging
from 4.60 mm to 8.21 mm75. Therefore the standard marker for the AOS insertion
should only be used as a guide. Imaging techniques such as computed tomography
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(CT) have been proposed to obtain accurate data of a patient’s cochlea prior to
surgery83.

1.3.2 Localised Drug Delivery in the Inner Ear
Minimising the damage to the inner ear and retaining the excitable sites for
stimulation are the keys to achieving the best performance for the cochlear implant.
The atraumatic cochlear implant design and advanced surgical techniques could
largely reduce the mechanical and acoustic trauma caused by cochlear implant
insertion and preserve the hair cells during the implantation. However, the
sensorineural hearing loss due to the damage of the hair cells has a secondary effect
which leads to the degeneration of spiral ganglion neuron cells84. The spiral ganglion
neurons are essential for the electrical stimulation of the cochlear implant as they are
part of the target of the stimulation and transmit signals containing sound
information back to the brain. Hence the application of pharmaceutical agents will
not only reduce and treat the trauma and inflammatory response caused by cochlear
implantation, but also prevent and revive the sensory and neural cells in the cochlea
from degeneration.

Localised delivery of pharmaceuticals has been identified and developed as a key
area of research for several reasons. The inner ear is relatively isolated and protected
by several homeostatic mechanisms including a blood-labyrinth barrier to maintain
the functional integrity of the inner ear fluid85,

86, 87

. Thus it is difficult for the

applied molecules to reach necessary concentrations in the inner ear through oral or
systemic administration. Studies have shown that systemic administration of
medications by injection or infusion leads to poorly controlled concentrations in the
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inner ear and exposes the rest of the body to adverse effects of the drugs88,

89

. The

isolation of the inner ear in fact makes it a good candidate for localised delivery,
which will limit the side effects for the rest of the body. The potential of using the
cochlear implant electrode array as a carrier for drug delivery has also attracted
broad attention. The advantage of using the electrode array as a drug carrier is
obvious, because no additional invasive surgery is needed after the implantation,
hence eliminating further damage to the inner ear or the risk of infection. Several
research teams have started to investigate the potential of developing an integrated
drug delivery system on the electrode array90, 91, 92.

1.3.2.1

Localised Delivery Substances

A wide range of substances have been identified or are under investigation for their
therapeutic effects in the inner ear to protect and preserve the hair cells, spiral
ganglion neurons and supporting cells of the cochlea. These substances include antiinflammatory agents, antioxidants, neurotrophic factors, as well as cells and genes.

Glucocorticoids have demonstrated their effects in both the brain and the inner ear
as anti-inflammatory agents. By binding with the glucocorticoid receptor,
glucocorticoids up-regulate the expression of anti-inflammatory proteins and downregulate the expression of pro-inflammatory proteins. Dexamethasone is one of the
most commonly used glucocorticoids as an anti-inflammatory drug, and has been
employed to treat inner ear disorders. Studies have shown the application of
dexamethasone effectively conserves hearing during cochlear implantation and
prevents post-surgery trauma and inflammatory responses93, 94. Localised delivery of
dexamethasone into the inner ear is preferred, not only because it reaches the
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effective concentration in a much shorter time compared to the systemic route, but
also the topical dexamethasone application does not result in systemic absorption in
the body95. Dexamethasone sodium phosphate is a stable prodrug that is commonly
used as a salt form of dexamethasone and will be converted efficiently into the free
dexamethasone after delivery into the human body96. The major difference between
the sodium phosphate and the base forms of dexamethasone is their solubility in
different solvents. Dexamethasone sodium phosphate is highly soluble in aqueous
solutions with almost no solubility in organic solvents while the dexamethasone base
has high solubility in organic solvents and very limited solubility in aqueous
solutions97. Both forms of dexamethasone are widely used.

Antioxidants such as trolox and ascorbic acid are often used to protect the spiral
ganglion neuron cells from trauma or ototoxicity. The antioxidant can counteract the
free radicals formed during the ototoxic trauma, thus demonstrate protective effects
on the spiral ganglion neurons and preserve their electrical responsiveness. Studies
have shown that treatment with antioxidants can improve the electrical hearing
threshold and increase the number of surviving spiral ganglion neurons98.

Neurotrophic factors are a family of proteins that act as regulators of neuronal
differentiation. The neurotrophins family including nerve growth factor (NGF),
brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin4/5 (NT-4/5) play important roles in neuronal differentiation and neuronal survival99.
BDNF and NT-3 are produced and released by the hair cells in the sensory
epithelium of the cochlea, thus the initial hair cell loss in the sensorineural hearing
loss leads to a secondary degeneration of spiral ganglion neurons due to the
insufficient neurotrophin supply100,

101, 102, 103

. The degeneration of spiral ganglion
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neurons progresses over time and largely limits the performance of the cochlear
implant, because the spiral ganglion neurons are not only a part of electrical
stimulation target, but also the path to transmit the auditory information to the brain.

Cell-based and gene therapies have also been employed in the treatment of
sensorineural hearing loss104. There are two major strategies. The first is to deliver
cells to replace damaged or degenerated hair cells, spiral ganglion neurons and
neurons in central nervous system105. This cell delivery provides potential benefits
including increasing the viability of neurons and other auditory cells or replacing the
missing cells required for processing and transmitting the auditory signals to the
brain. The second strategy is to produce protective or therapeutic molecules such as
BDNF and neurotrophin within the cochlea106,

107

. This can be achieved by

delivering genes to target cells in the cochlea or implanting cells that produce these
molecules naturally or through genetic modification.

1.3.2.2

Localised Delivery Techniques

There have been two main strategies to deliver drugs into inner ear, intratympanic
delivery and introcochlear delivery108. Intratympanic delivery involves positioning a
drug carrier in the middle ear and relying on the diffusion of drug through the round
window membrane into the scala tympani. Intracochlear method requires a
cochleostomy and directly delivers drugs into the inner ear.

The advantages of intratympanic delivery include ease of access, and less surgical
trauma compared to the intracochlear method. However, the round window
membrane presents a physical barrier for the drugs to diffuse through and acts to
select drugs with specific size and constitution109,

110

. Researchers have observed a
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great variability of the thickness and conditions of the round window membrane,
which makes it very difficult for dosage control from patient to patient111,

112

.

Furthermore, the delivery into the cochlea relies on drug dispersion throughout the
scala tympani, which may develop large concentration gradients and limited access
to the apical regions. The intracochlear delivery overcomes the disadvantages of
intratypanic delivery and provides direct access to neural and sensory cells in the
cochlea. The drawback of intracochlear delivery is the need for a cochleostomy
which leads to the risk of infection and surgical trauma. Therefore a strategy has
been proposed to integrate a drug delivery system into the cochlear implant to
eliminate multiple operations and at the same time to improve the device
performance. The materials and systems include inherently conducting polymers,
bioactive coatings, as well as sustained release materials, and will be reviewed in the
following sections.

1.3.2.2.1

Inherently Conducting Polymers

Inherently conductive polymers (ICPs) are a group of organic polymers that have
similar electrical and optical properties to those of metals and inorganic
semiconductors. It was first reported in 1977 by Alan MacDiarmid, Hideki
Shirakawa and Alan Heeger when they published their seminal work on increasing
the conductivity of polyacetylene by 10 million-fold, which opened a whole new
research area and won them the Noble Prize for Chemistry in 2000113. However,
polyacetylene has obvious limitations such as difficulty in processing and instability
in air. A group of polyheterocycles has attracted much more attention for their good
stability, conductivity and ease of synthesis. These polyheterocycles include
polypyrrole (PPy), polythiophene (PTh), polyaniline (PAn) and poly(3,4-
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ethylenedioxythiophene) (PEDOT). In particular, PPy and PEDOT have attracted
enormous interest,

as

they have been proved to

demonstrate

inherent

biocompatibility and possess favourable mechanical and electronic properties, and
therefore have been widely explored for a suite of biomedical applications, including
in drug delivery114, 115, 116.

ICPs are formed by oxidative polymerisation of monomers. The polymerisation can
be achieved either chemically by using a chemical oxidant, or electrochemically at
an electrode by applying an oxidising potential117. The electrochemical
polymerisation is often favoured in the application of drug delivery. The
polymerisation reaction of PPy can be represented simply as in Equation 1.1:

Equation 1.1 Oxidation of polypyrrole from pyrrole monomer solution.

A- is a counterion to balance the positive charge on the conducting polymer
backbone. The oxidation potential of the pyrrole monomer is higher than that of the
polypyrrole, so the newly formed polymer is in the oxidised form118. The counterion
is attracted by the positive charge and incorporated into the polymer in a process
normally called “doping”, and the counterion is also called a “dopant”. A theoretical
ratio between the PPy monomer unit and the counterion is 3 to 1, and ideally the
counterion is incorporated between the PPy planes119. However, the reported ratio of
the anionic dopant to the monomer unit is between 0.25 to 0.33120,

121, 122

. This is

because in the real polymerisation, the polymer chains are not planar but form a
29 | P a g e

distorted and crosslinked structure, hence the counterions are incorporated both by
ionic attraction and physical entrapment117.
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Figure 1.8 Atomic force microscopy topography images of polypyrrole-dextran
sulphate (PPy-DS) films. All films were electrochemical polymerised with 0.2 M
pyrrole at 0.25 mA/cm2 constant current density, while the dopant DS concentration
was 0.2 mg/mL for the top two films (A, B) and 20 mg/mL for the bottom two (C,
D); the polymerisation time was 1 min for films A and C and 10 min for C and D,
respectively123.

Research on ICPs for biomedical applications expanded largely during the 1980s and
1990s since ICPs were found to be compatible with many biological molecules, and
through the delivery of electrical stimulation ICPs were shown to be capable of
modulating cellular activities such as cell adhesion, migration and protein
secretion124,

125, 126

. In parallel with the development of bionic devices, researchers
30 | P a g e

have investigated the application of ICPs as neural electrode coatings due to their
demonstrated ability to interface and communicate effectively with biological
systems127. The neural interfacing electrode relies on effective ion exchanges
between the electrode and the surrounding tissue for stimulation and signal recording.
ICPs can achieve high surface area while maintaining a small geometric area. A
large surface area will increase the electrode capacitance and decrease the impedance,
thus improve signal-to-noise ratio, which will improve the performance of neural
probes. Studies show that the surface morphology of ICPs can be easily modulated
through electrochemical polymerisation conditions by varying polymerisation time,
current density, and dopant concentration (Figure 1.8)

123

. PPy has been widely

explored as a coating on neural probes aimed at optimising the traditional metal
electrode surface128,

129

. Therefore, employing ICPs as a drug delivery system will

perfectly suit the strategy of integrating drug delivery capabilities into the next
generation of the bionic device implants as discussed in the beginning of Section
1.3.2.

-

-

-

-

- 2e + 2A

+ 2e - 2A

Equation 1.2 Redox reaction of polypyrrole in electrolyte solution117.
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The basic mechanism underlying the ICP drug delivery system is that the ICPs can
undergo controllable and reversible redox reactions (Equation 1.2). As discussed
previously, PPy is in an oxidised state after synthesis, where the polymer backbone
is positively charged and the anions are doped into the polymer. When a reducing
potential is applied to the PPy film, the overall charge of the polymer backbone is
neutralised by the electrons, hence there is a loss of electrostatic attraction between
the film and the anionic dopant that results in the movement of mobile anions
(Equation 1.3 A)130. Anionic drugs such as dexamethasone phosphate and naproxen
sodium can be incorporated as dopants during the electrochemical polymerisation
process and have been successfully released from PPy films through the application
of a reducing potential131,

132, 133

. However, not all the anionic dopants can be

released during reduction as the mobility of the dopants depends on their size and
steric properties, as well as the morphology of the polymer133. For example, when
multicharged anions such as polystyrene sulfonate (PSS) or melanin are used as
dopants, they are immobilised within the PPy. However, this property can be
exploited and used to incorporate and release cationic drugs. During the redox
reaction, when the polymer backbone is reduced, anionic dopants are unable to
exchange out of the PPy films, and therefore the mobile cations in the surrounding
electrolyte solution will move into the polymer to balance the charge (Equation 1.3
B)121. Cationic dopamine was incorporated into PPy derivatives using this method,
where poly (N-methylpyrrole) films were prepared with PSS as the primary
immobilised dopant. Following the incorporation, when the ICP was oxidised the
overall charge became positive and the dopamine was released from the film134, 135.

(A)

PPy+/A- ↔ PPy0 + A-
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(B)

PPy+/A- + B+ ↔ PPy0/A-/B+

Equation 1.3 Redox reaction of PPy, where A- is an immobilised anionic dopant and
B+ is a cation.

The application of electrochemical redox processes for drug delivery systems
requires that the candidate drugs should not be electroactive in the range of the
potentials applied to the redox reaction, as the biological activity of the drug may be
compromised. Dexamethasone phosphate as discussed previously is a good
candidate, however, most bioactive molecules, especially pharmaceutical drugs, have
been reported to cause difficulties when incorporated during synthesis. These drugs
either interfere with the polymer growth or decrease the adherence of the polymer to
the underlying electrode130,

136

. A good adherence between the polymer and

underlying electrode is necessary for the application of the redox potentials required
to release the drugs. To overcome this issue, a double-layered synthesis was reported,
where a sophisticated dopant para-toluene sulphonic acid (pTS) was used to form an
initial thin layer on the electrode, followed by a second layer of both pTS and the
bioactive drug as co-dopants136.

The use of ICPs for drug delivery systems has many attractive advantages, including
precise control of release, improvement of neural interfacing electrodes and the
seamless incorporation into bionic implant devices. However, not all pharmaceutical
drugs possess a charge or have ionic precursors, therefore incorporation and release
by electrostatic attraction can only be applied to a limited range of drugs.
Nevertheless many novel approaches have been explored to overcome this limitation.
For example, a biotin-streptavidin binding system was developed based on PPy137.
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The anionic biotin was used as the primary dopant during the PPy synthesis, and the
films were then incubated with streptavidin. Because streptavidin has four biotin
binding sites, after adhesion to the biotin dopant at the PPy surface, it still possesses
open sites to bind biotin-labelled drugs. A biotinylated NGF138 was used for this
study, and showed that the biotinylated NGF was able to be incorporated and then
released during redox reactions while retaining its bioactivity (Figure 1.9).

Biotin
Biotinylated NGF
PPy
Streptavidin

PBS

Pt mesh

Figure 1.9 Schematic of electrically triggered release of biotinylated NGF from
biotin dopped PPy137.

For all the methods that have been discussed above, the drug loading capacity of a
conventional ICP film is limited by the ratio between the monomer and the dopant.
While increasing the electropolymerisation time will certainly result in the
incorporation of more drug into the film, it will also result in a much thicker film and
prevent the migration of drug molecules from inside the film to the surface layer. To
overcome this issue, novel strategies have been introduced in the ICP drug delivery
system. A sponge-like nanostructured PPy film139 was designed for drug delivery
(Figure 1.10 A). The electrode was first deposited with polystyrene nanobeads, and
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then

immersed

into

a

pyrrole

monomer

solution

to

carry

out

the

electropolymerisation. After the polymerisation the polystyrene nanobeads were
dissolved away in toluene, leaving a nanoporous PPy film on the electrode. This
nanoporous PPy film was then loaded with drugs and sealed with a thin PPy layer on
top to prevent the stored drug from leaking. The anti-inflammatory drug
dexamethasone and fluorescein sodium salt were able to be loaded into this
nanoporous PPy film, and be released on the application a voltage of -2.0 V or 0.5 V140.

Carbon nanotubes (CNTs) have also been incorporated into PPy films to act as
reservoirs to increase the drug loading capacity141. Multi-wall CNTs were first
treated with acid sonication to open the ends of the nanotubes and make them more
hydrophilic. The pretreated CNTs were loaded with dexamethasone and then sealed
with PPy through electropolymerisation (Figure 1.10 B). It was shown that this
approach not only effectively increased the drug storage, but also enhanced the
ability to release dexamethasone in a controlled manner and for a sustained period
using electrical stimulation. Incorporation of CNTs into ICPs can improve the
electrode performance, especially for the applications in high density chronic neural
stimulation. CNT-incorporated PPy or PEDOT exhibit remarkably lower impedance
by 1-2 orders of magnitude compared to conventional ICPs, and show much
improved mechanical and electrochemical stability during prolonged and intensive
electrical stimulation142, 143, 144.

ICP nanotubes have also been fabricated for precisely controlled drug release145. The
fabrication process involved electrospinning of dexamethasone loaded poly(lacticco-glycolic acid) (PLGA) onto a neural electrode, followed by electropolymerisation
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of PEDOT around the electrospun PLGA fibres (Figure 1.10 C). The PEDOT
nanotube coating effectively slowed down the dexamethasone release from the
PLGA fibres, and showed precise control over drug release through electrical
stimulation. The PEDOT nanotube coated neural electrode demonstrated enhanced
quality of recording signals by increasing the signal-to-noise ratio by 30% compared
to uncoated sites146.
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Figure 1.10 Schematics of different drug delivery system approaches. (A)
Nanoporous PPy film was prepared by (2) electropolymerising PPy on a polystyrene
nanobeads template (1), followed by dissolving the polystyrene (3) and loading drug
(4); the drug loaded film was then sealed with a thin layer of PPy, and could release
drug by applying potentials140. (B) Drug solution was filled into the interior of
pretreated CNTs through sonication (I); pyrrole was then added into the suspension
and formed PPy to seal the CNTs by electropolymerisation (II); the drug could be
released from CNT nanoreservoirs through diffusion or electrical stimulation141. (C)
Drug-containing PLGA was first electrospun onto an electrode, and then coated with
PEDOT (a); the drug release from PLGA fibres was slowed down by the PEDOT
nanotubes, and could be controlled by electrical stimulation (b); (c) and (d) are
scanning electron micrographs of PEDOT nanotubes145.

ICPs have shown great potential for biomedical applications. ICP based drug
delivery systems have attracted increasing attention due to their unique capability to
precisely control the release of bioactive molecules while at the same time to
simultaneously improving the electrical properties of the neural electrode. ICP drug
delivery systems have been proven to be versatile systems through which various
approaches can be employed to tailor the physiochemical properties and
functionality of the ICPs for specific biomedical requirements. In addition to the
approaches discussed above, the biocompatibility of ICPs can also be enhanced by
methods such as varying the dopant or through surface modification, which will be
reviewed in the following sections.

1.3.2.2.2

Bioactive coatings

The conventional materials used for bionic devices such as PDMS, platinum, and
gold all have very different mechanical properties and moduli compared to the
surrounding body tissue. This causes problems including foreign body response,
chronic inflammatory, and ultimately rejection of the implanted devices. Releasing
anti-inflammatory agents to the surrounding tissue could provide a solution to these
problems. For example nitrocellulose coatings have been developed for delivery of
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α-melanocyte stimulating hormone (α-MSH) and dexamethasone from silicon
recording electrode arrays147, 148, 149. The coating was tested both in vitro and in vivo
to show that the drug release from the coating reduced scar tissue formation without
adversely affecting the electrical performance of the silicon electrodes.

Another strategy is to coat the implant with materials that have mechanical
properties mimicking that of soft tissue, such as hydrogel. Hydrogels are crosslinked
hydrophilic polymer networks which can adsorb water from 10-20% up to thousands
of times of their dry mass150. Hydrogels are widely used in tissue engineering as
scaffold materials due to their high water content and physiochemical similarity to
native extracellular matrix151. Their porosity provides the capability for sustained
delivery of bioactive molecules, such as drugs, proteins, and growth factors. The
hydrogel network can be crosslinked through electrostatic or covalent bonds between
polymers. Recently a photo-crosslinkable hydrogel system has been investigated as a
neurotrophin-eluting coating for neural prosthetic devices152,

152

. The hydrogel was

based on poly(ethylene glycol) and poly(lactic acid) (PEGPLA). Neurotrophincontaining PEGPLA precursor solution was applied to an iridium oxide electrode
array surface, with crosslinking induced via UV irradiation. The drug eluting profile
of hydrogel coatings may be further enhanced through surface modification with
polylysine to promote neural adhesion153 or the incorporation of poly(ε-caprolactone)
(PCL) electrospun fibres to prolong the sustained release time154. Most importantly,
the coating showed little impact on the iridium oxide electrochemical properties.

1.3.2.2.3

Sustained Release Materials

Bionic devices such as the cochlear implant are designed to be implanted and
functional for a period of several years to decades. The implantation induced trauma
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and inflammation in some cases can accompany the implant for significantly longer
than the period immediately after implantation, and effect the ultimate performance
of the device for the rest of its functional life. The ability to mitigate or nullify the
impact of the initial harmful biological responses through the sustained release of
therapeutic drugs directly at the site of injury may provide enormous benefit that can
improve the quality of chronic neural recording and the delivery of electrical stimuli
to target tissues. The potential of using the silicone rubber coating on the cochlear
implant as a hybrid drug-eluting system has been investigated155. Therein it was
demonstrated that a sustained release period up to 600 days could be achieved, and
the drug release rate could be controlled by the drug loading percentage and the
crosslink density of the silicone rubber matrix.

Nanoparticles (NPs) have been exploited for sustained release of anti-inflammatory
agents and other bioactive molecules. Poly(lactic-co-glycolic acid) (PLGA) NPs
could be prepared using an oil-in-water emulsion/solvent evaporation method156,

157

or bulk emulsion technique158. PLGA NPs can be coated onto a medical device or
embedded into a hydrogel coating. Studies have shown dexamethasone loaded NP
coatings on an electrode surface to exhibit a sustained release profile for up to 3
weeks, during which the electrodes were able to maintain the initial low in vivo
impedance156. A similar approach was employed using poly(propylene sulphide)
NPs to prepare drug-eluting coatings for cortical neuroprostheses159. Poly(propylene
sulphide) NPs were loaded with dexamethasone and embedded in a poly(ethylene
oxide) matrix. Dexamethasone was released by both the oxidation of poly(propylene
sulphide) and diffusion. Compared to uncoated devices, NP coated electrodes
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showed an overall reduction in post-implantation impedance at the end of the 46 day
experiment.

1.3.3 Surface Modification
Surface modification of materials is one method employed to either enhance or
prevent protein and cellular adsorption to a given substratum. For materials
traditionally used for neural bionic devices, such as platinum and silicones, a range
of techniques have been employed to control biological interactions to the material
surface, including modifying the interfacial material properties or tethering specific
polymers to the material surface.

1.3.3.1

Surface Modification of Polydimethylsiloxane

Polydimethylsiloxane (PDMS) has been widely employed for biomedical
applications due to the ease of moulding, optical transparency, ease of binding with
other materials, non-toxicity and mechanical compliance with biological tissues160.
As such PDMS has been used for a range of biomedical implants and devices, as
well as in lab based microfluidic devices for bioseperations, biosensing and
bioassaying of materials and drug interactions with a range of cell types.

In order to limit nonspecific protein adsorption to the polymer surface, PDMS has
been functionalised either by modulating its inherent properties or grafting
biomolecules onto its surface. The surface chemistry, modulus and nano-roughness
can be modulated by altering the crosslinking ratio during PDMS polymerisation.
Combining these modification techniques with UV treatment activates the polymer
surface energy and was demonstrated to significantly alter the adhesion of Caco-2
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cells, which was largely found to be mediated by the nature of protein adsorption,
indicating an alternation of protein interaction with PDMS surface161.

PDMS has been functionalised with poly(ethylene oxide) (PEO)162, poly(ethylene
glycol) (PEG)163,

164

and zwitterionic chemistries (i.e. phosphorylcholine165) by

grafting of molecules to the PDMS surface. Grafting of PEG-NH2 to PDMS
modified with 3-glycidoxypropyltrimethoxysilane resulted in a decrease of
nonspecific protein adsorption of up to 80%164. PDMS modified with PEO chains
was shown to reduced adsorption of fibrinogen from buffer by 90% and from plasma
by 85%162. PDMS has also been surface functionalised by grafting polysaccharides
to the PDMS surface to impart specific biofunctionality to control subsequent protein
and cellular interactions166, 167. For example, heparin, one of the polysaccharides, had
been grafted to PDMS via a heterobiofunctional PEG spacer yielding surfaces that
exhibited low nonspecific protein adsorption.

1.3.3.2

Surface Modification of Platinum

Modulating the nano-topography of platinum has been demonstrated to alter the
binding of protein to the metal surface66. Therein the mass of bovine serum albumin
(BSA) binding to the platinum was found to increase with the increase in nanoroughness beyond the relative increase in surface area. The increase in adsorbed
mass on the rough platinum was found to result from a more compact, dehydrated
BSA conformation presented at the platinum interface that likely accommodated an
increase in mass density through more efficient protein packing at the substrate.
Surface modification of platinum electrodes with thiolated PEG has been shown to
decrease the adsorption of fibrinogen and BSA by 92%, however, the PEGylation of
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the platinum electrode resulted in a moderate increase in impedance over a broad
frequency rage below ~104 Hz74.

1.3.3.3

Surface Modification of Inherently Conducting Polymers

Inherently conducting polymers (ICPs) are a flexible material platform to which a
range of techniques may be used to modify polymer surface properties in an attempt
guide interfacial protein interactions. Plasma treatment of ICP materials has been
employed as a “link free” technique by which to covalently bind cell adhesion
molecules to the polymer surface168,

169

. Using this technique the proteins

tropoelastin and collagen I were covalently bound to polypyrrole, with modified
films exhibiting enhanced cellular adhesion and spreading compared to untreated
films168.

Proteins and peptides have also been incorporated into ICP films either by acting as
dopant species128,

129, 170

or entrapment in the polymer matrix via their presence in

the polymerising electrolyte during polymerisation170, 171, thus presenting the protein
chemistry at the material interface. The tethering of proteins to the conducting
polymer monomeric unit may also be used to present the protein at the polymer
interface. Monomers functionalised to produce amine reactive polypyrrole copolymers for the tethering of a range of proteins, including those presenting cell
adhesion motifs and growth factors, have been explored to enhance cellular
interactions with the ICP surface172, 173, 174. The chemistry of the dopant species may
also be exploited to bind proteins to functional groups on the dopant that are
presented at the polymer interface. Poly(lysine) and laminin have been tethered to
polypyrrole using the carboxylic acid groups on the polyglutamic acid dopant, and
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collagen I has been anchored to functional groups on the extracellular matrix dopant
chondroitin sulphate exposed at the polymer interface175, 176.

Although there has been significant effort expended in the optimisation of protein
interactions with ICP, few studies have focused on preventing non-specific protein
adsorption to the ICP surface177. Reactive coupling of poly(ethylene glycol) (PEG) to
electroactive polyaniline films via N-alkylation has been demonstrated to reduce
adsorption of the proteins BSA and γ-globulin to the polymer surface, as well as
inhibit platelet adhesion178. More recently, thiolated methoxy-PEG has been tethered
to the surface of electrochemically polymerised polypyrrole doped with dextran
sulphate (PPy-DS) via the thiol-ene reaction as a method to inhibit protein and
cellular adhesion179. Therein PEG modification of the conducting polymer surface
was optimised by increasing PEG molecular weight, and optimising the efficiency of
the thiol-ene binding by increasing reaction temperature and reaction solution pH.
Under optimised reaction conditions, the PEG modified PPy-DS films were found to
reduce adsorption of the important extracellular protein fibronectin from a 50 µg/mL
solution by 94%. The PEG modified PPy-DS was demonstrated to completely inhibit
the adsorption of primary skeletal myoblast cells under normal in vitro cell culture
conditions.

1.4 Fabrication

Techniques

in

Biomedical

Applications
Over the last decade, the emergence of the field of biofabrication has been celebrated
as a critical research discipline that promises to bridge the life, physical and
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engineering sciences to address global priorities. At the most fundamental level,
biofabrication has been defined as the “production of complex living and non-living
biological products from raw materials such as living cells, molecules, extracellular
matrices, and biomaterials”, and can be applied to diverse areas such as biomedical
science, sustainable energy generation, sensing and even the production of “animal
free” food and leather products180. Recent advancements in biomaterial fabrication
technologies and biomaterial chemistries has seen a dramatic increase in research
focusing on the development of three dimensional (3D) tissue engineering
scaffolds181,

182, 183

, and even the printing of live cells and tissue184,

185

. The scale,

morphology and spatial organisation of structures and biochemistries in three
dimensions demands a suite of innovative fabrication technologies be employed to
tackle the construction of biologically relevant structures. Biofabrication techniques
employed for these applications include wet spinning, electrospinning, extrusion
printing, laser sintering and biospraying. Of these, printing has been identified as a
particularly critical to meeting a number of materials fabrication challenges for
several niche biomedical applications.

1.4.1 Printing in Tissue Engineering
The application of printing technologies to the field of biomedical science, termed
bioprinting, has been defined as “the use of computer-aided transfer processes for
patterning and assembling living and non-living materials with a prescribed 2D or
3D organization in order to produce bio-engineered structures serving in regenerative
medicine, pharmacokinetic and basic cell biology studies”186. Printing may be
broadly separated into two categories, “contact” and “non-contact” printing. Contact
printing involves the direct transfer of a given “ink” from one surface to another, and
44 | P a g e

includes printing technologies such as dip pen lithography, extrusion printing and
soft lithography. Non-contact printing involves the delivery of the ink without direct
contact between the dispensing unit and the printed surface, with inkjet printing and
laser sintering examples of this method.

Tissue engineering involves the development of biological substitutes that restore,
maintain, or improve tissue function. This process may involve the assembly of three
dimensional constructs from a suite of materials designed to facilitate cell and tissue
ingrowth upon incubation into an in vivo or in vitro environment, the direct printing
of live cells to form pseudo tissue assemblies, or a combination of the two
approaches. Printing techniques have played an important role in the development of
three dimensional biomaterials, with both inkjet and extrusion printing employed as
additive fabrication techniques through which intricate structures may be developed.

Critical to the development of biofunctional tissue constructs is the spatial
distribution of bioactive growth factors and therapeutic drugs that may act to guide
cellular processes such as proliferation, migration and differentiation within
fabricated tissue engineering structures. While the spatial distribution of bioactive
compounds in three dimensions is seen as important to the eventual development of
functional biological structures, the loading of drugs into printable biomaterials has
also facilitated the exploration of employing biofabrication to produce drug delivery
coatings that may be printed onto biomaterial surfaces, or the complete fabrication of
drug eluting implants.
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1.4.2 Inkjet Printing
Inkjet printing has become a powerful tool for the precision patterning and
fabrication of intricate structures for biomedical applications187,

188, 189

. Inkjet

printing has been embraced by tissue engineering researchers not only due to the
ability to print structures with high resolution, but also due to the affordability and
accessibility of the basic technology, negating the need for extensive instrument
developmental work. The facile design of printed structures and patterns using
computer software is also a distinct advantage.

There are generally two types of inkjet printing techniques, drop-on-demand inkjet
printing and continuous inkjet printing190. Drop-on-demand inkjet printing
technology reproduces an image through the delivery of ink droplets only when
required, producing a positive image of the digital pattern. This is in comparison to
continuous inkjet printing technologies, where a constant stream of droplets are
ejected from the printer nozzle that are deflected from delivery to the substratum,
and as such the driving stimulus for the imaging corresponds to a negative image of
the print image. Drop-on-demand printing technologies are further characterised as
either thermal inkjet or piezoelectric inkjet printing. Thermal inkjet printing
(commonly known as bubble jet printing) generates a droplet through the heating of
the ink in a jet chamber. There are several limitations when applying thermal inkjet
technology to printing of biological materials. Biological inks may contain
biomolecules which are easily denatured at elevated temperatures, and the heating of
the ink would not be compatible with the printing of living cells that have a very
narrow acceptable temperature range in which they may remain viable. Piezoelectric
inkjet printing is based around the mechanical deformation of the printing nozzle
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wall via an electronic signal, resulting in the expulsion of a droplet from the nozzle
that is catapulted towards the given substratum. This method removes limitations
based on the ability for the ink to be compatible with heating to elevated
temperatures, and therefore is particularly amenable to the printing of biological
components.

For both thermal and piezoelectric inkjet printers, nozzle sizes are typically in the
range of 20 to 50 µm in diameter, with droplet volumes of ~ 10 to 80 pL, producing
final droplet diameters of 30-150 µm. In addition to the physical dimensions of the
nozzle, both the physicochemical properties of the ink, the surface tension between
the ink and nozzle material, as well as the surface energy of the printable substratum,
all conspire to mediate the final resolution and quality of the printed structure.

1.4.2.1

Reactive Inkjet Printing

Reactive inkjet printing exploits the inherent ability for inkjet printing to accurately
deliver micron-scale droplets in a spatially defined manner, allowing the addition of
tiny drops of reactants to one another upon a surface, with reactions occurring at
microscopic scales191. As such, this technique effectively allows material synthesis to
occur directly on the substratum. The mixing of the reactants on the surface has led
reactive inkjet printing to be employed as a high throughput combinatorial approach
to assay multiple material blends. The application of multiple print heads loaded
with a variety of reactive inks has been used to produce arrays of material
chemistries for a diverse range of materials including growth factors192, mixed
oxides193 and metal salts194.
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The use of reactive printing to fabricate two and three dimensional structures has
attracted increasing interest, with this technique demonstrated to be applicable to the
printing of a range of materials, including metals195, conducting polymers196,
hydrogels197 and polyurethanes198. Kröber and co-workers198 used reactive inkjet
printing to fabricate micron-scale polyurethane structures, including dots, lines and
pyramids. Two separate inks, one containing isophorone diisocyanate, and the other
consisting of an oligomer of poly(propylene glycol), a catalyst and crosslinking
agent, were printed from separate print heads reacting on the surface. Rapid
polymerisation ensued, with printed structures cured within 5 mins.

Reactive inkjet printing has been shown to be an excellent tool with which to
fabricate hydrogels, providing distinct advantages over bulk polymerisation
techniques. Hydrogels are typically crosslinked through the addition of two or more
compounds, making them amenable to the reactive inkjet printing process.
Additionally the ability to control the spatial distribution of hydrogel materials in
three dimensions allows control over the hydrogel micro and macro structure. An
ability to impart fine control of hydrogel internal structure makes reactive inkjet
printing particularly attractive for researchers in the biomedical science field, where
hydrogel characteristics such as micro and macro porosity are critical to the
development of 3D scaffolds for tissue engineering applications.

1.4.3 Extrusion Printing
Extrusion printing is a mouldless fabrication technique, also referred to as solid freeform fabrication or rapid prototyping, where material is forced through a nozzle to
form filaments and construct a 3D structure (Figure 1.11). An extrusion printer
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generally consists of two main units, a three-axis robot that controls the movement
and a dispensing system that extrudes material. The dispensing system is controlled
either pneumatically or volumetrically with nozzle diameters typically from 50 µm
to 500 µm.

Figure 1.11 Schematics of the extrusion printing approach151.

Extrusion printing technique has recently been explored in tissue engineering. Tissue
engineering (TE) is a multidisciplinary field that draws together the principles of
engineering and life sciences to develop artificial biological substitutes for the repair
or replacement of damaged or lost human tissues or organs, where scaffold
fabrication is heavily involved199. These scaffolds are made of biocompatible
materials, and combined with living cells, to make physiologically relevant
replacements for impaired tissues or organs that restore, maintain or improve tissue
function. To successfully support cell adhesion, proliferation and differentiation, the
fabricated scaffold should mimic the porous structure and biomechanical properties
of the extracellular matrix (ECM)200. This requires that scaffolds not only be made of
biocompatible materials, either natural or synthetic, but also that they possess desired
structure on both the macro and micro scales201, 202. For example scaffolds with pore
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sizes ranging from 200 to 400 µm are used for bone regeneration203,

204

, while pore

sizes between 20 to 125 µm are used for regeneration of adult mammalian skin205
and 45 to 150 µm for liver tissues206. The extrusion printing technique possesses the
advantages of being able to create required structures with good reproducibility and
homogeneity compared to conventional techniques such as solvent casting, melt
moulding, or fibre bonding that have been reported199, 207.

A

B

Figure 1.12 Schematics of a general process for tissue engineering of patient-specific
bone grafts208.

As opposed to conventional techniques that involve moulding or removal of
materials to fabricate 3D structures, extrusion printing involves fabrication with the
aid of computer software to design the structures and then constructs the designed
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structures from bottom up in a layer-by-layer fashion. The involvement of computeraided design in tissue engineering has provided the exciting opportunity to fabricate
patient-specific prostheses (Figure 1.12)208,

209

. Computed tomography (CT) or

magnetic resonance imaging (MRI) data can be collected and loaded into the
computer to generate a 3D model for the defect body part and then the model will be
imported into an extrusion printing system to construct the scaffold with designed
shape and pore size. A study demonstrated a custom-made scaffold for a patient with
a skull bone defect exactly followed the complex 3D contour of the patient’s skull,
which cannot be readily achieved through other conventional techniques (Figure
1.12 B).

1.5 Thesis Aims and Outline
This Ph.D. research project focuses on the development of drug delivery systems that
are suitable for incorporation into the cochlear implant device. The specific aims are
as follows:

To develop a controlled drug delivery system based on the incorporation of
therapeutic drugs into biocompatible composite organic conducting polymer
materials. This study involves the tailoring of polymer properties to optimise drug
delivery profiles, as well as to develop surface modification methodologies to
improve polymer biocompatibility and limit non-specific protein interactions critical
to enhancing the efficacy of the drug delivery systems.
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To engage cutting edge 3D fabrication techniques to construct intricately structured
drug eluting biocompatible and biodegradable conduits. This study requires the
optimisation of material composition, fabrication methodology and ultimate conduit
structure to optimise the degradation/drug eluting profile of the final structures.
Reactive inkjet printing and melt extrusion printing were engaged as the conduit
fabrication technologies for this component of the Ph.D. research project.
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Chapter 2
Experimental Theory and
Methodologies
Reagents and materials used in the study will be listed in this chapter. General
experimental theories and characterisation methods that have been applied to more
than one study will also be discussed. Detailed parameters and specific
measurements can be found in individual results and discussion chapters later in this
thesis.

2.1 Reagents and Materials
Table 2.1 Reagents
Reagents Name

Company

Pyrrole

Merck (Australia)

Dexamethasone

Spectrum Chemical Mfg. Corp. (New
Brunswick, NJ)

Dexamethasone sodium phosphate

Spectrum Chemical Mfg. Corp. (New
Brunswick, NJ)

Poly(ethylene glycol) methyl ether thiol,
Jenkem (USA)
MW 5000, 40000
Alginic acid sodium salt from brown
Sigma-Aldrich (Australia)
algae
Chitosan, low molecular weight

Aldrich (Australia)

Lactic acid

Sigma (Australia)

Triton™ X-100

Sigma-Aldrich (Australia)
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Polycaprolactone, Mn 80000

Aldrich (Australia)

Silicone

NuSil MED-4234, NuSil Technology
(USA)

Table 2.2 Materials
Materials

Company

Ag/AgCl reference electrode

BASi (USA)

Gold coated Mylar

CP Films Inc. (USA)

Cover glass

ProSciTech (Australia)

Table 2.3 Artificial perilymph recipe
Reagents Name

Weight (g)

Sodium Chloride (Ajax)

7.392

Potassium Hydrogen Carbonate (Ajax)

0.350

Sodium Hydrogen Carbonate (Ajax)

2.016

Tris(hydroxylmethyl)methylamine
(Ajax)

0.606

Calcium Chloride Dehydrate (Ajax)

0.1033

Make up a total volume of 1000 mL with deionised water and adjust pH to 7.4 with
HCl.

Pyrrole was distilled prior to use and stored at -20 °C under nitrogen and in the dark.
Other chemicals were used as received. MilliQ grade (18 MΩ/cm) deionised water
was used throughout this work.
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2.2 Polypyrrole Synthesis and Modification
The first part of this work (Chapter 3) involves electrochemical synthesis of
polypyrrole-dexamethasone composites and the surface modification of synthesised
composites.

2.2.1 Electropolymerisation of Polypyrrole (PPy)
Polypyrroles are formed by the oxidation of pyrrole monomers (Equation 2.1). The
oxidation can be carried out by electropolymerisation at a suitable anode by applying
a positive current or potential. Pyrrole monomers are oxidised near the working
electrode and the PPy polymer precipitates onto the electrode surface.

Equation 2.1 Oxidation of pyrrole, where n is the number of pyrrole monomers
oxidised, m relates to the polymer chain length and A- represents a counterion1.

The polymerisation is believed to be a radical-radical coupling mechanism2, with the
counterions, in this case dexamethasone phosphates, incorporated into PPy during
the polymerisation.

2.2.1.1

The Three-electrode Electrochemical Cell Set-up

All electrochemistry experiments in this work (otherwise specified) were carried out
in a three-electrode electrochemical cell (Figure 2.1), which consisted of a working
electrode, a counter electrode and a reference electrode. A platinum mesh was
employed as the counter electrode, and a Ag/AgCl (in 3 M NaCl, BASi, USA)
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electrode was used as the reference electrode. The three-electrode cell was connected
to an eDAQ e-corder 410 potentiostat/galvanostat and controlled by eDAQ software.

Reference electrode

Working electrode
(Anode)
Counter electrode
(Cathode)

Monomer solution
Figure 2.1 A schematic illustration of the three-electrode electrochemical cell.

2.2.2 Poly(ethylene

glycol)

methyl

ether

thiol

(PEG-SH)

Modification
The thiol groups in PEG-SH react with the PPy backbones and therefore change the
surface property of PPy films (Equation 2.2)3.

Equation 2.2 Polypyrrole reaction with thiol group3.
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In this work, PEG-SHs with two different molecular weights (5 000 and 40 000)
were used. Each of the PEG-SH was dissolved in deionised water to make up
solutions of 0.1 mM concentration. PPy films were treated with PEG-SH by either
submerging the film and supporting substrate in the solutions, or passing the
solutions across the surface of the PPy films within a flow chamber for the quartz
crystal microbalance study.

2.2.3 Quartz Crystal Microbalance (QCM) Monitoring
2.2.3.1

Quartz Crystal Microbalance Theory and Overview

The quartz crystal microbalance (QCM) is an extremely sensitive and versatile
technique that has been used in a wide variety of diverse research fields and for a
range of different applications. The technique was originally pioneered by Sauerbrey
who first described the capability to exploit the piezoelectric properties of quartz
crystals as a mass sensor. The quartz crystal sensor is the fundamental element of the
QCM. It typically consists of a wafer thin piece of A-T cut quartz which has metal
electrodes coated upon upper and lower surfaces (Figure 2.2).
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Optical axis
35° 10'

B

A

C

Figure 2.2 Schematics of (A) A-T cut of a quartz crystal (cut with an angle of 35°10’
to the optical axis)4; and (B) upper and (C) lower surface of metal coated QCM
quartz crystal.

On application of an alternating voltage between the two electrodes, an internal
mechanical stress is generated within the quartz crystal via the piezoelectric effect,
causing it to oscillate at a given frequency (in the MHz range) which is also known
as the resonance frequency (f). The mass bound to either of the electrodes results in a
reduction in the resonance frequency. Sauerbrey first developed the relationship
between the resonance frequency change and the mass adsorbed to the sensor surface
in Sauerbrey equation (Equation 2.3).

𝐶𝑓 =

2𝑛𝑓02
(𝜌𝑞 𝜇𝑞 )

1⁄
2

Equation 2.3 Sauerbrey equation, where Cf is the sensitivity factor, n is the harmonic
at which the quartz crystal sensor is driven, f0 is the fundamental resonance of the
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quartz crystal (in Hz), ρq is the density of quartz (2.648 g/cm3) and µq is the shear
modulus of quartz (2.947 × 1011 g/cm·s2).

Equation 2.4 is used to calculate the mass loadings from the frequency change.

∆𝑚 = −𝐶𝑓 · ∆𝑓

Equation 2.4 The relationship between the mass adsorbed to the QCM crystal and the
resonance frequency change, where ∆m is the mass change, Cf is the sensitivity
factor and ∆f is the frequency change.

The Sauerbrey equation is based on the assumption that the adsorbed mass is rigid
(e.g. elastic), forms a homogenous coverage over the electrode sensor surface and
does not exceed ~2% of the weight of the quartz crystal. Essentially the adsorption
of a rigid mass to the sensor surface is treated as an extension of the thickness of the
quartz resonator itself and therefore the Cf is a fundamental property of the quartz
and does not consider the properties of the adsorbed species. One of the distinct
benefits of the QCM technique is its incredible sensitivity, with modern instruments
capable of measuring a surface adsorbed mass on the order of 1.8 ng/cm2.

QCM was initially employed as a simple mass sensor that measured the adsorption
of gas-phase species to the electrode surface; however the technique was soon
developed to allow crystal oscillation on fluids, opening up a suite of new
applications, such as electrochemistry, immunology and even cell biology. QCM
was developed to measure not just the mass deposition via the decrease of the
resonance frequency, but also the viscoelastic properties of the adsorbed mass via the
dissipation factor (D). The dissipation factor is a measure of the damping of the
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resonating quartz sensor by the adsorbed mass, measured by the time dependant
decay of the shear wave propagating from the sensor surface during oscillation. A
stiff, elastic mass that absorbs little energy makes little or no change in the duration
of decay time of the shear wave. A decrease in the decay time denotes an inelastic,
viscoelastic mass that damps the crystal during oscillation and absorbs considerable
energy as the shear wave propagates through the material. The QCM with dissipation
monitoring (QCM-D) has been proved as a powerful surface characterisation tool
that can be applied to both rigid and soft, hydrated adsorbed layers not only for the
quantification of the mass, but also the characterisation of the mechanical properties
of the adsorbed material.

An enormous advantage of the QCM-D technique is the ability to functionalise the
metal electrode sensor surface with a range of polymer materials, and to measure and
characterise subsequent binding events to the polymer surface. The metal electrode
surface can be functionalised directly with a range of different chemicals via
electrostatic interactions or chemisorption (e.g. poly(ethylaminmine) or alkanethiol
binding, respectively) of a single molecular layer or even with much thicker polymer
networks using a range of techniques including spin coating, dip coating, layer by
layer deposition or electropolymerisation of conducting polymers onto the electrode
surface (Figure 2.3). The maximum thickness of the polymer material depends on the
specific mechanical properties of the adsorbed layer (i.e. viscoelasticity) and must
not exceed a maximum mass as to disturb the ability of the quartz sensor to resonate
at the fundamental frequency (~2 % of crystal mass).
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Protein

Polymer
Upper electrode

Quartz crystal
Lower electrode
Cross-section view
Figure 2.3 Schematic illustrations of a QCM crystal sensor with a polymer
functionalised layer and the binding of protein onto the polymer surface.

2.2.3.2

Electrochemical Quartz Crystal Microbalance

Electrochemical quartz crystal microbalance (EQCM) is designed to have the
capability of applying a potential on the upper electrode, which allows
electrochemical reactions to take place at the electrode surface, therefore enabling
the monitoring of electrochemical reaction processes. In this work, a Stanford
Research Systems (SRS) QCM200, in conjunction with an eDAQ potentiostat, was
employed to monitor the mass deposition during electropolymerisation of PPy/DexP.
Chromium/gold coated quartz crystals (5 MHz, 25.4 mm in diameter) were used.
The gold electrode surface was cleaned with ethanol prior to experiments. A threeelectrode electrochemical cell was set up in the vial at the end of QCM probe (Figure
2.4), and approximately 4 mL monomer solution was added in the vial each time.

78 | P a g e

Reference electrode

B

Monomer solution
Counter electrode

QCM sensor

EQCM probe
(connected to the eDAQ potentiostat)

A

Figure 2.4 Schematic illustrations of (A) EQCM three-electrode electrochemical cell
set-up and (B) the cross-section view.

2.2.3.3

Quartz Crystal Microbalance with Dissipation

Quartz crystal microbalance with dissipation (QCM-D) has the capability to analyse
the mechanical properties of the layer bound to the surface of electrode, or to the
surface of the polymer coated on the electrode. In this work, QCM-D crystal sensors
were coated with PPy/DexP by electropolymerisation. A Q-Sense E4 system (QSense AB, Västra, Frölunda, Sweden) was employed to study the PEGylation and
the protein adsorption of PPy/DexP. As opposed to the SRS EQCM, Q-Sense E4
system employed enclosed flow chambers (Q-Sense axial flow module QFM401)
driven by a precise peristaltic pump that was capable of addressing four chambers
simultaneously.

One advantage of the QCM-D technique is that a number of models may be utilised
to further characterise the nature and properties of the mass adsorbed to the sensor
(or the coated material) surface (i.e. mass, thickness, modulus). The binding of PEG79 | P a g e

SH to the PPy/DexP surface induced not only large shifts in the frequency, but also
the dissipation parameter. Large D shifts are characteristic of surface bound layers
that possess considerable viscoelasticity, or inelastic properties. The simplest and
most commonly used model to characterise adsorbed layer properties from QCM-D
data is the Sauerbrey model (Equation 2.3). This model however is dependent on the
mass coupled to the sensor surface to be rigid or elastic (i.e. negligible D shift), and
therefore is unsuitable for the system described herein. The more complicated
viscoelastic Voigt model was required to determine the specific properties of the
adsorbed PEG-SH layers. The Q-tools software package (Biolin Sci, AB,
v.3.0.10.286) was used to apply the Voigt model to determine the mass of PEG-SH
and protein adsorbed to the modified sensor surface.

2.3 Reactive Inkjet Printer
The second part of this work (Chapter 4) involves developing an inkjet printing
technique for the application of reactive inkjet printing a hydrogel drug delivery
system.

2.3.1 Inkjet Printing System
A reactive inkjet printer was built in house for this study. The printer consisted of
four main components: the printhead rack, ink supply, vacuum pressure control and
substrate stage (Figure 2.5).
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Figure 2.5 A schematic illustration of the reactive inkjet printer.

Piezocrystal inkjet printheads (Xaar 126/80, UK) were used in this system (Figure
2.6). Each printhead had 126 nozzles of 50 µm diameter and spaced 137.1 µm apart,
which gave a maximum print width of 17.2 mm. When the ink was injected from the
inlet, it travelled through a stainless steel mesh with holes of approximate 8 µm
diameter into a 2 mL reservoir, where the ink was distributed into individual
channels that connected each nozzle. Peizocrystals were fixed at the walls of each
ink channel, and when activated, the peizocrystal walls applied a pressure to the ink
forcing a controlled volume to be ejected out of the corresponding nozzle. The
printheads were connected to the control box and driven at a working frequency of
5200 Hz, with software controlling every single nozzle on each printhead. Xaar
126/80 printheads jetted approximately 80 pL droplets for commercial inks, and this
volume varied with different custom ink formulations. Therefore the system needed
to be adjusted for different ink formulations, and the volume of inkjet droplets
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needed to be calibrated accordingly. In this work, phenol red and crystal violet were
used to indicate printing quality and calibrate the droplet volume.

A

Inlet

Electronic
connector

Outlet

B
126 nozzles

C
Single nozzle

0.5 mm

Nozzle plate

Figure 2.6 Photographs of (A) Xaar 126/80 inkjet printhead, (B) view of the nozzle
plate, and (C) a close-up view of the nozzle plate under micro-camera.

NordsonEFD Optimum® syringe barrels with a volume of 10 mL were adopted as
ink supply reservoirs in this inkjet printing system (Figure 2.5-1). The syringe
barrels were set up at approximately 10 cm – 15 cm above the nozzle plate level and
at an angle of 30°. The ink reservoirs were linked to the inlets of the printhead by
Teflon tubing with connectors, and a small section of flexible tubing (Tygon ® R3603) with a tube clamp added along the Teflon tubing to control the ink flow. In
general, 5 mL of ink solution was applied to each ink reservoir prior to printing.

A NordsonEFD Ultimus™ fluid dispenser, with gas output directly connected to the
ink reservoirs, was used for vacuum and pressure control ensuring that excessive ink
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did not flow through the printheads in normal operation and permitting intermittent
purging of fluid through the printheads when required. As illustrated in Figure 2.6,
the printing nozzles had a fixed diameter and were opened to the air; therefore, a
vacuum pressure was necessary to hold the ink solution in place. The vacuum
pressure should be such that it is strong enough to cancel the gravity force but not to
pull the ink back to the channels. As a result, the ink was wetting the nozzle plate but
not dripping out of the printhead. The applied vacuum pressure was related to the ink
loading volume and the position (height) of ink supply reservoirs, and was adjusted
with each experiment to provide the optimised output. The printheads required
purging before and after every printing session to make sure the ink was distributed
evenly into each nozzle channel, therefore an appropriate dispensing pressure was
given to the ink reservoir to force the ink through the nozzles. Excess ink was wiped
from the nozzle plates with a lint-free cotton swab.

The substrate stage was driven by a precise motion control motor system (Reliance
Cool Muscle, Australia). The substrate stage was made of polycarbonate, with
machined inlays to accommodate different substrates and orientations. As shown in
Figure 2.5, the printhead rack was fixed to the base frame and the printheads were
mounted to the rack with adjustable screws. Positioning of printed patterns onto a
given surface relied on the movement of the substrate stage, which had a single-axis
movement. The stage movement was controlled by software, and the position of the
stage was detected by an optical encoder (Renishaw). The operation of the printhead
was driven by the position of the optical encoder, such that when a certain point on
the encoder was reached a signal was sent to the printhead drive electronics to
instruct that a specific pixel should be printed. When the stage moved to an indicated
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position, it triggered the printhead to print with the programmed patterns. The
printhead mount was mechanically fixed so that there was an offset of 2 mm between
the printhead nozzle plate and the substrate surface.

2.3.2 Reactive Inkjet Printing
Two printheads were employed in reactive inkjet printing of hydrogels. One
printhead was to deposit the chitosan ink formulation and the other for the alginate
ink formulation. As demonstrated in Figure 2.5, the printheads were mounted on the
frame and the stage was driven to move forwards and backwards along a single axis.
The printheads were programmed to jet every time the stage moved forward, and
deposit ink at desired positions.

2.4 Extrusion Printing
The third part of this work (Chapter 5) involved utilising a melt extrusion printer to
fabricate polycaprolactone scaffolds for dexamethasone loading and delivery.

A melt extrusion printer, the SPS1000 Bioplotter from the Korean Institute of
Machinery and Materials (KIMM) and Mechatronics for Technology (M4T), was
employed to extrude polycaprolactone scaffolds. The SPS1000 Bioplotter (Figure
2.7) had an X-Y-Z motion control system with positioning resolution of 1 µm. The
stainless steel barrel had switchable tips of different sizes from 100 µm to 500 µm,
and was surrounded by the heating element, which had the capability of heating it up
to 200 °C. The top of the barrel was sealed and connected with an air supply to
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control the pressure in the barrel. The precise pressure control system was able to
produce extrusion pressure up to 400 kPa.
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8 - Heating element
9 - Extrusion tip
10 - Stage

Figure 2.7 Photographs of KIMM/M4T SPS1000 Bioplotter.

2.5 Drug Release
Two different methods were applied for drug release, namely electrical stimulated
release and passive release.
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2.5.1 Electrical Stimulated Release
Electrical stimulated release method was used in Chapter 3. The experiments were
carried out in a three-electrode cell at room temperature. The polymer films were set
as working electrodes, and artificial perilymph was used as the electrolyte solution.
The electrochemical cell was connected to an eDAQ potentiostat and controlled by
the software eDAQ Chart. During the stimulation a negative potential was applied to
the polymer films. An aliquot artificial perilymph solution was taken out at each time
point and the same amount of fresh solution was added.

2.5.2 Passive Release
Passive release study was performed on samples prepared in Chapter 4 and 5. The
samples were incubated in artificial perilymph and kept in a water bath at 37 °C. At
each time interval, an aliquot was removed from the release solution and the same
amount of fresh artificial perilymph was added.

2.6 Characterisation
2.6.1 Electrochemical Characterisation
The electrochemical properties of PPy/DexP were investigated using cyclic
voltammetry. Cyclic voltammetry (CV) is a type of potentiodynamic electrochemical
measurement. In a three electrode cell, a potential waveform is applied as a linear
ramp against time between the working electrode and the auxiliary electrode, and
when the potential reaches a set point, the working electrode’s potential ramp is
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inverted. The current at the working electrode is monitored and plotted versus the
applied potential to give the cyclic voltammongram. CV can be used to study the
electrochemical properties of materials deposited on the working electrode, such as
conducting polymers and can provide information on oxidation and reduction
potentials of a material and the electrochemical active surface area for a given
electrolyte.

In this work, CV was performed by an eDAQ eCorder 401 Potentiostat with the
potential measured against an Ag/AgCl reference electrode. Data was analysed using
eDAQ eChem and Chart software.

2.6.2 Profilometry
A number of different profilometry instruments, including a stylus profilometer, an
optical profilometer and an atomic force microscope (AFM), were used in this work
to measure the surface profiles of fabricated samples.

2.6.2.1

Stylus Profilometry

A Dektak Stylus Profiler was used to characterise the thickness of PPy/DexP films.
The system operates by a diamond tip stylus physically making contact with the
sample surface and the stage moving front to back so the stylus scans across the
sample. The stylus is mechanically coupled to the core of a linear variable
differential transducer (LVDT), and the movement of the tip actuates the LVDT to
convert movements in electrical signals.
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A

B

Stylus

Figure 2.8 Close-up photograph of Dektak 150 profiler (A) and a diagram of the
Dektak 150 architecture (B).

A LVDT is a very sensitive transducer; however, the tip of the profilometer is
conical and has a finite rounded shape, which interacts with the sample being
scanned. The vertical sensitivity is in the nanometre range; however, steep edge
profiles are distorted due to the shape of the tip as indicated in the illustration. Small
radius tips are better but more likely to be damaged by mishandling.

The Dektak Stylus Profiler has a vertical measuring range of 1 mm with the
resolution at 1 angstrom max, and can perform a line scan as long as 55 mm. The
stylus force can be varied from 0.03 mg to 15 mg. In this work, the samples were
measured with the “hill & valley” scan mode and the stylus force was set at 0.5 mg.

Stylus tip angle

Trace
Sample step

H
H

Figure 2.9 Schematic illustration of profile’s edge distortion due to the stylus tip
shape.
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2.6.2.2

Optical Profilometry

A Veeco Wyko NT9100 Optical Profiler was used to measure the roughness of
PPy/DexP films and the topography and 3D structures of inkjet printed hydrogels.
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Figure 2.10 Photographs of the Veeco Wyko NT9100 Optical Profiler.

An optical profilometry is a non-contact method for surface height measurement.
The Veeco Wyko NT9100 Optical Profiler uses white light interferometry to detect
the surface profiles varying from 50 nm to 10 μm. The data were analysed with
WYKO Vision software.

2.6.2.3

Atomic Force Microscopy

Atomic force microscopy (AFM) was performed with an Asylum Research MFP 3D
SA AFM. The roughness and surface area of PPy/DexP films were examined using
AFM. In addition to providing topographic images of the PPy/DexP films, AFM
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imaging also provided quantitative measures of polymer surface roughness and
interfacial surface area.

AFM is a mode of scanning probe microscopy that provides ultra-high resolution
images of a sample surface that, in some instances, can be in the sub-nanometre
range. The cantilever typically possesses a pyramidal shaped tip with a tip diameter
in the range of ~15 nm. AFM imaging fundamentally involves the raster scanning of
a micro-cantilever across a sample surface. The cantilever, typically made from
silicon or silicon-nitride, images the surface by measuring changes in the deflection
of the lever away from a predetermined set point deflection value, which ensures a
constant force is applied to the sample during scanning. The deflection of the
cantilever is measured using a laser that is directed onto the back of the cantilever,
and reflected into a photo-diode. As the cantilever deflects as a function of the
surface features during raster scanning across the surface, this shift is measured as a
change in the laser point position on the diode, and generates a feedback response in
the Z-piezo that controls the Z height of the cantilever. The Z-Piezo corrects for the
change in deflection of the cantilever by either moving the cantilever towards or
away from the surface, retaining a constant force onto the substrate. This change in
the Z-piezo displacement is then correlated with a specific X-Y coordinate during
scanning and used to produce a topographic image that makes up the standard AFM
height images employed within this thesis.

The resultant 3D topographic image can be used to quantify a range of polymer
surface properties, including surface area and surface roughness, which are not
possible using other standard imaging techniques such as optical microscopy.
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2.6.3 Scanning Electron Microscopy
Scanning electron microscopy was performed using a Jeol7500 field emission
scanning electron microscope (FE SEM). PPy/DexP films and PCL/Dex scaffolds
samples were sputter coated with a thin layer of gold (approx. 10 nm) to obtain clear
images. An accelerating voltage of 5 kV was applied, and the working distance was
set between 5 mm and 10 mm.

2.6.4 Goniometry
The surface tension of ink formulations for inkjet printing in Chapter 4 was detected
using a DataPhysics OCA20 goniometer, and the data was analysed by using
DataPhysics SCA21 software. The surface tension was measured using the pendant
drop method by injecting the measuring solution gradually into the air through a flat
needle tip, until the droplet reached its largest volume hanging at the tip against
gravity force. The surface tension was calculated using the Equation 2.5 below:

𝛾=

∆𝜌𝑔𝑅 2
𝛽

Equation 2.5 Surface tension equation, where γ is the liquid-air surface tension, β is
the shape factor, ∆ρ is the difference in density between fluids at the interface, g is
acceleration due to gravity and R is the radius of the drop curvature at the drop’s
apex.

2.6.5 Rheometry
An AR G2 Rheometer (TA Instrument Ltd) was employed to study the rheological
properties of materials used for inkjet printing and extrusion printing, in Chapter 4
and 5, respectively.
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Rheometry is the measuring technology used to determine rheological data of
materials, such as flow behaviour of liquids at different temperature or shear rate.
Three terms/parameters are commonly used in rheometry, shear stress, shear rate,
and viscosity. The two-plates-model is used to define these fundamental rheological
parameters (Figure 2.11). The shear stress τ (pronounced “tou”) is defined as:

𝐹
𝐴

𝜏=

Equation 2.6 Definition of the shear stress, where F is the shear force (unit: N), and
A is the shear area (unit: m2). The unit of the shear stress is Pa.

The shear rate γ̇ (pronounced “gamma-dot”) is defined as:

𝛾̇ =

𝑣
ℎ

Equation 2.7 Definition of the shear rate, where v is the velocity at the shear plate
(unite: m/s), and h is the distance between the two plates (unit: m). The unit of the
shear rate is 1/s.

v

A

F

v
h
v=0
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Figure 2.11 Schematic of a two-plates-model demonstrating flow velocity of a fluid,
where F is the shear force, A is the shear area, h is the distance between the two
plates, and v is the velocity of the fluid.

For all flowing fluids, the molecules display relative motion between each other, and
this is always combined with internal frictional forces, which is expressed as a flow
resistance against the shear stress applied to the fluids. This flow resistance can be
determined in terms of the viscosity η (pronounced “etah”), and is defined as:

𝜂=

𝜏
𝛾̇

Equation 2.8 Definition of viscosity, where τ is the shear stress, and γ̇ is the shear
rate. The unit of the viscosity is Pa.s.

2.6.5.1

Flow Behaviour

The rheological properties of fluids are commonly measured as a relation between
the shear stress and the shear rate. The measurement can be present either with a
shear stress profile or a shear rate profile, as shown in Figure 2.12.

A τ

B γ̇

t

t
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Figure 2.12 Schematics of rheolometry measurement preset profiles: (A) shear
stress/time function as a ramp, and (B) shear rate/time function as a ramp.
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Figure 2.13 Schematics of rheolometry measurement results: (A) the relation
between the shear stress and the shear rate, (B) the viscosity as a function of the
shear rate. The flow curves represent (1) idealviscous fluid, (2) shear-thinning fluid,
and (3) shear-thickening fluid, respectively.

The type of fluid falls in three categories according to their flow behaviour:
idealviscous fluid, shear-thinning fluid, and shear-thickening fluid (Figure 2.13).
When an increasing shear rate is applied, the shear stress of an idealviscous fluid
shows a linear relation with the shear rate, and its viscosity keeps constant.

2.6.5.2

Cone-and-Plate Measuring System

A cone-and-plate measuring system (Figure 2.14) was used to perform rheological
tests in this study. A cone-and-plate measuring system consists of a circular cone
(generally with a small cone angle between 1° to 4°) and a plate. Usually the cone is
the upper part and can be controlled with different settings (e.g. shear rate, shear
stress), and the plate is the stationary part. A truncated cone is often used in most
rheological tests for practical reasons. The truncated cone needs to be set accurately
as such that the imaginary cone tip is touching the lower plate.
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R

α

a

Figure 2.14 A schematic of the cone-and-plate measuring system, where R is the
cone radius, α is the cone angle, and a is the truncation gap.

The advantage of using the cone-and-plate measurement is that the shear rate is
constant in the entire conical gap, therefore homogenous shear conditions can be
achieved. When an angular velocity ω is applied, the shear rate is:

𝛾̇ =

𝜔∙𝑟
= 𝜔 ∙ tan 𝛼
ℎ

Equation 2.9 Definition of shear rate 𝛾̇ in a cone-and-plate measuring system, where
ω is the angular velocity, r is the radius at any point in the conical gap, h is the
distance to the plate at the same point, and α is the cone angle.

According to Equation 2.9, the shear rate is defined by the cone angle and the
applied angular velocity, therefore the shear rate is constant across the conical gap.
The cone-and-plate measuring system is preferred for rheological tests of fluid,
especially those with low viscosity.
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2.6.6 Thermal Gravimetric Analysis
Thermal gravimetric analysis (TGA) was performed on a TGA Q500 TA
Instruments mass analyser. The scans were performed on platinum pans at a heating
rate of 10 °C/min from room temperature to 800 °C under nitrogen.

2.6.7 Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) thermograms were obtained using a TA
Instruments DSC Q100 differential scanning calorimeter equipped with a
refrigerated cooling system. 5 mg to 10 mg of PCL or PCL/Dex samples were
prepared using standard aluminium pans and sealed by pressing top and bottom pans
together. The samples were heated from -90 °C to 200 °C at a rate of 20 °C·min-1,
and cooled down from 200 °C to -90 °C at a rate of 5 °C·min-1.

2.6.8 Detection of Dexamethasone
2.6.8.1

UV-visible Spectroscopy

Dexamethasone sodium phosphate (DexP) release was detected using a Shimadzu
UV-1600 UV-visible spectrophotometer. Spectrum measurement was performed on
samples, and the peak value at 242 nm was recorded. A calibration curve of DexP in
artificial perilymph was obtained from standard solutions with concentrations of 10,
20, 30, 40 and 50 µm. The concentration of release samples were calculated from
this calibration curve.

2.6.8.2

High Performance Liquid Spectroscopy

High performance liquid spectroscopy (HPLC) had the advantage of high sensitivity,
and was performed using a Shimadzu LC-20 HPLC system with an Atlantis® T3
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column (Waters Corp.) Different mobile phases were used for detection of
dexamethasone (Dex) and dexamethasone phosphate (DexP) (Table 2.4). All
solutions and solvents were filtered and degassed before injection into the HPLC
system. The samples were prepared by filtering through 0.22 µm PVDF syringe
filters. A sample volume of 20 µL was injected at a flow rate of 1 mL/min and the
absorbance results were detected at 242 nm using a UV-visible detector.

Table 2.4 Mobile phases
Sample

Mobile Phase

Dexamethasone

Deionised water (65%)

Dexamethasone
sodium phosphate

0.02 M
dihydrogen
(50%)

Methanol (35%)

sodium
phosphate Methanol (50%)
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Chapter 3
Conductive and Protein Resistant
Polypyrrole Films for
Dexamethasone Delivery
3.1 Introduction
Inherently conducting polymers (ICPs) have in recent years attracted enormous
interest in the area of biomaterials development due to their inherent
biocompatibility and their ability to perform multiple biologically relevant functions1,
2, 3, 4

. Research has been particularly focused on the use of ICPs in bionic biomedical

devices, such as the cochlear implant, due to their low impedance, ability to record
or apply electrical stimuli to promote cell survival, growth and tissue function, and
the unique capability to perform electrochemically controlled drug delivery. While
ICPs show enormous promise for a range of biomedical applications, there remain a
number of key challenges that must be addressed to maximise the ability for the
materials to effectively perform their desired in vivo function. One major challenge
for all biomaterials that are introduced into an in vivo environment is limiting the
foreign body or inflammatory responses to the biomaterials employed in the
implanted device. Biomaterial derived inflammatory responses may originate from a
number of sources, including tissue damage during implantation and non-mechanical
compliance between the biomaterial and the surrounding tissues5,

6, 7

. A key trigger

of inflammatory and foreign body response to implanted biomaterials is the
nonspecific protein adsorption to the device surface. It is well known that proteins
will adsorb to a biomaterial surface within seconds of incubation of the material into
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an in vitro or in vivo environment8. Both the composition of the adsorbed protein
conditioning film, as well as the conformation of the surface bound protein
molecules themselves, can act in concert to promote foreign body responses and
inflammatory responses through facilitating a range of biochemical cascades that
may act upon surrounding cellular and tissue function, as well as instigate cellular
reactions from cells and tissues in direct contact with the biomaterial itself7. This can
ultimately lead to device failure and unexpected risks for patients9. Critical to
controlling inflammatory and foreign body response to implanted materials is to
develop mechanisms through which to reduce the inflammatory response to
implantation associated damage at the surgical site, and to inhibit the protein
interaction with the biomaterial surface.

In this study, a multifunctional polypyrrole based system has been developed to
electrochemically deliver the anti-inflammatory drug dexamethasone. Additionally
this system was modified to render the surface resistance to nonspecific protein
adsorption. This study investigates different conditions for the electropolymerisation
of dexamethasone sodium phosphate doped polypyrrole (PPy/DexP) films, their
impacts on PPy/DexP properties (e.g. morphology, impedance), and the electricallystimulated drug release profiles. Poly(ethylene glycol) methyl ether thiol (mPEG-SH)
with different molecular weights were introduced to modify the PPy/DexP film
surface and a quartz crystal microbalance (QCM) was used to study the PEGylation
of the PPy/DexP films, as well as interaction of the protein fibrinogen with
PPy/DexP films before and after mPEG-SH modification. The effect of PEGylation
on the release of DexP was also investigated.
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3.2 Methods
The fundamental theories and general experimental methods for the experiments and
sample characterisations have been discussed in Chapter 2. The detailed
experimental conditions and parameters used in this study are as below.

3.2.1 Electropolymerisation of Polypyrrole films
3.2.1.1

Preparation of Monomer Solutions

The monomer solutions for polypyrrole electropolymerisation were made up with
0.2 M pyrrole and different concentrations of dexamethasone sodium phosphate
(DexP), dissolved in deionised water. Three different DexP concentrations were used,
5 mM, 10 mM and 15 mM. Stock solutions of DexP were made and kept in a
refrigerator

at

4 °C.

Before

electropolymerisation,

DexP

solutions

were

deoxygenated for 30 mins via bubbling with nitrogen gas, and 0.2 M pyrrole was
added into the deoxygenated solution. Monomer solutions were prepared fresh prior
to electropolymerisation.

3.2.1.2

Preparation of Working Electrodes

Gold coated Mylar films were used as working electrodes for polypyrrole synthesis
and drug release experiments. These films were cut into strips of 1 cm wide and
4 cm long. The strips were cleaned with ethanol in a sonicating bath, rinsed with
ethanol and deionised water and dried under nitrogen. A reactive area (where the
polypyrrole was electrochemically polymerised) of 1 cm×1 cm was masked at one
end of gold Mylar strips. The reactive areas were rinsed with ethanol and dried under
a stream of nitrogen gas prior to polymerisation.
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3.2.1.3

Electropolymerisation of PPy/DexP Films

PPy/DexP films were electropolymerised in a three-electrode electrochemical cell
(as described in Section 2.2.1.1), using gold coated Mylar as the working electrode.
The electrochemical cell was connected to an eDAQ potentiostat and controlled by
eDAQ Chart software. PPy/DexP films were grown by galvanostatic deposition to a
total charge density of 1 C/cm2. Three different current densities were applied, such
that films were grown for a shorter time by a higher current density. The growth
conditions for each film are listed in Table 3.1.

Table 3.1 Different growth conditions for PPy/DexP films.

PPy/DexP Film

DexP
Concentration
(mM)

Current
Density
(mA/cm2)

Growth
Time (s)

5 mM/0.5 mA

5

0.5

2000

5 mM/1.0 mA

5

1.0

1000

5 mM/1.5 mA

5

1.5

667

10 mM/1.5 mA

10

1.5

667

15 mM/1.5 mA

15

1.5

667

3.2.2 Poly(ethylene

glycol)

methyl

ether

Total
Charge
Density
(C/cm2)

1 C/cm2

thiol

(PEG-SH)

Modification
The thiol groups in PEG-SH have been demonstrated to react with the PPy backbone
via a thiol-ene reaction, forming a covalent bond, and therefore change the surface
properties of PPy films (Equation 3.1)10.
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Equation 3.1 Polypyrrole reaction with thiol group10.

In this work, PEG-SHs with two different molecular weights (5 000 and 40 000)
were used. Each PEG-SH was dissolved in deionised water to make up solutions of
0.1 mM concentration. PPy films were treated with PEG-SH by submerging the film
and supporting substrate in 0.1 mM of the respective PEG-SH solutions. After PEGSH treatment, the films were rinsed thoroughly with deionised water and dried under
nitrogen gas for further characterisation.

3.2.3 Quartz Crystal Microbalance Methods
Two different QCM systems were used in this study. The electropolymerisation of
PPy/DexP was studied using the EQCM system, a Stanford Research Systems
QCM200. The mPEG-SH modification and protein adsorption were studied using
the QCM-D system, a Q-Sense E4 system (Q-Sense AB, Västra, Frölunda, Sweden).

3.2.3.1

Preparation of EQCM System

The Stanford Research Systems QCM200 was used in conjunction with an eDAQ
potentiostat to monitor the mass deposition during electropolymerisation of
PPy/DexP. Chromium/gold coated quartz crystals (5 MHz, 25.4 mm in diameter)
were used. The gold electrode surface was cleaned with ethanol prior to experiments.
A three-electrode electrochemical cell was set up in the vial at the end of the QCM
probe. Conditions described in Section 3.2.1.3 were applied to electropolymerise
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PPy/DexP, and approximately 4 mL of fresh monomer solution was added in the vial
for each polymerisation.

3.2.3.2

Preparation of QCM-D Quartz Crystal Sensors

The QCM-D sensor (QSX301) was an A-T cut quartz crystal coated with gold
electrodes on its upper and lower surfaces (14 mm in diameter), exhibiting a
fundamental resonance frequency of 4.95 MHz ± 50 kHz. Before experiments, the
QCM-D sensor was cleaned by incubating in Piranha solution (concentrated
sulphuric acid: 30% hydrogen peroxide (7:3)) for 3 minutes and rinsed thoroughly
with deionised water and dried under a stream of nitrogen gas.

3.2.3.3

Polymerisation of PPy/DexP onto QCM-D Quartz Crystal

Prior to the study of PEG-SH modification or protein adsorption, the QCM-D quartz
crystal sensor was modified with a PPy/DexP layer. The upper electrode on the
QCM-D sensor was used as the working electrode in a three-electrode
electrochemical cell for electropolymerisation of PPy/DexP, and different conditions
as described in Section 3.2.1.3 were applied. The gold contacts on the rear of the
QCM-D sensor were protected during the electropolymerisation to prevent any
disruptive polymer deposition. After polymerisation, the QCM-D sensor was
removed from the electrochemical cell and rinsed with deionised water and dried
with nitrogen gas.

3.2.3.4

PEG-SH Modification of PPy/DexP Films

PPy/DexP coated QCM-D sensors were transferred into the Q-Sense axial flow
module (QFM401) and equilibrated in deionised water for 24 hours at a controlled
temperature of 22 °C ± 0.02 °C, with deionised water flowed through the chamber at
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a constant rate of 10 µL·min-1. Films were equilibrated for such a period of time to
allow the frequency (f) and dissipation (D) to stabilise as the gradual hydration of the
conducting polymer layer causes the f and D to drift. Once stable, a 0.1 mM solution
of either 5 000 (5k) or 40 000 (40k) molecular weight PEG-SH was introduced into
the axial flow chamber at the constant rate of 10 µL·min-1 for 30 minutes. Thereafter
the chamber was rinsed with deionised water at the same flow rate until the f and D
stabilised. All experiments were undertaken in triplicate.

3.2.3.5

Protein Adsorption

Fibrinogen (Fb) from human plasma was used in the protein adsorption experiments.
0.5 mg/mL Fb dissolved in 0.9% NaCl solution was prepared fresh for each
experiment. For the study of protein adsorption on the PPy/DexP surface, PPy/DexP
coated QCM-D sensors were transferred into the Q-Sense axial flow module
(QFM401) and equilibrated with 0.9% NaCl solution for 24 hours at 22 °C ± 0.02 °C
by pumping the solution through at a flow rate of 10 µL/min. 0.5 mg/mL Fb solution
was then introduced into the system, at the same flow rate for 30 minutes. Thereafter
the chamber was rinsed with 0.9% NaCl solution until the f and D stabilised.

For the study of protein adsorption on PEGylated PPy/DexP surface, after
PEGylation of PPy/DexP experiments (as described in Section 3.2.3.4), the QCM-D
monitoring was continued with protein adsorption experiments performed as
described above.

3.2.4 Drug Release
Electrically stimulated release method was used in this work, and passive release
experiments were also performed as controls. The experiments were carried out in a
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three-electrode cell. The polymer films were set as the working electrodes and
artificial perilymph was used as the electrolyte solution. The electrochemical cell
was connected to an eDAQ potentiostat and controlled by the software eDAQ Chart.
During stimulation, a constant negative potential (-500 mV) was applied to the
polymer films. A 1 mL aliquot of artificial perilymph solution was taken out at each
time point and fresh artificial perilymph solution added.

The collected artificial perilymph samples containing DexP were detected with a
Shimadzu UV-1600 UV-visible spectrophotometer. Spectrum measurements were
performed on the samples, and the peak value at 242 nm (λmax of DexP) was
recorded.

3.3 Results and Discussion
3.3.1 Effect of Growth Condition on PPy/DexP films
3.3.1.1

Growth Conditions and Electrochemical Properties

Two sets of different growth conditions were investigated for their influence on a
range of polymer physiochemical and electrochemical properties, as well as drug
release profiles. As listed in Table 3.1, the influence of electropolymerisation current
density was studied by keeping a constant DexP concentration of 5 mM while
changing the current density (0.5 mA/cm2, 1.0 mA/cm2, and 1.5 mA/cm2); and the
influence of DexP concentration was studied by using a 1.5 mA/cm2 current density,
and changing the DexP concentration from 5 mM to 15 mM. There were three
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different conditions applied in each set of condition variations, however the
5 mM/1.5 mA PPy/DexP films were used for the analysis of both sets, which is why
there are data for 5 different films presented instead of 6 films in total.

The potential generated during galvanostatic polymerisation is shown in Figure 3.1.
An instant rise of potential was recorded for all the growth conditions and the
potential steadily decreased with time. This is due to the dynamic nature of the
polymerisation process. Immediately upon the application an oxidising potential at
the working electrode, monomers are being oxidised in the solution and forming
chains through radical-radical coupling11. When the polymer chain reaches a critical
length and exceeds the solubility limit, the polymer precipitates onto the working
electrode surface. Once the initial layer of PPy is deposited, it becomes a reactant,
and the polymerisation occurs more readily on the already-deposited surface than in
the solution or on the bare electrode. Additionally, the PPy layer has been shown to
possess lower impedance than the bare gold electrode due to its high surface area12.
Therefore after the deposition of the initial PPy layer onto the anode surface, the
potential starts to drop.
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A

B

Figure 3.1 Chronopotentiograms over the first 200 seconds of electropolymerisation
of PPy/DexP films, (A) polymerisations at different current densities, and (B)
polymerisations at different dopant concentrations.

With 5 mM DexP concentration in the polymerising solution, the potential generated
during galvanostatic polymerisation increased with an increase in current density
(0.5 mA/cm2<1.0 mA/cm2<1.5 mA/cm2).

Conversely,

increasing

the

DexP

concentration when applying the same current density (1.5 mA/cm2) was found to
result in a reduction in the potential during polymerisation (5 mM>10 mM>15 mM).
The potential recorded between the working and counter electrodes is determined by
both the current and the resistance of the electrolyte solution and the deposited film.
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In these experiments, the working electrode area was 1 cm2, therefore the applied
currents were 0.5 mA, 1.0 mA, and 1.5 mA, respectively. With the same DexP
concentration in the polymerising solution, the solution resistance remained the same,
and the potential increased with an increase of the applied current (Figure 3.1 A),
which indicates the electrolyte solution resistance is the driving factor rather than the
impedance of the PPy layer. However it’s worth noting that the potential drop was at
a higher rate after the initial rise, when a higher current was applied, which is due to
a faster deposition of PPy. When the same current was applied (1.5 mA), the
potential decreased with the increase of DexP concentration (Figure 3.1 B), due to
the decrease of the resistance of the electrolyte solution at a higher DexP
concentration.
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A

B

Figure 3.2 Cyclic voltammetry of PPy/DexP films, performed in artificial perilymph
at a scan rate of 50 mV/s vs. Ag/Ag+, (A) films polymerised at different current
densities, and (B) films polymerised with different dopant concentrations. The 10th
cycle is shown and the arrows indicate the direction of the potential scan.

Cyclic voltammetry (CV) analysis of PPy/DexP in artificial perilymph electrolyte
(Figure 3.2) indicates there was little difference in electrochemical properties of the
prepared films, independent of the current density and DexP concentration during the
polymerisation. CV analysis provides information about the electrochemical
properties and redox reaction of the conductive materials as the potential applied to
the materials is swept in a cyclic manner. PPy is known to have switching properties
with oxidation and reduction peaks shown during a CV scan11. However, DexP has
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been proved not to be an excellent dopant, and a DexP doped PPy single layer has
been shown not to possess obvious redox peaks13, 14.

3.3.1.2

Mass Deposition and Mechanical Properties

EQCM was employed to characterise the mass and mechanical properties of the
PPy/DexP films as a function of current density, and the concentration of DexP in
the polymerisation solution. The Stanford Research Systems QCM employed for this
part of the study allows the measure of two parameters: the frequency (f) and the
resistance (R). While the frequency provides a measure of the mass adsorbed to the
sensor surface, the resistance, which is closely related to the dissipation (D)
measurement parameter that is available on more modern QCM systems, provides a
measure of the viscoelastic properties, or the mechanical properties, of the adsorbed
mass15,

16, 17

. The Sauerbrey model was employed to quantify the mass of polymer

polymerised onto the QCM sensor surface (as described in Section 2.2.3.1). There
was no substantial difference in the total mass of the films deposited on the QCM
sensor as a function of the current density (Figure 3.3), with films grown at
0.5 mA/cm2 illustrating a film mass of 603 ± 14 µg/cm2, with 1.0 mA/cm2 and
1.5 mA/cm2 growth conditions illustrating mass values of 564 ± 35 µg/cm2 and 562
± 29 µg/cm2, respectively. All films were grown to the same charge density
(1 C/cm2), and therefore it would be expected that there would be little overall
variation in the mass of each of the films as a function of the current density. While
total film mass did not vary as a function of the current density, it did vary as a
function of the concentration of the dopant DexP in the polymerisation solution
(Figure 3.3). Polymer film mass increased with an increase in DexP concentration,
with a DexP concentration of 15 mM demonstrating the greatest film mass (843 ±
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16 µg/cm2), followed by the 10 mM (676 ± 19 µg/cm2) and 5 mM films (562 ±
29 µg/cm2), respectively.

Figure 3.3 Mass deposition of PPy/DexP films electropolymerised at different
current densities and DexP concentrations, measured with EQCM. N=3; error type is
95% confidence interval standard deviation.

There was however a difference in the mechanical properties of the films even
though the total film mass did not vary as a function of the current density. The mean
viscoelasticity increased with an increasing current density (Figure 3.4). Film
mechanical properties are determined by investigating the ratio of the viscoelastic
properties of the adsorbed mass (resistance) per unit of adsorbed mass (frequency)
(R/f). As this ratio increases, the adsorbed mass is deemed more viscoelastic, or more
hydrated and soft18. The ratio of the films grown at 1.5 mA/cm2 (0.0043 ± 0.0001) is
substantially greater than both the 1.0 mA/cm2 (0.0013 ± 0.0002) and 0.5 mA/cm2
(0.0009 ± 0.0009).
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Figure 3.4 Mechanical properties of PPy/DexP films electropolymerised at different
current densities and DexP concentrations, measured with EQCM. N=3; error type is
95% confidence interval standard deviation.

The mechanical properties of the PPy/DexP films were also found to vary as a
function of the dopant DexP concentration. The viscoelasticity of the polymer films
was larger grown from the DexP concentration of 10 mM (0.0104 ± 0.006), however
films grown at a DexP concentration of 15 mM demonstrated a considerable
reduction in viscoelasticity, demonstrating a R/f ratio of 0.0019 ± 0.0006.

3.3.1.3

Film Topography

The PPy/DexP film surface roughness increased with an increase in current density
(Figure 3.5), however decreased with an increase in the concentration of the dopant
DexP in the polymerisation electrolyte (Figure 3.6). PPy/DexP films grown at
0.5 mA/cm2 demonstrated a RRMS roughness value of 133 ± 7.5 nm, with RRMS
roughness increasing for films grown at 1.0 mA/cm2 (171 ± 8.6 nm) and 1.5 mA/cm2
(203 ± 8.8 nm), respectively. Films grown with at 1.5 mA/cm2 with a DexP
concentration of 5 mM demonstrated the greatest surface roughness, compared to
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both 10 mM (114 ± 10 nm) and 15 mM (99 ± 9 nm) DexP concentrations, with the
later illustrating the lowest mean RRMS value of all PPy/DexP films studied.

5mM/0.5mA

5mM/1.0mA

5mM/1.5mA

Figure 3.5 Roughness and AFM images of PPy/DexP films electropolymerised at
different current densities. N=3; error type is 95% confidence interval standard
deviation.
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5mM/1.5mA

10mM/1.5mA

15mM/1.5mA

Figure 3.6 Roughness and AFM images of PPy/DexP films electropolymerised at
different DexP concentrations. N=3; error type is 95% confidence interval standard
deviation.

An increase in current density has previously been shown to increase polymer
surface roughness, with this relationship also seen in this system. However, few
studies have investigated the influence of dopant concentration on surface
topography. Herein surface roughness was found to decrease with increasing DexP
concentration. This is contrary to previous studies that have reported conducting
polymer surface roughness to increase with an increase in the concentration of the
dopant anion in the polymerisation electrolyte19. Studies where the monomer/dopant
ratio in the polymerisation electrolyte has been varied have produced differing
results in terms of the interfacial roughness of PPy films. An increase in the
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concentration of p-toluene sulfonate (pTS) (0.0025M to 0.1M) was found to increase
surface roughness of the resulting electrochemically polymerised films19. A similar
result was also found in another study where an increase in the dopant concentration
of PPy with poly(styrenesulfonate) (PSS) resulted in an increase in surface
roughness20.

The specific influence of a counterion on polymer properties is known to be highly
dependent on the specific anion employed during polymer synthesis21. A previous
study demonstrated that an increase in the concentration of the biological dopant
dextran sulphate (DS) in the polymerisation electrolyte was shown to decrease
surface roughness and decrease film thickness in electrochemically polymerised PPy
films22. Therein XPS data confirmed an increase in dopant present at the polymer
surface as the dopant concentration was increased; however, FTIR demonstrated the
doping of the PPy to remain constant. The increase in DS concentration was
proposed to increase the entrapment of excess dopant in the polymer matrix,
resulting in a less porous polymer film, and therefore a smoother polymer interface.
A similar mechanism is likely to be occurring herein, with the increase in DexP
concentration in the polymerising monomer solution increasing the entrapment of
excess dopant in the polymer matrix.

The entrapment of dopant mechanism can also be applied to explain the increase in
film mass as a function of DexP concentration (Figure 3.3). PPy/DexP films grown
at the same charge density would be expected to result in equal polymerisation of
PPy/DexP polymers within the film mass, based on the stoichiometry of the system.
The increase in mass as a function of the increase in the dopant concentration in the
polymerisation electrolyte is therefore likely to be derived from the entrapment of
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dexamethasone within the polymer matrix during polymer polymerisation. This is
supported by the incremental increase in the total mass of the polymer film as a
function of increasing DexP concentration.

An increase in the DexP concentration in the polymerisation electrolyte also resulted
in variations in the mechanical or viscoelastic properties of the polymer films (Figure
3.4). The viscoelasticity of the PPy/DexP films decreased for films grown with
5 mM to 15 mM DexP in the polymerisation electrolyte, with films grown at 10 mM
DexP concentration demonstrated the highest mean R/f ratio, however illustrating a
large 95% confidence interval range around the mean. The increase in polymer
rigidity (i.e. decrease in viscoelasticity and R/f ratio) for films grown at 5 mM to
15 mM DexP concentration may result from an increase in the density and/or
internal organisation of the polymer film stemming from the increase in entrapped
dopant within the polymer matrix. A decrease in polymer surface roughness as a
function of increasing DexP concentration in the polymerisation electrolyte is also
indicative of a decrease in the porosity of the polymer film, which is suggestive of an
increase in film density. An increase in PPy film shear modulus (e.g. rigidity) with
increasing dopant concentration has previously been demonstrated for PPy doped
with DS22. Conversely, polymer rigidity was demonstrated to decrease (increasing
viscoelasticity and R/f ratio) as a function of increasing current density during
electrochemical polymerisation (Figure 3.4). This increase in polymer viscoelasticity
was coupled with an increase in surface roughness, suggesting an increase in the
polymer viscoelasticity is the result of an increase in polymer porosity, and therefore
hydration, resulting in a softer, highly hydrated polymer film.
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3.3.2 Protein Interaction and PEG-SH Modification
The surface adsorption of the protein fibrinogen to the PPy/DexP films was
evaluated using the QCM-D technique. The change in the frequency parameter,
which is a measure of the mass adsorbed to the polymer surface, was normalised for
the interfacial polymer surface area (that varied as a function of the current density
and DexP concentration). The increase in the interfacial surface area was quantified
by comparing the actual surface area of the films using 3D AFM topographic images
to the geometric AFM scan area (Table 3.2). While there was no significant trend in
the mass of Fb adsorption on the PPy/DexP films grown as a function of increasing
current density or DexP concentration, the mean Fb adsorption was considerably
greater on films grown at 1.5 mA/cm2 (158 ± 75 Hz), compared to both the
0.5 mA/cm2 (120 ± 21 Hz) and 1 mA/cm2 (111 ± 28 Hz) growth conditions (Figure
3.7). Conversely, there was a general decrease in mean Fb adsorption with increasing
DexP concentration, with films grown with 5 mM DexP in the polymerising
electrolyte demonstrating a mean Fb adsorption of 158 ± 75 Hz, followed by films
grown with 10 mM (113 ± 13 Hz) and 15 mM (91 ± 8 Hz), respectively.

Table 3.2 Increase in the interfacial surface area of the PPy/DexP films compared to
the geometric AFM scan area.
PPy/DexP
Films

5 mM/
0.5 mA

5 mM/
1.0 mA

5 mM/
1.5 mA

10 mM/
1.5 mA

15 mM/
1.5 mA

Surface
Area

102.5%

104.2%

105.9%

102.8%

102.6%
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Figure 3.7 Protein adsorption onto PPy/DexP films, measured with QCM-D. N=3;
error type is 95% confidence interval standard deviation.

PEG-SH binding to PPy/DexP was also measured using the QCM-D technique.
PEG-SH binding varied as a function of the current density used during PPy/DexP
polymerisation, and the molecular weight of the PEG-SH (Figure 3.8). For films
grown with varying current density, the binding of 5k MW PEG-SH increased with
the increase of current density while the binding of 40k MW PEG-SH decreased.
The greatest reactive binding of the 5k MW PEG-SH was illustrated on the films
grown at 1.5 mA/cm2 (38 ± 0.5 Hz), with films grown at 0.5 mA/cm2 and
1.0 mA/cm2 demonstrating similar adsorption values (27 ± 6 Hz and 24 ± 3 Hz,
respectively). The 40k MW PEG-SH demonstrated a decrease in binding as a
function of increasing current density, presenting Δf of 71 ± 5 Hz, 61 ± 13 Hz and 52
± 1 Hz for current densities of 0.5, 1.0 and 1.5 mA/cm2, respectively. The binding of
5k and 40k MW PEG-SH also showed contrasting trends against the varying of the
DexP concentration in the polymerising solution. Binding of 5k MW PEG-SH was
greatest for films grown with 5 mM DexP concentration in the monomer solution (38
± 0.5 Hz), with similar binding demonstrated for films grown with10 mM and
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15 mM Dex concentrations (22 ± 0.5 Hz and 22 ± 1.6 Hz, respectively). Conversely
the mass of 40k MW PEG-SH binding to PPy/DexP was greater for films grown
with the two greatest DexP concentrations (69 ± 12 Hz and 61 ± 5 Hz for 10 mM and
15 mM Dex concentrations, respectively), compared with films grown with 5 mM of
the Dex dopant (52 ± 1.3 Hz).

Figure 3.8 PEG-SH modification of PPy/DexP films, measured with QCM-D. N=3;
error type is 95% confidence interval standard deviation.

PEG-SH modification of the PPy/DexP films consequently influenced the
subsequent ability for Fibrinogen (Fb) to bind to the polymer surface (Figure 3.9).
For PPy/DexP films grown at varying current densities, PEG-SH modification, with
both the 5k and 40k MW PEG-SH, substantially reduced Fb adsorption compared to
the control (unmodified) PPy/DexP films for all polymerisation current densities
(Figure 3.9). While there was no substantial difference between Fb adsorption as a
function of PEG-SH molecular weight for all three current densities, mean Fb
adsorption was least for both molecular weight PEG-SHs for the 1.0 mA/cm2 films
(24 ± 15 Hz and 30 ± 15 Hz for 5k and 40k MW PEG-SH, respectively). Conversely,
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PEG-SH modification of PPy/DexP as a function of DexP concentration illustrated
considerable differences between the ability of the surface modification to resist Fb
adsorption as a function of PEG-SH molecular weight. PPy/DexP modified with the
40k MW PEG-SH illustrated less Fb adsorption relative to the 5k PEG-SH modified
films (Figure 3.9). However, the modification with 5k MW PEG-SH showed no
reduction of protein adsorption for the films grown with DexP concentrations of
10 mM and 15 mM. Mean Fb adsorption was least for the 40k PEG-SH modification
for the 5 mM/1.0 mA film among all growth conditions.

Figure 3.9 Fibrinogen protein adsorption against control PPy/DexP films and 5k and
40k MW PEG-SH modified PPy/DexP films, measured by QCM-D. N=3; error type
is 95% confidence interval standard deviation.

The PEGylation of surfaces has been widely employed as a method through which to
protect a surface from non-specific protein interactions. PEG is widely accepted to
function through presenting a highly mobile and conformationally dynamic polymer
brush layer, that together with high hydration and water structuring at the molecule
surface, presents an inert substrate to the surrounding environment and a steric
exclusion zone at the substratum23,

24, 25

. A number of variables have been
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demonstrated to be critical to optimising the efficacy of the PEG layer to dissuade
surface protein interactions, including PEG surface grafting density and the
intermolecular interactions/organisation of the PEG chains, which in concert
influences both surface coverage and PEG polymer brush conformation at the
substrate surface26,

27, 28

. Surface adsorbed PEG at low densities is proposed to

present a mushroom type conformation on the surface, conformationally uninhibited
by neighbouring PEG molecules. In this regime, neighbouring PEG molecules and
their highly hydrated solvation shell are not forced to overlap, and therefore there
remain gaps between the surface adsorbed PEG chains through which suitably sized
proteins may navigate to reach the underlying polymer surface, drawn by attractive
forces including van der Waals, electrostatic and hydrophobic interactions.
Additionally, the mushroom-like conformation of PEG acts to minimise the distance
between the top of the PEG brush polymer and the surface, and therefore this
distance may not be sufficient to impede attractive forces between proteins in the
interacting solution and the underlying substratum.

Increasing the PEG density on the surface decreases the space between the PEG
chains, forcing neighbouring PEG polymer brushes to interact and overlap. The
repulsive intermolecular interactions of the PEG chains forces the PEG molecules
away from each other, driving the surface bound PEG chain to extend away from the
substratum surface. The elongation of the PEG chain forces a regime shift from a
mushroom to a brush type conformation29. In this organisation, PEG density on the
surface is increased, reducing the likelihood of gaps between the PEG brush chains,
as well as increasing the overall height of the PEG brush layer from the substratum
surface. Increasing the molecular weight of surface bound PEG, and therefore
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increasing the overall chain length, has also been demonstrated to enhance the
protein resistant properties of surface bound PEG layers, and is thought to act by
increasing the overall thickness of the PEG bound layer, and therefore sterically
hindering potential adsorbent protein molecules from reaching the underlying
surface29.

The reactive binding of PEG-SH to PPy/DexP was characterised as a function of
PEG molecular weight, as well as the current density employed during polymer
polymerisation, and the concentration of the dopant DexP in the polymerisation
electrolyte. Previously, the binding of PEG-SH to polypyrrole doped with the
biological dopant dextran sulphate (DS) was investigated as a method through which
to prevent non-specific adsorption of the important extracellular protein fibronectin
to the polymer surface18. Therein, PEG-SH binding increased as a function of
increasing PEG molecular weight as measured by QCM-D, and was correlated to the
increase in overall mass of the PEG-SH binding to the polymer surface. Herein the
mass of PEG-SH binding was greater for 40k MW PEG, relative to the 5k MW PEG;
however this is less than an 8 to 1 ratio that would be expected from the difference in
PEG molecular weight if the overall binding densities were the same. Therefore it
can be proposed that the binding density is likely to be considerably less for the
larger MW PEG-SH, where repulsive steric interactions for the larger MW PEG-SH
prevent high surface binding densities, compared to the smaller 5k MW PEG-SH. A
similar mechanism has previously been proposed to underlie the differences in total
PEG-SH binding of PEG-SH to PPy/DS films as measured via QCM-D18.

PEG-SH binding to the PPy/DexP films was normalised against the actual surface
area of films resulting from the various growth conditions as measured using AFM
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(Figure 3.8). While the total mass of 5k MW increased as the polymer
polymerisation current density increased, the opposite trend was seen for the 40k
MW PEG-SH, where binding mass decreased. As seen in Figure 3.5, the surface
roughness of the PPy/DexP films increased with an increase in polymerisation
current density. Previously, it has been demonstrated that along with an increase in
surface roughness, an increase in current density during polymer growth also
increases the porosity of the polymer. The analysis of polymer mechanical properties
(Figure 3.4) herein supports this study. The R/f ratio increased dramatically with
increased current density, indicating the film was more hydrated and “soft”, likely
due to higher porosity. Therefore the increase in 5k PEG-SH binding with increasing
surface roughness may result from the increase in the porosity of the polymer film,
providing additional binding sites on the polymer backbone. The decrease in the
binding of the 40k PEG-SH with increasing current density is also likely the result of
access of the PEG-SH molecule to binding sites on the polymer. Contrary to 5k MW
PEG-SH, the increase in PPy/DexP surface roughness reduced the ability for the
relatively large 40k MW PEG-SH molecules to access areas between the small
nodular features on the polymer surface, therefore reducing the overall available area
for surface binding, and as such, decreasing the overall density of PEG-SH
molecules on the polymer surface. A similar mechanism likely applies to the PEGSH binding to PPy/DexP films as a function of DexP concentration (Figure 3.8). As
shown in Figure 3.6, the surface roughness decreased with increasing DexP
concentration, therefore the binding of 5k MW PEG-SH decreased while the binding
of 40k MW PEG-SH increased.
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PEG-SH modification of the PPy/DexP films was demonstrated to considerably
reduce the adsorption of the protein fibrinogen (Fb) to the surface of PPy/DexP films
grown under all conditions (Figure 3.9). Previously, PEG-SH modification of
polypyrrole doped with the biological dopant dextran sulphate was shown to
considerably reduce the adsorption of the extracellular matrix protein fibronectin
(FN) to the polymer surface18. Therein, the efficacy of employing PEG-SH of
varying molecular weights to resist FN adsorption was tested, with an increase in
PEG-SH molecular weight from 1k, 5k, 20k and 40k MW demonstrated to
correspond to a decrease in protein binding at the polymer interface. A similar
relationship is evident here, with the 40k MW PEG-SH demonstrating average lower
Fb adsorption values compared to PPy/DexP modified with the 5k MW PEG-SH,
with the difference demonstrated to be substantial for PEG-SH modification to the
films grown with higher DexP concentrations (10 mM and 15 mM) (Figure 3.9).

Interestingly, PEG-SH modification using the 5k MW PEG on films grown with
10 mM and 15 mM concentrations of DexP in the electrolyte failed to exhibit a
considerable reduction in fibrinogen adsorption compared to the control films
(Figure 3.9). Total reactive binding of the 5k PEG-SH was found to decrease with an
increase in DexP concentration from 5 mM to 10 mM and 15 mM (Figure 3.8). As
discussed previously (Section 3.3.1.3), increasing the concentration of DexP may
result in enhanced entrapment of DexP in the polymer matrix, increasing the
presence of the dopant at the polymer surface and therefore reducing the comparative
presence of PPy. This effectively reduced the overall available binding sites for the
PEG-SH to react, hence reducing overall thiol-ene binding. Depending on the
organisation of the DexP at the polymer interface, the dopant rich areas at the
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polymer interface incompatible for thiol-ene binding may occupy several hundred
square nanometres, providing areas that are too large for the relatively short 5k MW
PEG-SH molecules to “overlap” or “protect” when binding to peripheral regions
around these areas. Conversely, increasing the PEG-SH MW may provide a
mechanism by which the limited availability of potential binding sites and presence
of reactively benign “dopant rich” areas may not impede the overall efficacy of the
PEG-SH protection of the surface. Increasing the PEG-SH chain length would
increase the overall width of the solvation shell, particularly when in a mushroomtype conformation. The increasing of this solvation shell may assist in protecting
areas that do not exhibit suitable chemistry for reactive thiol-ene binding. Therefore
the increase in DexP concentration during PPy/DexP polymerisation does not inhibit
the ability for the 40k MW PEG-SH modification to resist the adsorption fibrinogen
to the polymer surface.

3.3.3 Drug Release Studies
The electrical stimulated release of DexP was performed in artificial perilymph by
applying a constant -500 mV potential to the PPy/DexP films. The 5 mM/1.5 mA
films illustrated the most DexP release both as a function of current density or DexP
concentration (Figure 3.10). The PPy/DexP films showed DexP release profiles
during the 4 hours stimulation. At the end of stimulated release, the 5 mM/1.5 mA
films released a mean value of 242.0 µg of DexP, while the 5 mM/0.5 mA and
5 mM/1.0 mA films released 85.4 µg and 70.2 µg, respectively. The PPy/DexP films
polymerised with higher DexP concentrations were proposed to have higher DexP
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content, however the release profile of DexP decreased with an increase in DexP
concentration presented in the polymerising solution. The 10 mM/1.5 mA and
15 mM/1.5 mA films released 108.4 µg and 82.1 µg of DexP respectively, which is
much less than the 5 mM/1.5 mA films (242.0 µg). This result correlates to the
roughness and mechanical properties of the PPy/DexP films. The 5 mM/1.5 mA
PPy/DexP film is shown to have the highest surface roughness and porosity, which
promotes the interaction with the electrolyte solution, and the porous structure will
also enhance the mobility of DexP molecules out from the bulk film.

Figure 3.10 DexP release in artificial perilymph at room temperature for 4 hours.
N=3; error type is 95% confidence interval standard deviation.
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Figure 3.11 DexP release in artificial perilymph at room temperature for 4 hours,
plotted against the square root of time.

While no considerable DexP release was found under the condition where no
potential was applied (data not shown), demonstrating the release was
controlled/triggered by the stimulation, the DexP release profiles were also plotted
against the quare root of time, to study the mechanism underlying the stimulated
release (Figure 3.11). A linear relationship was demonstrated between the DexP
release and the square root of time, which was consistent with a diffusion controlled
release mechanism30, 31, indicating the release of DexP under the stimulation was by
diffusing through the PPy films.
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3.3.3.1

Release from PEG-SH Modified PPy/DexP

The 5 mM/1.5 mA PPy/DexP films were then chosen to be PEG-SH modified with
the aim of developing a protein-resistant DexP release system. The 5k and 40k MW
PEG-SH modified films showed almost identical DexP release profiles during the 4hour stimulation. However the amount of DexP released from PEG-SH modified
films were largely reduced, with 131.5 µg and 131.6 µg for 5k and 40k respectively,
compared to 242.0 µg from the un-modified films (Figure 3.12). The CV analysis
shows little difference between the modified and un-modified films, which indicates
little change of electrochemical properties due to PEG-SH modification. The
decrease of DexP release therefore would be due to the hydrated layer of PEG on the
PPy/DexP surface, which reduced the mobility of DexP molecules and thus impeded
their ability to penetrate out from the PPy/DexP film into the surrounding electrolyte
solution.

Figure 3.12 DexP release from PEG-SH modified 5 mM/1.5 mA PPy/DexP films in
artificial perilymph at room temperature for 4 hours. N=3; error type is 95%
confidence interval standard deviation.
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Figure 3.13 Cyclic voltammetry of PEG-SH modified and un-modified PPy/DexP
films (5 mM/1.5 mA), performed in artificial perilymph at a scan rate of 50 mV/s vs.
Ag/Ag+. The 10th cycle is shown and the arrows indicate the direction of the
potential scan.

A reduction in the DexP release rate due to the ability for the PEG-SH layer to
impede the migration out from the film surface has advantageous implications for the
drug delivery system. While DexP migration is inhibited, the CV results indicate that
the movement of small ions across the PEG-SH layer are not inhibited, and therefore
polymer electro-activity is not affected. This is critical as the release of therapeutic
drugs from carrier materials employed in controlled drug eluting scaffolds, including
organic conducting polymer based systems, typically suffer from a “burst” type
release upon incubation in an in vitro or in vivo environment. The ability for the
PEG-SH layer to reduce protein adsorption and reduce the rate of DexP release,
while maintaining polymer electro-activity, has the potential to have significant
implications for the development of drug eluting conducting polymer based devices,
as well as development of low fouling conducting polymer based electrodes, that are
currently the focus of intense research for a diverse suite of biomedical applications.
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3.4 Conclusions
In this chapter, I have demonstrated the fabrication of a hybrid drug delivery system,
with the capability of releasing an anti-inflammatory agent as well as demonstrating
protein resistance. By varying the conditions for electropolymerisation-current
density and DexP concentration- the PPy/DexP films showed various film
morphology and mechanical properties. Increase of current density produced
PPy/DexP films with increased surface roughness and porosity, while increase of
DexP concentration reduced the surface roughness and porosity. Increase of
polymerisation time or DexP concentration would both result in PPy/DexP films
with higher mass deposition.

The PEG-SH modification of PPy/DexP films followed a thiol-ene reaction
mechanism. PEG-SHs with two different molecular weight (5k and 40k) were used
to investigate the effect of PEG chain length against the effect of different PPy/DexP
film properties on the PEG-SH modification and protein adsorption. The reaction
between PEG-SH and PPy/DexP followed contrasting trends with different PEG-SH
molecular weight. The 5k MW PEG-SH reaction density increased with the increase
of PPy/DexP surface roughness and porosity, while the 40k MW PEG-SH reaction
density decreased. Both 5k and 40k MW PEG-SH demonstrated considerable
reduction of protein adsorption on the PPy/DexP surface despites the change of
current density. However the 40k MW PEG-SH illustrated distinct advantage over
the 5k MW PEG-SH when the reaction region was limited on the PPy/DexP film
surface.
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The electrical stimulation of DexP release profiles also varied with the different
PPy/DexP properties. The 5 mM/1.5 mA PPy/DexP films released the largest
amount of DexP after 4-hour stimulating under a constant negative potential.
PPy/DexP films with PEG-SH modification demonstrated a reduction in DexP
release, due to limited DexP mobility and retention of the DexP in the PEG layer.
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Chapter 4
Reactive Inkjet Printing
Hydrogels for Drug Delivery
4.1 Introduction
In recent years, inkjet printing has drawn increasing interest due to the enormous
potential for its application as a versatile tool for free-form fabrication of various
materials rather than the conventional printing of electronic data onto paper or
transparencies. Inkjet printing has several advantages over other conventional
fabrication technologies, including non-contact deposition, micron-scale patterning,
easy designing and low cost. It has been widely used in numerous applications
including organic light-emitting diode displays1, electronic devices2, 3, 3D rapid
prototyping4 and tissue engineering5, 6. As a result many different kinds of materials
have been investigated for these applications, such as conducting polymers7,
biomaterials8, as well as proteins9, 10 and even living cells11, 12.

Hydrogels are crosslinked hydrophilic polymer networks. They can absorb water
from 10-20% up to thousands of times of their dry mass13. Hydrogels are widely
used in tissue engineering as scaffolding materials due to their high water content
and physiochemical similarity to native extracellular matrix 14. Their porous structure
allows cell encapsulation and growth, as well as the diffusion of nutrients and
metabolites. Their porosity also provides an environment for the loading and
subsequent release of drugs and growth factors to a specific target area, making
hydrogels ideal candidates as reservoirs and vehicles for drug delivery.
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Alginate-Chitosan hydrogels have been studied for the purpose of cell
transplantation15, DNA encapsulation16 and drug release systems17,

18

. Chitosan has

been recognised to promote the adhesion of cells and proteins to alginate-based
hydrogels, and act as a stabilising agent for the hydrogel scaffolds. While the fast
gelation rate between alginate and chitosan is a major issue in terms of controlling
the formation and fine structural resolution of features of hydrogels using standard
fabrication techniques, inkjet printing may provide a solution for many of these
issues. Inkjet printing provides the ability to react the alginate and chitosan directly
on the substratum at incredibly small material volumes and feature sizes, removing
issues associated with the pre-gelation of the hydrogel when materials are premixed
prior to deposition on a surface using other fabrication techniques; a process that also
greatly impedes the ability to fabricate reproducible and high resolution structures
both in two and three dimensions.

In this study, a multiple printhead inkjet printer was developed to print alginatechitosan hydrogels (as described in Section 2.3). The recommended surface tension
of the ink fluid is around 30 mN/m and the ideal viscosity should be below 10 mPa.s
for the Xaar printheads used in this printing system19. The goal for this work is to
investigate and optimise the ink formulations for alginate and chitosan to achieve the
optimum single ink printing with alginate or chitosan, as well as the reactive printing
of alginate-chitosan hydrogel with both inks. Phenol red or dexamethasone 21phosphate disodium was mixed into the alginate ink before printing and loaded in the
printed alginate-chitosan hydrogel samples, and their in vitro release was studied.
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4.2 Experimental Set-up and Methods
4.2.1 Reactive Inkjet Printing System
The reactive inkjet printer and printing methods were used as described in Section
2.3.

4.2.2 Polymer Ink Formulation Preparation
Deionised water and 1 v/v% lactic acid were used as solvents for alginate and
chitosan, respectively. 0.5 wt% alginate and chitosan stock solutions were prepared
by dissolving 0.5 g of polymer in 100 mL of solvent and stirred overnight on a
magnetic stirrer. Fresh polymer solutions were made weekly. The surface tension of
aqueous solution is generally above 60 mN/m. Therefore, to reduce the surface
tension of the alginate and chitosan solutions for inkjet printing, 10 v/v% Triton™ X100 (dissolved in deionised water) was used as a surfactant. Different polymer
concentrations and surfactant additions were investigated for optimum printing
output. To prepare ink formulations, desired amounts of polymer and surfactant
stock solutions were mixed and diluted with solvent, and either phenol red dye or
DexP was then added up to the desired concentration. 10 minutes of low intensity
bath sonication (Branson B5500R-DTH) was applied to the ink solutions for the
purpose of homogeneous dispersing and degasing prior to printing.

4.2.3 Substrate Treatment
Cover glass, polyethylene terephthalate (PET) films and polydimethylsiloxane
(PDMS) films were used as printing substrates in this work. PDMS films were made
from implant grade liquid silicone rubber (LSR30), composed of base and
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crosslinker components that were mixed at a weight ratio 10:1, and dissolved in
hexane. The mixture was then cast in Teflon moulds. After 6 hours, the cast films
were cured at 110 °C for 30 min. After removal from Teflon moulds, PDMS films
were incubated in deionised water for 24 hours and cleaned with ethanol and
deionised water prior to use.

Cover glasses and PET films were rinsed with ethanol and deionised water and dried
under nitrogen gas prior to experiments. To make the surface hydrophilic and
suitable for printing, the PDMS films were treated with oxygen plasma for 60 s using
a plasma cleaner (Harrick Cleaner, PDC-32G-2, New York, USA) with high
frequency level and chamber pressure at ~1000 mTorr.20

4.2.4 In-vitro Release
The in-vitro drug release from printed hydrogels was performed in artificial
perilymph. With phenol red as a model molecule, printed hydrogels were immersed
into 2 mL artificial perilymph in plastic cuvettes, and phenol red release measured at
559 nm

(λmax

of

phenol

red)

using

a

Shimadzu

UV1800

Ultraviolet

Spectrophotometer.

DexP release was performed in 2 mL artificial perilymph and at regular time
intervals an aliquot (200 µL) was removed from the incubating artificial perilymph
solution, which was immediately replaced with the same volume of fresh artificial
perilymph solution. A Shimadzu HPLC system was employed to detect DexP. The
reason a different method was chosen is because the residual alginate and chitosan in
the sample solution interferes with the UV spectrum of DexP21, therefore the
polymers should be removed from the samples prior to detection. To remove
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dissolved polymers in the samples, all the release samples were first freeze-dried at 30 ºC for 60 hours, and then placed in a vacuum oven at 40 ºC overnight. 1 mL
Methanol was then added to the dry material to extract DexP, followed by vortex
mixing and centrifuging with a bench top centrifuge. After centrifugation, the clear
solutions were collected and filtered with 0.2 µm regenerated cellulose syringe filters
(Phenomenex). The HPLC mobile phase was 50% 0.02 M NaH2PO4 and 50%
methanol and ran at a flow rate of 1 mL/min. A sample volume of 20 µL was
injected into the column (C18, Waters Atlantis T3®) and DexP was detected at
242 nm (λmax of DexP) by a UV-Vis detector in the Shimadzu HPLC system.

4.3 Results and Discussion
4.3.1 Ink Formulations
Ink surface tension and viscosity are two critical parameters important for the
efficacy of inkjet printing. Low viscosity is critical to allow rapid ink refilling in the
printhead during printing (less than 200 µs). The surface tension must also be low,
allowing the ink to distribute evenly into the channels in the printhead for jetting;
however, it must also be high enough to prevent ink dripping out from the nozzles22.
Pressure control is also essential for inkjet printing, and typically a vacuum pressure
between -1 kPa to -3.5 kPa is applied at the nozzle plate23. Vacuum varying outside
this range will generally cause the ink to either leak out of the nozzles, covering the
nozzle plate and inhibiting jetting (low pressure), or alternatively the ink may be
drawn back through the nozzle plate, leaving no ink in the channels to jet (high
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pressure). The pressure was controlled by a vacuum pressure control system
(NordsonEFD Ultimus™) and adjusted accordingly for each experiment.

4.3.1.1

Ink Surface Tension

To reach the recommended surface tension of 30 mN/m, a non-ionic surfactant,
Triton™ X-100, was chosen to reduce the surface tension of the ink solutions. In
theory, higher surfactant concentration results in lower surface tension, until
reaching a concentration above which micelles form in solution and additional
surfactant contributes to the micelle component, at which point the surface tension of
the solution remains constant. This concentration is called the critical micelle
concentration (CMC).

To determine the CMC of Triton™ X-100 in water and the surface tension at its
CMC, deionised water solutions with increasing concentrations of Triton™ X-100
from 10-5 v/v% to 10 v/v% were prepared and their surface tension measured with a
goniometer (OCA20). (Figure 4.1). The CMC of Triton™ was determined to be at
0..022 v/v%, where the solution exhibited its lowest surface tension of
approximately 30 mN/m (which is similar to the value of 0.22 to 0.24 mM reported
in the Sigma Product Information Sheet). This value is in the optimum range for
piezoelectric inkjet printing and therefore 0.1 v/v% Triton™ X-100 was used for all
ink formulations.
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CMC

Figure 4.1 Effect of Triton™ X-100 concentration on surface tension in deionised
water.

4.3.1.2

Ink Viscosity

The low viscosity alginic acid sodium (alginate) and low molecular weight chitosan
used in this work had reported viscosity values of 4-12 mPa·s and 20-300 mPa·s at
1 wt%, respectively. Polymer solutions normally behave as non-Newtonian fluids,
with their viscosity varying with changes in polymer concentration and dependent on
the shear rate applied. The piezoelectric inkjet printheads used in this work had
working shear rates between 1 000 /s to 100 000 /s as reported24.

To study the effect of shear rate on alginate and chitosan solutions, a continuous
ramp step measurement was performed with a TA AR-G2 Rheometer. Results in
Figure 4.2 show that alginate and chitosan solutions both had high viscosity near the
shear rate 1 /s, however the viscosity values dropped rapidly between 1 /s to 100 /s
when a higher shear rate was applied. After 100 /s the viscosity decreased slowly
until it reached a constant value at a shear rate around 500 /s. This result indicates a
shear thinning behaviour for both alginate and chitosan solutions, illustrating the
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polymer solutions would have constant viscosities at the printheads’ working shear
rates.

A

B

Figure 4.2 Effect of shear rate on shear stress and viscosity of (A) alginate and (B)
chitosan solutions.
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Figure 4.3 Effect of different polymer concentrations and sonication treatment on the
viscosity.

Diluted polymer solutions from 0.1 wt% to 0.5 wt% were prepared to measure their
viscosity as a function of concentration (Figure 4.3). Continuous ramp step
measurements between 1 /s to 1 000 /s were performed with a TA AR-G2 Rheometer.
The measured solutions showed the same shear thinning behaviour as in Figure 4.2
and their viscosity at the shear rate 1 000 /s was recorded. Results in Figure 4.3 show
the viscosity values of alginate and chitosan at a shear rate of 1 000 /s. For both
alginate and chitosan, in the range of 0.1-0.5 wt%, the viscosity increased linearly,
from 3.26 mPa·s to 8.64 mPa·s and 3.32 mPa·s to 14.07 mPa·s respectively, with
chitosan solutions demonstrating a higher viscosity than alginate solutions at the
same concentration. The effect of the addition of Triton™ X-100 and the sonication
treatment was also tested. As the results shown in Figure 4.3 reveal, Triton™ X-100
and sonication did not have a significant effect on the ink solution viscosity.
Ultrasonic treatment is known to have an impact on the viscosity of polymer
solutions or lead to degradation of polymer chains25, 21. However, in a recent study, it
was also found the absence of chain degradation in homogeneous polystyrene
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solutions under the low-intensity sonication after 29 hours26. Herein, it is likely the
impact of the power and the period of the sonication bath did not lead to polymer
chain degradation in the ink solutions. Therefore, the viscosity of the ink solution,
which is dependent on molecular weight and concentration of polymer solution27,
was not affected by the sonication treatment. The low impact of Triton™ X-100 on
the ink solution viscosity also suggests weak interactions between the non-ionic
surfactant and the polymers, especially in dilute polymer solutions28, which has been
observed in previous studies29, 30, 31.

4.3.1.3

Ink Formulation Test

Based on the surface tension and viscosity results, 0.2 wt% was chosen as the
optimal concentration for alginate and chitosan formulations, with an addition of 0.1
v/v% Triton™ X-100 as the surfactant. These ink formulations gave a viscosity value
of approximately 5 mPa·s and a surface tension around 30 mN/m at the inkjet printer
working conditions.

With optimised ink formulations, alginate and chitosan were able to be inkjet printed.
Ink jettability (the ability for standard output quality and reproducibility) was tested
using the pattern shown in Figure 4.4 (A) – the left rectangle region demonstrates the
reliability of printing large scales, the middle area with short lines are able to
indicate if any nozzles stop jetting or fire at a wrong angle, and the right section
demonstrates the patterning ability. For easy observation, phenol red and crystal
violet were added into alginate and chitosan ink formulations respectively, and the
printing results are shown in Figure 4.4. As illustrated therein, good jettability was
achieved with both alginate and chitosan ink formulations.
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A

B

C

Figure 4.4 Pictures of (A) designed (input) pattern for ink jettability test and printed
(output) pattern on paper with (B) alginate ink formulation with phenol red and (C)
chitosan ink formulation with crystal violet.

4.3.2 Single Ink Printing
4.3.2.1

Droplet Volume Calibration

Xaar 126/80 printheads had a droplet volume of 80 pL for standard oil based inks,
however, the droplet volume was expected to change when transferring to the
aqueous ink formulations due to the change of physical and chemical properties.
Phenol red and crystal violet were employed to calibrate the droplet volumes. With
the optimised ink formulations, 0.5 g/L phenol red was dissolved in the alginate ink
formulation and 0.5 g/L crystal violet was dissolved in the chitosan ink formulation.
Two separate printheads were used for each different ink formulation respectively.
Samples from 10 layers to 50 layers of 50 × 50 dots squares were printed onto PET
strips. After drying, the printed samples were redissolved in 3 mL deionised water
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and their concentrations were measured by UV-vis spectroscopy. Equation 4.1 was
used to calculate the real droplet volume.

𝑉=

𝐶 × 𝑉𝑤
𝐶0 × 𝑎 × 𝑏 × 𝑛

Equation 4.1 Droplet volume calibration, where V is the real droplet volume, C is
measured concentration of phenol red or crystal violet, Vw is the deionised water
volume the samples redissolved into, C0 is the concentration of phenol red or crystal
violet in the ink formulations, a and b are the length and width of printed area (by
dots) and n is the number of printed layers.

The real droplet volume was found to be around 120 pL with minor variations
between different printheads as well as variations in system settings such as printing
frequency and waveforms. The droplet volume is an important variable for materials
deposition by inkjet printing, particularly for the production of materials designed for
precise drug loading and release.

4.3.2.2

Patterning Abilities

4.3.2.2.1

Printing of Dots

To test the patterning abilities, individual dots were first printed, with either the
alginate or chitosan ink formulations. One advantage of inkjet printing is the
precision of ink deposition. As demonstrated in Figure 4.5 A and C, a single dot was
printed onto a PET membrane with alginate ink for 50 layers, with each layer being
precisely deposited on top of the previous layer. However, in some cases the faulty
deposition of ink was observed that may result from several mechanisms, including
the shifting of the substrate during stage movement, or the partial clogging of
nozzles resulting in the jetting of ink at a wrong angle (Figure 4.5 B and D).
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Therefore, a range of specific variables must be optimised in order to obtain
optimum inkjet printing results.

A

500 µm

C

B

500 µm

D

Figure 4.5 Optical profilometry images of 50 layers printed alginate dots: top view
(A) and 3D view (C) of a precise deposited dot; and top view (B) and 3D view (D) of
a shifted deposited dot.

The cross-sectional profile of a 50 layer alginate dot (Figure 4.6) reveals a straight
and clear edge of the dot, illustrating the high precision of the droplet deposition
during the inkjet printing process. The dot demonstrated an elevated surface around
the edge compared to that in the middle; with this phenomenon typically known as
the ring-stain or coffee-stain effect32, and is caused by capillary flow. Liquid tends to
evaporate faster at the pinned edge of initial position, and is subsequently
replenished by liquid from the dot interior. The resulting outward flow carries the
dissolved or dispersed material to the edge. Therefore greater mass accumulates at
the edge of the dot than in the middle of the printed dot.
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Figure 4.6 Optical profilemetry image and the cross-sectional profile of a 50 layers
alginate dot.

Figure 4.7 Relation between the number of layers and height/width of printed dots.
N=5; error type is 95% confidence interval standard deviation.

The relation between the number of printed layers and the height and width of
printed dots was studied by printing dots onto PET membranes with the dots
subsequently measured with an optical profiler (Veeco Wyko NT9100). Results are
shown in Figure 4.7. The application of droplets from 10 to 50 printed layers
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illustrated no substantial difference in dot width (~165 µm), demonstrating the
effective and precise deposition of inkjet printing as discussed above. The height
increased linearly with the number of printed layers, presenting an average height
increase of ~0.112 µm per 10 layers.

4.3.2.2.2

Printing of Lines

Lines were printed by nozzles jetting along the stage movement axis. The piezocrystal inkjet printer used in this work had a resolution of 188 DPI, and the minimum
jetting distance was 135 µm. Since the printed dots had diameters around 165 µm,
when printed with the minimum jetting space, adjacent dots merged with each other
and therefore formed continuous tracks. The key factors that affect the patterns’
uniformity are the surface energy of the substrate, the wettability of the ink
formulations with the substrate, and the volume of the droplets. Preferably, the
surface energy of the substrate should not be too low, as this may introduce bulges
into the printed structures and local broadening of the edge of the lines33. Good
wettability of the ink formulations with the substrate leads to broad lines throughout
the printed structures. Therefore, to achieve desired features, it is critical to optimise
the surface energy of the substrate with the ink formulations. Very often, a change in
droplet volume (generally realised as a decrease in volume) due to clogging of the
nozzles, or defects in the printhead, may also result in the printer failing to print
uniform features.
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Printing direction

Figure 4.8 Schematics of the printing of lines with the inkjet printer.

A

B

C

D

Figure 4.9 Optical profilometry images of 40 layers printed lines (A and B) and their
cross-sectional profiles (C and D), respectively.
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Figure 4.10 Relation between number of layers and height/width of printed lines.
N=5; error type is 95% confidence interval standard deviation.

Figure 4.8 illustrates optical profilometry images of the printing of 40 layers of
alginate in the form of lines on glass slides. In Figure 4.8 A, the adjacent dots failed
to join together and resulted in a printed structure resembling the shape of a string of
beads. The cross-sectional profile (Figure 4.8 C) clearly reveals that they remained
individual dots. The printed line illustrated in Figure 4.8 B was printed in an
improved form and the cross-sectional profile (Figure 4.8 D) shows a more uniform
height profile along the line.

In Figure 4.9, the height of printed lines showed a similar trend as dots, and
increased linearly from 0.107 µm to 0.461 µm with the number of printed layers
from 10 to 50. However the average height was lower than that of the dots, which
was 0.104 µm per 10 layers compared to 0.112 µm per 10 layers with dots. The
width of printed lines decreased from 223 µm to 200 µm with the number of printed
layers from 10 to 50, which differed to the variation demonstrated for the single dot
printing, with the printed lines also found to be wider than the diameters of dots.
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When printing with continuous lines, more ink was deposited onto the substrate at
one time, compared to printing single dots, therefore increasing the wettability of the
ink with the substrate, and therefore produced broader features during the printing of
lines compared to dots.

4.3.2.2.3

Printing of Areas

A small square area (Figure 4.10) was formed by printing 16 (4 × 4) adjacent dots. X
direction is the axis where the nozzles align on the printhead and Y direction is the
axis of the stage movement. The jetting spacing along the Y direction was 135 µm
while the centre of the nozzles were 137 µm apart on the nozzle plate, therefore the
square had a slightly better resolution along the Y direction. The factors that affect
line printing also apply here with the printing of small areas. For example, clogging
of nozzles, jetting at wrong angles or even blockage of nozzles will lead to the
failure of forming the desired features. As demonstrated in Figure 4.10 C, a gap was
formed due to one of the nozzles jetting at a wrong angle. In contrast, when a much
larger area was printed (Figure 4.10 D), the defect by wrong angle printing was less
obvious, and the feature had good coverage and uniformity along both X and Y axis.
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C

X

D

2mm
500 µm

Figure 4.11 Optical profilometry images of printed structures with alginate ink: (A)
top and (B) 3D view of a 4 × 4 square, (C) top view of a defected square, and (D)
photograph of a large printed area.

4.3.3 Reactive Printing of Multiple Inks
In the study of the printing of multiple inks, two printheads were set up on the
reactive printer. Each printhead had its own reservoir and connection to the control
electronics. Developed alginate and chitosan inks were filled in the two reservoirs,
respectively.

This process was considerably different from single ink printing. The first layer of
polymer was printed onto the substrate and formed features like single ink printing
as discussed above. However, when a second layer of opposite charged polymer is
deposited onto the first layer crosslinking takes place at the interface of these two
layers (due to the gelation rate being fast between alginate and chitosan), which
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prevents the second layer from spreading. Hence the secondary droplets remain in
the dot shape that forms on deposition onto the structure (as shown in Figure 4.11,
image (A), (B), and (C)). The substrates used for printing were glass, PET and
plasma treated PDMS in image (A), (B), and (C) respectively. The three different
substrates had different contact angle values of 23.7°, 58.2° and 6.8° respectively. It
is shown in Figure 4.11 that the same morphology of printed hydrogel structures
formed on glass, PET and treated PDMS indicating the surface energy between the
substrates and the first layer of ink solution was not a determining parameter for the
quality of the printed hydrogel structures. It was also noted that when printing
aqueous ink solutions onto untreated PDMS, which had approximate contact angle
of 114.9°, no such structures could be formed (Figure 4.11 D).

A

Glass

B

PET

C

Treated PDMS

D

PDMS (untreated)

Figure 4.12 Optical microscopy images of 20 bi-layers hydrogel printed on (A) glass,
(B) PET membrane, (C) plasma treated PDMS membrane, and (D) untreated PDMS
membrane. (Dark area is hydrogel, and the scale bar represents 200 µm.)
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A

B

Figure 4.13 Optical profilometry of (a) printed hydrogel on glass and (b) the crosssectional profiles of printed hydrogel with different number of layers.

Optical profilometry measurements were performed on the hydrogel structures
printed on glass substrates (Figure 4.12). It shows that the height increased with
more alginate-chitosan bi-layers deposited. Coffee-stain effect was also observed
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during hydrogel fabrication. The rate of solvent evaporation was greater towards the
pinned edge lines, which led the solvent to flow outwards and at the same time
taking to the edge the soluble materials, which in this case, were small molecular
dyes or DexP and polymers that had not crosslinked immediately after printing. At
the edge of the printed areas there was an increase in the accumulation of both dye
and polymer materials, resulting in the structure being thicker at the edge than in the
middle. This was confirmed with both 2D and 3D profile images. The average height
was 0.15 µm, 0.5 µm and 1.0 µm for 10, 30 and 50 bi-layers of printed alginatechitosan hydrogel, respectively.

Table 4.1 shows the optical microscopy images of hydrogel samples printed on PET
and plasma treated PDMS membranes. The coverage of printed hydrogel on the
substrate increased with the printing of more layers. Because the plasma treated
PDMS membranes had lower surface energy and were more flexible than PET
membranes, the hydrogel was distributed more evenly when more bi-layers were
printed, with the dot shape less obvious when 50 bi-layers of hydrogel was printed
on plasma treated PDMS than those on PET membranes.
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Table 4.1 Optical microscopy images of different number of layers of alginatechitosan hydrogel printed on PET and plasma treated PDMS. (Scale bar represents
200 µm).
Hydrogel Printed on PET

Hydrogel Printed on PDMS

10
bi-layers

20
bi-layers

30
bi-layers

40
bi-layers
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50
bi-layers

4.3.4 In vitro Release
Samples of 50 × 50 dot square areas were printed with alginate and chitosan ink
formulations. Phenol red or DexP was mixed into the alginate ink before printing.
After droplet volume calibration (Section 4.3.2.1), the amount of phenol red and
DexP incorporated into the printed hydrogel samples were obtained and shown in
Table 4.2.

Table 4.2 Amount of phenol red and DexP incorporated in printed hydrogels.
Number of layers

Amount of phenol red (μg)

Amount of DEX (μg)

10

1.553

3.883

20

3.106

7.765

30

4.659

11.648

40

6.213

15.530

50

7.766

19.413

A 24 hour in vitro release study was performed on the printed hydrogel samples.
Phenol red samples were released in 2 mL artificial perilymph in 1 cm × 1 cm
cuvettes at room temperature, and the concentration of phenol red release was
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recorded in situ with a UV-Vis spectrometer at the time points of 10, 30 minutes, 1,
2, 4, 6, 8, and 24 hours. The DexP release aliquots were collected at 30 minutes, 1, 2,
4, 8, and 24 hours and analysed by a Shimadzu HPLC. Results are shown in Figure
4.13 and Figure 4.14.

Similar release patterns were found with both phenol red and DexP. The results
reveal that more drug released during the same time interval when there was more
drug incorporated in the hydrogel. Burst release occurred in the first 2 hours during
which up to 70 % of incorporated drug was released, which is due to the hydrophilic
property and the high porous structure of the alginate-chitosan hydrogel. The
increase in hydrophilicity facilities the penetration of water into the printed hydrogel
structures, thus making the structure more permeable to water soluble molecules
such as phenol red and DexP.

It was observed that for the same amount of incorporated small molecules, the
release speed of those from PDMS was slower than that from the PET membranes.
This could be explained by the possibility that the drugs diffused into the porous
silicone rubber membranes during printing. The PDMS membranes are more
hydrophobic and have a dense structure compared to hydrogel, which makes it less
permeable for water and small molecules. Therefore the drugs exhibited a longer
retention time when printed onto the PDMS membranes.
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Figure 4.14 Phenol red release from alginate-chitosan hydrogel printed on PET and plasma treated PDMS.
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Figure 4.15 Dexamethasone sodium phosphate release from alginate-chitosan hydrogel printed on PET and plasma treated PDMS.
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Table 4.3 DexP release rate from inkjet printed alginate-chitosan hydrogel.
0-1hr
(ng/min)

1-8hr
(ng/min)

8-24hr
(ng/min)

Total release
(µg)

PET 20

82.28

5.05

1.29

8.53

PET 30

76.92

13.82

2.22

12.55

PET 40

106.43

12.59

3.34

15.33

PET 50

171.73

22.12

1.56

21.09

PDMS 20

80.31

2.32

1.18

6.92

PDMS 30

71.61

16.00

1.62

9.46

PDMS 40

75.91

12.40

2.66

12.31

PDMS 50

181.71

6.59

0.76

14.40

The DexP release rate per minute was calculated and listed in Table 4.3. The rate and
total drug release was proportional to the number of bi-layers of hydrogel printed.
It’s reported that the drug release from neural electrodes has an effective radius of
500 µm34, which makes the DexP released from the printed hydrogel at a rate of 0.30.7 µM/min for the first hour (Equation 4.2). This is in the range of DexP effective
concentration to reduce inflammatory tissue reaction35.

𝐶=

𝑣𝑟
𝜋𝑅 2

Equation 4.2 The concentration 𝐶 of drug release in vivo, where 𝑣𝑟 is the drug
release rate, 𝑅 is the effective radius of the drug release device.
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4.4 Conclusions
In this chapter the inkjet printing of alginate and chitosan biomaterials has been
demonstrated, as well as reactive inkjet printing of alginate-chitosan hydrogel
structures onto glass, PET and PDMS membranes. Phenol red and DexP were also
printed into the alginate-chitosan hydrogel to show the ability of fabricating a
hydrogel drug delivery system using reactive inkjet printing.

The alginate and chitosan ink formulations were developed and optimised by using
low concentration alginate and chitosan aqueous solutions with addition of Triton X100 surfactant.

A range of features were successfully printed with developed inks by single ink
printing. The resolution of the printed features was affected by the surface energy
and wettability between the substrates and the ink formulations, and the clogging and
wrong angle jetting of the nozzles could cause the defects in the printed structures.
Due to the nature of fast crosslinking of alginate-chitosan hydrogel, the reactive
printed hydrogel had a dot-shaped morphology and the area coverage increased
when more layers of hydrogel were printed.

The drug loaded hydrogel samples exhibited a burst release during the first 2 hours
in artificial perilymph. The DexP had a release rate of 0.3-0.7 µM/min in the first
hour, and this rate could be adjusted by printing hydrogel with a different number of
bi-layers.
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Chapter 5
3D Extrusion Printing
Polycaprolactone Scaffolds for
Dexamethasone Delivery
5.1 Introduction
The use of biocompatible and biodegradable materials for biomedical applications
has attracted enormous interest in a diverse suite of applications since the FDA
approved the use of biodegradable sutures in the 1960s1. Biodegradable synthetic
polymers such as poly(glycolic acid), poly(lactic acid), poly(trimethyl carbonate)
and polycaprolactone have been widely investigated for uses as resorbable sutures,
intraluminal grafts, temporary vascular grafts and conduits for peripheral nerve
regeneration, drug delivery systems and various immobilisation devices used to fix
structures for orthopaedic applications such as screws, pins and rods2,

3, 4

. A

significant attraction to these materials is the ability to tune the material structure to
control the degradation rate, the ease through which they are degraded via hydrolysis
of the ester linkage, and the ability for the body to absorb and remove the resulting
polymer degradation products from the site of implantation via various metabolic
pathways. While biodegradable materials hold enormous promise for a range of
therapeutic biomedical applications, critical to realising their potential in these areas
is the development of polymer fabrication techniques capable of constructing
intricate three dimensional (3D) structures that are demanded by many of the
potential applications, which require the scaffold to possess certain geometrical
structures on both macro and micro scales to mimic the porous structure of the
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extracellular matrix and support cell adhesion, proliferation and differentiation5,

6, 7

.

For example, scaffolds with pore sizes ranging from 200 to 400 µm are used for
bone regeneration8, 9, while pore sizes between 20 to 125 µm are used for
regeneration of adult mammalian skin10, and 45 to 150 µm for liver tissues11.

The application of solid freeform fabrication techniques for 3D tissue engineering
scaffolds is widely seen as being critical to the engineering of functional biomedical
materials for a host of therapeutic biomedical applications. Solid freeform
fabrication is currently an area of intense interest to those looking to innovate in the
manufacturing industry, where a range of different additive fabrication techniques
have been developed to allow the construction of complex 3D structures through the
sequential stacking of 2D patterns in a layer-by-layer fashion. Techniques and
instrumentation have been developed to allow the 3D printing of metals (laser
sintering), UV curable polymers (stereolithgraphy), thermoplastics (fused deposition
lithography) and hydrogels (reactive extrusion printing), with the later typically
involving the printing of material into a bath containing a crosslinking agent.
Additive fabrication has in the past decade been recognised as being critical to
driving research in the biomaterials field, where significant effort has been directed
at moving from 2D to 3D material architectures that are more applicable for the
ultimate requirements desired for in vitro or in vivo scaffold or devices.

Of the biodegradable synthetic polymers, the polycaprolactone (PCL) has attracted
significant interest due to their flexibility and their highly processable nature.
Polycaprolactone is a synthetic polyester that has been investigated for use in several
biomedical applications. It has attracted significant interest for use in drug delivery
systems as they possess good biocompatibility, exhibit relatively slow degradation
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rates compared to other biodegradable polymers, and are highly processable12,

13, 14

.

PCL has a relatively low glass transition temperature (~ -60 °C) and a low melting
point (60 °C)15, making it particularly attractive for melt extrusion printing processes
that have been demonstrated as being a powerful technique through which to
fabricate intricate 3D scaffolds for a range of biomedical applications.

Herein I demonstrate the application of melt extrusion printing to fabricate 3D
scaffolds constructed of PCL loaded with the anti-inflammatory drug dexamethasone.
I investigate the processability of PCL loaded with varying concentrations of
dexamethasone, and demonstrate the ability to control the release of dexamethasone
from intricately fabricated 3D scaffolds.

5.2 Methods
5.2.1 Preparation of Dexamethasone Loaded Polycaprolactone
Dexamethasone (Dex) loaded Polycaprolactone (PCL) (MW 80 000, Sigma) was
prepared with three different Dex/PCL weight ratios: 1%, 2%, and 4%. Dex was first
dissolved in chloroform by adding 1 mg of Dex into 20 mL chloroform, then PCL
was added according to the weight ratio listed above. The mixture was stirred with a
magnetic stirrer for at least 5 hours until the PCL was fully dissolved. The mixture
was then poured into glass petri dishes and placed in the fumehood until the
chloroform had evaporated at room temperature. The PCL-Dex materials were
subsequently placed under vacuum at room temperature for 24 hours.
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5.2.2 Melt Extrusion Printing
A melt extrusion printer SPS1000 Bioplotter from the Korean Institute of Machinery
and Materials (KIMM) and Mechatronics for Technology (M4T) was employed to
extrude PCL scaffolds. Details of the Bioplotter were described in Section 2.4.1. The
structures of the scaffolds were designed with the Bioplotter software and loaded
into the M4T software to control the printing process. PCL-Dex material was cut and
rolled to load into the printer barrel. The extruding pressure was set at 400 kPa. The
heating temperature and the printing (feed) speed were controlled by the temperature
control system and the M4T software, respectively. 300 µm internal diameter
stainless steel tips were used for extruding the PCL-Dex material.

5.2.3 Characterisation of PCL-Dex
5.2.3.1

Polarised Light Microscopy

A Nikon OPTIPHOT-POL polarised light microscope was used to obtain the
polarised images of the PCL-Dex material. The microscope was mounted with a
Nikon DS-Fi1 camera which was run by a Nikon DIGITAL SIGHT DS-U3 driver. A
hot stage was mounted to the sample stage of the microscope which had the
capability to heat up the samples to 200 °C.

5.2.3.2

Thermogravimetric Analysis

Thermal gravimetric analysis (TGA) was performed on a TA Instruments Q500.
Scans were performed at a heating rate of 10 °C/min from room temperature to
800 °C under a nitrogen atmosphere. The TGA data were plotted as temperature
versus weight%, from which the onset and final decomposition temperature were
obtained.
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5.2.3.3

Differential Scanning Calorimetry

Differential scanning calorimetry (DSC) thermograms were obtained using a TA
Instruments Q100 equipped with a refrigerated cooling system. 5 mg to 10 mg
samples of PCL-Dex were prepared using standard aluminium pans and sealed by
pressing the top and bottom pans together. The samples were heated from -90 °C to
200 °C at a rate of 20 °C/min, and cooled down from 200 °C to -90 °C at a rate of
5 °C/min. Two cycles were performed on each sample, with a 24-hour isothermal
period at 200 °C between the two cycles. The quoted Tm refers to the onset
temperature.

5.2.3.4

Rheometry

The rheology and viscosity studies were performed with a TA Instruments AR-G2
rheometer using a cone-plate configuration. The cone has a 2° angle with a 40 mm
diameter. A 0.5 °C/min temperature ramp was performed over the temperature range
of 85 °C to 150 °C at a shear rate of 5 /s. The continuous ramp procedure was
performed with a ramp rate increasing from 0.01 /s to 50 /s at temperatures of 85 °C,
100 °C and 120 °C respectively. Because the PCL and PCL-Dex are solid at room
temperature, the material was first cast into disks with approximate sample volume
required by the rheometer, then placed in the middle of the plate, and melted at
80 °C. The cone was set to the measuring position after the material fully melted.

5.2.4 Dex Release from PCL-Dex Scaffolds
The printed PCL-Dex scaffold samples were incubated in 3 mL artificial perilymph
and kept in a water bath at 37 °C. At each time interval, an aliquot was removed
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from the release solution, and immediately the same amount of fresh artificial
perilymph was added to replace the removed solution.

5.3 Results and Discussion
5.3.1 PCL-Dex Materials
The PCL-Dex materials acquired from the solvent casting method produced white
translucent films (Figure 5.1). The presence of Dex in the PCL-Dex materials was
not obvious in such films using optical microscopy. Polarised light microscopy with
a heating stage was then employed. The PCL was transparent after being heated to
80 °C, and the crystalline structure of Dex was observed through the polarised light
microscope. The images obtained at 85 °C, 100 °C and 120 °C were identical for
each sample, hence only images at 85 °C are shown in Table 5.1.

Figure 5.1 Photo of a piece of PCL-1%Dex film.

Polarised light images were also taken for the neat PCL polymer and Dex. PCL
showed no crystalline structures above its melting temperature (~60 °C). Crystals of
Dex were clearly formed in the Dex sample, and different sizes of the crystals were
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shown in the same sample. Similar crystalline structures were found in PCL-Dex
materials, with different size distributions illustrated. The different sizes of Dex
crystals were likely due to the evaporation rate of the solvent when casting the PCLDex films. Studies have shown that when using the solvent casting method to
prepare polymer-Dex films, the solvent evaporation rate will affect the crystalline
particle size16, 17. Dex forms larger crystals at a slow solvent evaporation rate, while
much smaller crystals present in films at a fast solvent evaporation rate.

Table 5.1 Polarised optical images of PCL, Dex and PCL-Dex at 85 °C, with 0 ° and
90 ° polarised light respectively. Scale bars represent 100 µm. Arrows indicate the
Dex crystals.
Polarised
angle

light

0°

90 °

PCL
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Dex

PCL-1%Dex

PCL-2%Dex
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PCL-4%Dex

5.3.1.1

Thermogravimetric Analysis (TGA) and Differential Scanning

Calorimetry (DSC)
PCL and Dex both commenced decomposing at approximately 250 °C, as
demonstrated by the TGA plots (Figure 5.2 A). PCL showed a simple decomposition
profile with a single transition temperature, and had completely decomposed by
600 °C. Dex showed three transitions during the decomposition, decomposing
completely by 700 °C. The PCL-Dex materials showed similar decomposition
profiles as PCL, with degradation commencing at 250 °C and complete
decomposition occurring by 600 °C. This is due to the relatively small amount of
Dex in the PCL-Dex materials. However, the PCL-Dex with a higher amount of Dex
in the polymer exhibited a faster decomposition rate between 200 °C and 400 °C
(Figure 5.2 B and C).

174 | P a g e

A

B

C

Figure 5.2 TGA of (A) PCL and Dex, and (B) weight loss and (C) derivative of
weight loss of PCL-Dex material with Dex ratio at 1%, 2% and 4%, respectively.
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The TGA data indicated PCL-Dex materials to possess good thermal stability at
temperatures below 200 °C. DSC can be used to obtain further information regarding
polymer characteristics by analysing the transition temperature and heat flow. DSC
analyses demonstrated that the thermal behaviour of the neat PCL polymer was as
reported15, and adding Dex into the PCL affected the melting, crystallisation, and
glass transition temperature (Figure 5.3). Increasing the Dex/PCL ratio decreased the
melting temperature (Tm), both onset and peak Tm (Table 5.2). The glass transition
temperature increased with an increase of the Dex/PCL ratio, from -61.6 °C to 58.7 °C. The crystallisation temperature also increased with an increase in the
Dex/PCL ratio, except for PCL-4%Dex, which exhibited a lower crystallisation
temperature than PCL-1%Dex and PCL-2%Dex respectively, yet was still higher
than neat PCL. Two cycles of DSC measurements were performed on each sample,
with a 24-hour isothermal period at 200 °C. The second cycle showed identical
transition temperatures for each sample (data not shown), which indicates the
excellent thermal stability of the PCL-Dex materials at a temperature range below
200 °C.
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Figure 5.3 DSC of Dex, PCL and PCL-Dex materials.

Table 5.2 Summary of DSC data on Dex, PCL, and PCL-Dex materials.
Samples

Melting
(°C)

(Tm) Crystallisation Glass
(Tc) (°C)
(°C)

Onset

Peak

Dex

-

-

PCL

54.1

PCL-1%Dex

Transition

(Tg)

Onset

Middle

Finish

-

-

-

-

61.3

27.5

-64.2

-61.6

-55.9

51.7

59.3

31.4

-64.4

-60.3

-57.4

PCL-2%Dex

52.2

57.8

34.2

-63.6

-60.1

-55.8

PCL-4%Dex

51.7

57.4

29.8

-62.1

-58.7

-53.9

5.3.1.2

Flow behaviour of PCL-Dex Materials

The viscosity value of a given material is always dependent on the temperature of the
sample, especially with high-viscosity materials. In most cases the viscosity
decreases when the sample is heated18. Svante A. Arrhenius (1859-1927) first
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developed a general yet accurate equation to describe the change in viscosity for
both increasing and decreasing temperature, which is known as Arrhenius equation18:
𝑐2

𝜂(𝑇) = 𝑐1 ∙ 𝑒 𝑇

Equation 5.1 Arrhenius equation, where η is the fluid viscosity, T is the temperature
(unit: K) (T[K]=T[°C]+273.15 K), c1 is the viscosity coefficient (unit: Pa.s), and c2 is
the temperature coefficient (unit: K).

The temperature dependent viscosity of each material was tested with the TA AR G2
rheometer, and results were fitted with the Arrhenius model (Figure 5.4). The curves
fit closely to the Arrhenius model, which indicates the PCL and PCL-Dex materials
to be thermo-rheologically simple, and do not undergo changes to their structural
character in the temperature range of 85-150 °C.

Table 5.3 Summary of coefficients and standard error for the Arrhenius model fitted
to the temperature dependent viscosity curves, standard errors were given by the TA
Data Analysis.
PCL

1% Dex/PCl

2% Dex/PCL 4% Dex/PCL

c1 (Pa.s)

4.742E-3

2.087E-3

6.344E-3

1.938E-3

c2 (K)

4134.4

4225.5

3692.2

4371.3

Standard error

5.205

7.895

8.120

7.218

The viscosity change at three different temperatures (85 °C, 100 °C, and 120 °C) was
also measured as a function of shear rate (Figure 5.5). Due to an instrument
limitation, the maximum shear rate that could be applied to the materials was 50 /s.
PCL and PCL-Dex materials showed constant viscosity in the shear rate range
between 0.01 /s to 50 /s, implying that they are Newtonian in this shear rate range.
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Figure 5.4 Temperature dependent viscosity curves of PCL and PCL-Dex materials at different Dex/PCL ratios. The solid lines represent fits
to the Arrhenius equation.
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A

B

C

D

Figure 5.5 Viscosity changes as a function of shear rate at different temperatures for PCL (A), and PCL-Dex materials at different Dex/PCL
ratios (B, C, D).
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5.3.2 Scaffolds Design and Fabrication
5.3.2.1

Rheometry Model of Extrusion Printing

P1

∆h
L

D

P2

Figure 5.6 Diagram of fluid flow in a uniform circular tube/capillary from a fluid
reservoir. P1 and P2 are pressure values applied to the fluid and at the opening of the
tube/capillary respectively, L is the length of the tube/capillary, D is the diameter of
the tube/capillary, and ∆h is the distance between the top and the bottom of the fluid.

The general theory and methodology based on the two-plates-model has been
discussed in Chapter 2. Herein, a tube/capillary model, which was developed from
the two-plates-model, provides an improved fit for the extrusion printing process
(Figure 5.6). The Hagen/Poiseuille relation was proposed for the definition and
calculation of the rheological parameters19. The shear stress “at the wall” of the
tube/capillary is defined as:

𝜏𝑤 =

𝐷 ∙ ∆𝑃
4∙𝐿
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Equation 5.2 Definition of the shear stress in a tube/capillary, where D (unit: m) is
the diameter of the tube/capillary, ∆P (unit: Pa) is the pressure drop, and L (unit: m)
is the length of the tube/capillary.

In this work, ∆P can be calculated as:

∆𝑃 = 𝑃1 − 𝑃2 − 𝜌 ∙ 𝑔 ∙ ∆ℎ

Equation 5.3 Equation of pressure drop during the extrusion printing, where P1 is the
pressure applied by the pressure control system, P2 is the pressure at the opening of
the printing tip, ρ is the density of the material, g is the gravity of earth, and ∆h is the
distance between the top and bottom of the fluid.

When a pressure of 400 kPa is applied to the extrusion system, the 𝜌 ∙ 𝑔 ∙ ∆ℎ value is
small compared to (P1-P2), hence it can be ignored, and the ∆P can be seen as
constant, even when the ∆h of the material varies during the printing process.

The shear rate “at the wall” is defined as:

𝛾̇𝑤 =

32 ∙ 𝑄
𝜋 ∙ 𝐷3

Equation 5.4 Definition of the shear rate in a tube/capillary, where Q (unit: m3/s) is
the volume flow rate, D is the diameter of the tube/capillary.

Hence the viscosity of the fluid is:

𝜂=

𝜏𝑤 𝜋 ∙ ∆𝑃 ∙ 𝐷4
=
𝛾̇𝑤 128 ∙ 𝐿 ∙ 𝑄
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Equation 5.5 Equation of the viscosity of the fluid in a tube/capillary, where ∆P is
the pressure drop, D is the diameter of the tube/capillary, L is the length of the
tube/capillary, and Q is the volume flow rate.

Therefore the volume flow rate can be calculated as:

𝑄=

𝜋 ∙ ∆𝑃 ∙ 𝐷4
128 ∙ 𝐿 ∙ 𝜂

Equation 5.6 Equation of the volume flow rate of the fluid in a tube/capillary, where
where ∆P is the pressure drop, D is the diameter of the tube/capillary, L is the length
of the tube/capillary, and η is the viscosity of the fluid.

The tips used in the extrusion printing process are small enough to be seen as
tubes/capillaries at the end of the material reservoir. Tips of 300 µm internal
diameter were used in this work (Figure 5.7). The length of the tips could not be
ascertained due to their geometry, however the value should be constant within the
same set of tips. Therefore, as indicated in Equation 5.6, when the material is
extruded with a given tip at a constant pressure, the volume flow rate is dependent on
the fluid viscosity.

A

B

200µm
Figure 5.7 Picture of a precision tip used in the extrusion printing (A), and the tip
opening under an optical microscope (B).
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5.3.2.2

Pressure and Temperatures

Extrusion printing stability and reproducibility were tested by printing samples with
several strands at different temperatures and with different feeds (printing speed).
Multiple samples were printed for each condition (Figure 5.8).

Figure 5.8 Photos of printed strands for testing the relationship between the
diameters and printing conditions.

As shown in Equation 5.6, at a given viscosity value, the fluid flow rate is constant.
The flow rate can be calculated as:

𝑄=

1
∙ 𝜋 ∙ 𝑑 2 ∙ 𝑣𝑓
4

Equation 5.7 Equation of flow rate, where d is the diameter of the printed strand, and
vf is the feed (printing speed).

Hence the relation between the strand diameter, the printing speed, and the viscosity
of the material can be derived from Equation 5.6 and Equation 5.8:

1
𝜋 ∙ ∆𝑃 ∙ 𝐷4
∙ 𝜋 ∙ 𝑑 2 ∙ 𝑣𝑓 =
4
128 ∙ 𝐿 ∙ 𝜂
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therefore,

∆𝑃 ∙ 𝐷4
𝑑=√
32 ∙ 𝐿 ∙ 𝜂 ∙ 𝑣𝑓

and the viscosity was proven to be correlated to the temperature (Equation 5.1),
hence:

𝑑=√

1
∆𝑃 ∙ 𝐷4
∆𝑃 ∙ 𝐷4
1
−
=√
∙ √
∙
𝑣
𝑓 2
𝑐2
32 ∙ 𝐿 ∙ 𝜂 ∙ 𝑣𝑓
32 ∙ 𝐿
𝑇
𝑐1 ∙ 𝑒

Equation 5.8 The relation between the strand diameter d (unit: μm) and the printing
speed vf (unit: mm/min).
∆𝑃∙ 𝐷 4

At constant extrusion pressure, the value of √

32∙𝐿

can be seen as a constant

coefficient a.

The results in Figure 5.9 reveal good agreement between theory (Equation 5.8) and
experiment (correlation coefficient, R2>0.99) (Table 5.4), demonstrating a good
stability of the extrusion printing system employed in this work for the PCL-Dex
scaffold fabrication.
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A

B

C

D

Figure 5.9 Diameters of the printed strands as a function of temperature and feed speed, solid lines represent fits to Equation 5.8. (n=7)
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Table 5.4 The values of coefficient a, and the correlation coefficient R2 when the
diameter of the printed strands as a function of temperature and printing speed fitted
with Equation 5.8 using average a value.
PCL

1% Dex/PCL

2% Dex/PCL

4% Dex/PCL

85 °C

70106.4

56864.7

49661.4

59653.5

100 °C

72447.5

57747.0

54200.7

60725.3

120 °C

77060.1

61216.67

57763.0

64636.8

a
Average

R2

61840.3

85 °C

0.9975

0.9980

0.9993

0.9985

100 °C

0.9993

0.9984

0.9983

0.9977

120 °C

0.9996

0.9971

0.9997

0.9982

The standard deviation values of the diameters of the printed strands are too small to
be shown in Figure 5.9. There is no considerable difference between PCL and
different PCL-Dex materials. It is worth noting that only a 300 μm tip was used in
the extrusion printing in this work, however the printed strands’ diameter varied
from 200 μm to 1600 μm which is 5 times of the actual size of the printing tip. This
is due to the nature of the extrusion printing in this work. The deposition of the
printed strand depends on the friction between the extruded material and the
substrate/previous layer of deposited material, as well as the tensile force of the
extruded material. While printed at a higher speed, the extruded material is stretched
during the deposition, therefore the strand diameter is thinner than the extrusion tip
diameter; and when printed at a lower speed, the material accumulates at the
extrusion tip, and deposited strands have larger diameters than the extrusion tip.
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5.3.2.3

Printed Scaffolds and Porosity

The PCL-Dex scaffolds were designed as 10 mm × 10 mm scaffolds with a 4 layer
lattice structure. Each layer was printed at a 45° angle relative to the previous layer
and the spacing between the centres of strands in the same layer is 1 mm (Figure
5.10). With each material, scaffolds with strands of two different diameters (250 µm
and 350 µm) were printed using the conditions obtained previously.

A

500 μm

B

C

1 mm

1 mm

Figure 5.10 Pictures of the printed PCL-Dex scaffold (A), and side view (B) and top
view (C) of the designed pattern.
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Printing this lattice structure with different strand diameters was designed to
generate scaffolds with different porosities. The porosity of the scaffolds can be
calculated as12:

𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 =

𝑉 − 𝑉′
× 100%
𝑉

Equation 5.9 Equation to calculate the scaffold porosity, where V is the apparent
volume of the printed scaffolds, V’ is the true volume of the printed scaffolds.

Based on this equation, the average porosity for the scaffolds with 250 µm strands
and 350 µm strands are 70.1% and 60.9%, respectively.

5.3.3 Dex Release
Dex release experiments were performed by incubating printed PCL-Dex scaffolds
in artificial perilymph solution at 37 °C for 6 weeks, during which Dex release was
sampled at several time points and the results plotted both by the mass and the
percentage of Dex release (Figure 5.11). The mass release profiles and the
percentage release profiles illustrated opposing release trends. For the mass release,
the scaffolds printed with PCL-4%Dex released the most Dex, with 1657 (±32) µg
released from the 350 µm scaffolds and 915 (±37) µg from the 250 µm scaffolds,
respectively, while PCL-1%Dex scaffolds released the least amount of Dex, with
542 (±4) µg from the 350 µm scaffolds and 280 (±4) µg from the 250 µm scaffolds,
over the 6 week period. The PCL-2%Dex scaffolds released 975 (±12) µg Dex from
the 350 µm scaffolds and 554 (±12) µg from the 250 µm scaffolds.
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A

C

B

D

Figure 5.11 Dex release profiles from PCL-Dex extrusion printed scaffolds. (n=5, error bars are too small to be seen in the figures.)
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While total Dex release increased with increasing Dex loading in the scaffolds, the
percentage release was greater for scaffolds possessing lower Dex loading
concentrations (lower Dex/PCL ratios). The PCL-1%Dex released more Dex by
percentage than the PCL-2%Dex and PCL-4%Dex scaffolds (97.04 (±0.76)% and
101.06 (±1.59)% from 350 µm and 250 µm scaffold, respectively) (Figure 5.11 B,
D). The rate of Dex release was not only influenced by Dex loading, but also
scaffold architecture. The 250 µm scaffolds demonstrated a faster percentage release
rate than the 350 µm scaffolds for all Dex/PCL ratios, likely due to their higher
porosity (Figure 5.11 B, D). Scaffolds with lower Dex/PCL ratios also demonstrated
a faster percentage release rate than the scaffolds with higher Dex/PCL ratios, and
reached the maximum release much earlier than the scaffolds with higher Dex/PCL
ratios. PCL-1%Dex scaffolds reached the maximum release at 120 hours for the
250 µm scaffolds and 408 hours for the 350 µm scaffolds, while PCL-2%Dex
scaffolds reached the maximum release at 506 hour and 672 hour for the 250 µm and
350 µm scaffolds, respectively. PCL-4%Dex scaffolds showed a more sustained
release throughout the 6 week period, both from the 350 µm and 250 µm scaffolds.
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A

B

Figure 5.12 First 24 hours of Dex release from PCL-Dex scaffolds, (A) Dex release
from 350 µm scaffolds, and (B) Dex release from 250 µm scaffolds.

The maximum amount of Dex released from the PCL-Dex scaffolds increased with
an increase in the Dex/PCL ratio in the scaffolds, however in the first 24 hours
(particularly the first 8 hours) the PCL-1%Dex, PCL-2%Dex and PCL-4%Dex
scaffolds demonstrated similar Dex release (Figure 5.12). As the mass of Dex
released from the various scaffolds was similar, scaffolds with lower Dex/PCL ratios
illustrated higher percentage release during this period (PCL-1%Dex > PCL-2%Dex >
PCL-4%Dex) (Figure 5.11 B&D). This suggests that the release of Dex from the
PCL-Dex scaffolds is likely through a simple diffusion mechanism, which is
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dependent on the dimension and the diameter of the strands used to construct the
scaffolds20, 21.

A

B

Figure 5.13 Dex release profiles from 4-layer and 8-layer extrusion printed 2%
Dex/PCL scaffolds (n=3).

PCL-2%Dex with 250 µm diameter strands and 8 layer scaffolds were also printed to
compare their release profile with that demonstrated for 4 layer structures. The 8
layer scaffolds released a maximum of 1109 (±24) µg of Dex, which is twice the
Dex released from the 4 layer scaffolds (554 (±12) µg) (Figure 5.13). However the 8
layer scaffolds released at a slower rate than the 4 layer scaffolds, with the 4 layer
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scaffolds reaching 50% Dex release by 72 hours while the 8 layer scaffolds reached
50% Dex release by 120 hours. The 4 layer scaffolds reached 75% release by 506
hours while it took the 8 layer scaffolds 1008 hours to reach the same percentage
release. The difference between the release profiles of the 4 layer and 8 layer
Dex/PCL scaffolds could be due to the difference in the porosity, (70.1% and 68.9%,
respectively, Equation 5.9), facilitating the release of the Dex more easily from the 4
layer structured scaffolds.

5.3.4 Scaffolds Morphology
The PCL-Dex scaffold morphologies before and after Dex release were studied using
scanning electron microscopy (SEM) (Table 5.5) The 350 µm scaffolds and 250 µm
scaffolds showed similar morphologies in the SEM images, hence to simplify the
data, only SEM images of 350 µm scaffolds are shown in the table. As illustrated in
the images, the Dex was presented in a crystallised form on the scaffold surface,
however it was rather difficult to observe the crystallised Dex at the cross section of
the scaffolds. It demonstrated that, before Dex release, more Dex crystals appeared
on the scaffold surface for materials with a higher Dex/PCL ratio.

Table 5.5 SEM images of 350 µm PCL-Dex scaffolds before and after Dex release.
After Release

Surface

1% Dex/PCL
Scaffold

Before Release
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Cross Section
Surface

4% Dex/PCL Scaffold
Cross Section
Surface

2% Dex/PCL Scaffold
Cross Section

After 6 week release in artificial perilymph at 37 °C, the overall gross morphology of
the printed PCL-Dex scaffolds showed no obvious visual differences compared to
prior to release (pictures not shown). However, the formation of cracks and cavities
on the scaffold surface were observed with scanning electron microscope (SEM)
(Table 5.5). The scaffold cross section showed less cavity formation compared to the
surface morphology.

The formation of cracks on the scaffold surface is likely due to the degradation of
PCL. Polymer degradation is generally defined as “the chemical reaction resulting in
a cleavage of main-chain bonds producing shorter oligomers, monomers, and/or
other low molecular weight degradation products”22. These low molecular weight
degradation products will be gradually removed from the polymer system, and the
loss of material from polymer bulk is referred to as “erosion”. Studies have
demonstrated that the degradation of PCL is due to the hydrolysis of polymer23,

13

,

and the hydrolytic cleavage of polymer backbones generally occurs first at the
polymer surface22, 24. For PCL, the rates of hydrolysis of the polymer and diffusion
of the low weight degradation oligomers or monomers are faster than the rate of
water intrusion into the polymer bulk, and therefore the erosion of PCL will remain
at the surface without affecting the internal structure of the polymer bulk13. Thus the
change in polymer morphology is more obvious on the PCL-Dex scaffold surface
than in the cross sectional area after Dex release (Table 5.5).
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Figure 5.14 Weight loss after Dex release from PCL-Dex scaffolds for 6 weeks. N=5;
error type is 95% confidence interval standard deviation.

The overall weight loss is between 4% and 6% after Dex release from PCL-Dex
scaffolds for 6 weeks in artificial perilymph at 37 °C (Figure 5.14). The hydrolysis
rate of PCL in saline solution is slow, studies have shown as little as 0.72% mass
loss after 6 months in phosphate buffer saline13. However the distinction of weight
loss between the 350 µm and 250 µm PCL-Dex scaffolds is insignificant (as shown
in Figure 5.14).

5.4 Conclusions
In this chapter, Dex loaded PCL 3D scaffolds were fabricated by the melt extrusion
printing technique. The PCL-Dex materials were determined to be thermally stable
and processable. Melt extrusion printing parameters were optimised to allow for the
fabrication of highly reproducible strand structures using a custom built SPS1000
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Bioplotter developed by KIMM with IPRI, with the highest reproducibility
demonstrated.

The release of Dex from melt extrusion printed 3D lattice structures fabricated from
PCL-Dex of varying Dex loading concentrations and strand diameters was
investigated under physiologically relevant conditions. Total Dex release was
increased with increasing Dex loading in the PCL-Dex material, with total
percentage release greatest for scaffolds with lower Dex loading concentrations.
Strand diameter also influenced the rate of Dex release, with percentage release
greater for scaffolds constructed from 250 µm strands, compared to the 350 µm
strands. Increasing Dex percentage release with decreasing strand diameter was
proposed to be driven by an increase in scaffold porosity with decreasing strand
diameter.

The PCL-Dex scaffolds showed insignificant structural change after Dex release,
however, microcracks and cavities were formed on the surface of the scaffolds due to
the hydrolytic degradation of the PCL. The overall weight loss after 6 weeks was
between 4% to 6%.
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Chapter 6
General Conclusions and Future
Work
In summary, the fabrication of drug delivery systems for dexamethasone (Dex) and
dexamethasone sodium phosphate (DexP) has been demonstrated in this Ph.D.
project. Various biofabrication techniques were applied to develop the drug delivery
systems for biomedical applications, including electropolymerisation of conducting
polymers, inkjet printing of hydrogels, and extrusion printing of 3D scaffolds.

6.1 Conclusions
6.1.1 Conductive and Protein Resistant Polypyrrole Films for
Dexamethasone Delivery
This part of work focused on the fabrication of a hybrid drug delivery system based
on the conducting polymer polypyrrole, with the capability of releasing an antiinflammatory agent (DexP) as well as demonstrating protein resistance, with the later
designed to enhance material biocompatibility. The influence of a range of
electropolymerisation conditions (current density and DexP concentration in
polymerisation electrolyte) were investigated for their impact on fundamental
polymer properties that may act to modulate the release of DexP from the polymer
films. Varying the current density during polymerisation, as well as the DexP
concentration in the polymerisation electrolyte significantly influenced polymer
201 | P a g e

interfacial roughness and mechanical properties, which were deemed to be
associated with polymer porosity. Increasing the current density during
electrochemical polymerisation increased surface roughness and film porosity, while
an increase of DexP concentration reduced surface roughness and porosity. The
modulation of these film properties significantly affected the release of DexP from
the polymers. The largest amount of DexP released after 4 hours of stimulation under
a constant negative potential was demonstrated for films grown at a current density
of 1.5 mA/cm2 and a 5 mM DexP concentration. These polymerisation conditions
produced the roughest film morphology, as well as films that were relatively
viscoelastic, or highly hydrated and porous in nature, compared to other films
produced using different polymerisation conditions. The increase in interfacial
surface area and film porosity are likely to aid in the active transport of DexP from
within the polymer matrix itself and into the surrounding electrolyte.

In order to enhance the ability of the polymeric device to deliver therapeutic drugs to
the target cells and tissues in an in vivo environment, the biocompatibility of the
polymer surface was improved by limiting non-specific protein adsorption. Protein
adsorption to biomaterials on implantation can induce significant inflammatory and
foreign body responses, ultimately leading to the encapsulation of the device in
fibrotic tissue that can significantly affect the ability for the device to deliver
therapeutic concentrations of drug to the desired tissues. The PPy/DexP polymer
surface was functionalised with the known protein resistant chemistry PEG by
exploiting the thiol-ene reaction mechanism. Using two different molecular weights
of thiolated PEG (PEG-SH) (5k and 40k), it was demonstrated that the surface
density of the smaller molecular weight PEG-SH on the PPy/DexP increased with an
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increase in polymer surface roughness and porosity, while the opposite was evident
for the 40k MW PEG-SH. PEG-SH modification of the PPy/DexP surface was
demonstrated to considerably reduce protein adsorption for all polymer growth
conditions and PEG-SH molecular weights, however the 40k PEG-SH imparted the
greatest protein resistant properties to the PPy/DexP surface. Furthermore, the
surface functionalization of the PPy/DexP films with PEG-SH exhibited a reduction
in DexP release, likely due to limited DexP mobility and retention of the DexP in the
PEG layer. The modulation of DexP release by the presence of the PEG-SH layer is
particularly significant as the release of therapeutic drugs from carrier materials
currently under investigation for use as drug eluting scaffolds typically suffer from a
‘burst’ type of release upon incubation in an in vitro or in vivo environment. The
ability of the PEG-SH surface modification layer to both reduce protein adsorption,
as well as the rate of DexP release from the bulk polymer, while maintaining
polymer electroactivity, has the potential to have an enormous impact on the future
design of drug eluting conducting polymer based devices, as well as more broadly as
ultra-low fouling organic electrodes for applications such as cell and tissue
stimulation/recording and biosensing.

6.1.2 Reactive Inkjet Printing Hydrogels for Drug Delivery
This part of work focused on the inkjet printing of alginate and chitosan onto PET,
glass and PDMS using a custom designed and in-house built inkjet printing system.
This inkjet printing system was utilised to construct DexP loaded alginate-chitosan
hydrogels to fabricate an inkjet printed drug eluting hydrogel. Inkjet printing has
attracted increasing interest in the area of biomaterials fabrication as it possesses
several advantages over conventional fabrication technologies, including non-contact
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printing, micron-scale patterning of features, ease of use and low setup costs. These
properties are particularly attractive for the fabrication and patterning of hydrogel
structures on existing implantable device surfaces, such as the cochlear implant, that
may require the precise deposition of hydrogel and/or drug at specific sites on the
implant surface, and on a range of different substrates, depending on the nature and
construction of the device.

Herein I have demonstrated for the first time the application of reactive inkjet
printing to fabricate alginate-chitosan hydrogels loaded with the therapeutic drug
DexP with the aim of constructing a hydrogel based drug delivery system. Alginate
and chitosan based materials are traditionally troublesome to use with traditional
fabrication techniques due to the quick gelation time between the two materials,
which becomes a major problem when attempting to control the formation of fine
structural features of hydrogel structures using standard fabrication techniques.
Inkjet printing does not suffer the same issues experienced by other techniques,
allowing the alginate and chitosan to react directly on the substratum at incredibly
small volumes and feature sizes, removing issues associated with the pre-gelation of
the hydrogel when materials are premixed prior to deposition on a surface using
other techniques such as extrusion printing. A range of ink properties were optimised,
including ink formulation, surface tension and viscosity, to ensure the printability of
the two materials. Excellent reproducibility was demonstrated, allowing the printing
of high resolution alginate-chitosan hydrogel structures on a range of surfaces, as
well as the ability to deliver DexP from the hydrogel material. The drug loaded
hydrogel samples showed a burst release during the first 2 hours in artificial
perilymph. The DexP had a release rate of 0.3-0.7 µM/min in the first hour, and this
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rate could be adjusted by printing hydrogel with different number of bi-layers. The
release rate was determined to be suitable to develop an effective therapeutic
concentration of DexP within 500 µm radius from the device surface, which is one of
the requirements to provide a suitable anti-inflammatory effect within the vicinity of
neural electrodes.

6.1.3 3D Extrusion Printing of Polycaprolactone Scaffolds for
Dexamethasone Delivery
The final part of this Ph.D. project focused on the fabrication of Dexamethasone
loaded PCL 3D scaffolds using the melt extrusion printing technique. PCL is widely
accepted as a biocompatible material. PCL-Dex was prepared by a solvent casting
method with Dex/PCL ratios varying from 1% to 4%. The PCL-Dex materials were
analysed with a series of characterisation methods including TGA, DSC and
rheology. It was demonstrated that the materials possess good thermal stability at
temperatures below 200 °C. The viscosity of the PCL-Dex materials were
temperature dependent, however at specific temperatures the materials demonstrated
Newtonian behaviour in the shear rate range between 0.01 /s to 50 /s. The PCL-Dex
materials were determined to be thermally stable and processable, and a custom built
melt extrusion printer, the SPS1000 Bioplotter, was employed to fabricate 3D PCLDex scaffolds. The relationship between the printing parameters (e.g. temperature,
feed speed) and the printed PCL-Dex structures was investigated and optimised for
high reproducibility. Scaffolds with two different strand diameters (250 µm and
350 µm) were printed with each Dex/PCL concentration.
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The release of Dex from melt extrusion printed 3D lattice structures fabricated from
PCL-Dex of varying Dex loading concentrations and strand diameters was
investigated under physiologically relevant conditions. Total Dex release was
greatest with increasing Dex loading in the PCL-Dex material, with total percentage
release greatest for scaffolds with lower Dex loading concentrations. Strand diameter
also influenced the rate of Dex release, with percentage release greater for scaffolds
constructed from 250 µm strands, compared to the 350 µm strands. Increasing Dex
percentage release with decreasing strand diameter was proposed to be driven by an
increase in scaffold porosity with decreasing strand diameter. The PCL-Dex
scaffolds showed insignificant structural change after Dex release, however
microcracks and cavities were formed on the surface of the scaffolds due to the
hydrolytic degradation of the PCL. The overall weight loss after 6 weeks was
between 4% and 6%.

6.2 Future Work
6.2.1 Conductive and Protein Resistant Polypyrrole Films for
Dexamethasone Delivery
Engaging surface modification to reduce the non-specific protein adsorption adds an
exciting new dimension to conducting polymer drug delivery systems. The thiol-ene
reaction in this work can be employed to modify the conducting polymer surface
with a diverse suit of molecules, to manipulate the interfacial properties. In addition
to the further development of low-fouling drug delivery systems, future work should
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also focus on applying surface modification of conducting polymer drug delivery
systems to promote beneficial protein adsorption, and therefore encourage
interactions between the biomedical device and specific cell and tissue. In this way,
the performance of the implanted devices can be greatly improved.

Future work may also be directed towards the application of additive fabrication
techniques. For example, inkjet printing of thiolated molecules can easily create
micro-scale patterns of single or multiple functional chemistries, on the conducting
polymer surface. The patterning of these chemistries may be employed to direct the
targeted binding of specific cell and/or tissue types, or present chemical gradients
across the implant surface that may direct biological interactions and/or the rate of
subsequent drug elution from the implant surface. Additionally this chemical
patterning can be designed for the purpose of bio-sensing, providing feedback
signals to the biomedical devices, which can be applied in the closed-loop control
(i.e. direct the release of drug from the polymer), as discussed in Section 1.1.

6.2.2 Reactive Inkjet Printing Hydrogels for Drug Delivery
Employing hydrogels as reservoirs for drug delivery systems may increase the drug
loading capacity, however the burst release could be a disadvantageous factor where
prolonged or highly controlled release is demanded. To address this issue, a few
methodologies should be the focus of further studies. The burst release is due to the
porous and hydrophilic nature of the alginate-chitosan hydrogel, making the drug
diffuse out of the hydrogel network at a very high rate. This situation can be
improved by increasing the crosslink density with a different crosslinking agent.
Modifying the hydrogel molecules to be less hydrophilic can also retard the diffusion
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of the drug in aqueous environment. These methods may be effective at improving
the retention of the drug in the hydrogel matrix, allowing for a much longer release
period.

6.2.3 3D Extrusion Printing of Polycaprolactone Scaffolds for
Dexamethasone Delivery
Computer aided 3D extrusion printing provides the ability to customise biomedical
devices to fit individual patients. The work herein demonstrated the possibility of
using 3D printing to fabricate drug delivery systems. Future studies can be carried
out on different biomaterials, such as PDMS and polyurethane, which are readily
used in biomedical devices. Depending on the material properties, (where melt
extrusion printing is not applicable for all the materials), different methods, such as
UV crosslinking or solvent printing, can be applied to different materials after
optimisation of printing conditions.

A combination of different fabrication techniques should also be investigated to
achieve the best outcome for patient-oriented drug delivery systems. For example,
the combination of the extrusion printing and inkjet printing can provide the bulk
structure with the extrusion printing and more defined surface details with the inkjet
printing. The application of additive fabrication techniques to provide directed drug
loading within a scaffold in 3D, as well as impart fine control over the material nanoand micro-scale features, provides enormous scope for not just incremental, but
revolutionary development in the area of drug delivery research.
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